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(57) ABSTRACT
The invention concerns compounds o f Formula (I)
(I)
N —  N
(2006.01)
(2006.01)
N NH2
orpharmaceutically-acceptable salts thereof, wherein R1 and 
R2 have any o f the meanings defined hereinbefore in the 
description; processes for their preparation, pharmaceutical 
compositions containing them and their use in the treatment 
o f cell proliferative disorders.
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Figure I : X-Ray Powder Diffraction Pattern Example I Form A
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Figure 2: DSC Thermogram Example I Form A
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Figure 3: X-Ray Powder Diffraction Pattern Example 3 Form A
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Figure 4: DSC Thermogram Example 3 Form A
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Figure 5: X-Ray Powder Diffraction Pattern Example 3 Form B
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Figure 6: DSC Thermogram Example 3 Form B
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Figure 7: X-Ray Powder Diffraction Pattern Example 3 Form C
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Figure 8: DSC Thermogram Example 3 Form C
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Figure 12: Tumour Growth Inhibition by Example 3 in  Combination with PARP 
inhibitor (OIanarib) MCF7 xenograft model
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Figure 13: Tiimoiir Growth Inhibition by Example 3 In Combination with AZD8186
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C H E M IC A L  COM POUNDS
[0001] This application claims the benefit under 35 U.S.C 
§119(a)-(d) o f PatentApplicationNo. 13305078.1 (EP), filed 
23 Jan. 2013.
[0002] The invention concerns certain novel aminopyra- 
zine derivatives, or pharmaceutically-acceptable salts 
thereof, which possess anti-cancer activity and are accord­
ingly useful in methods o f treatment o f the human or animal 
body. The invention also concerns processes for the manufac­
ture o f said aminopyrazine derivatives, pharmaceutical com­
positions containing them and their use in therapeutic meth­
ods, for example in the manufacture o f medicaments for use 
in the prevention or treatment o f cancers in a warm-blooded 
animal such as man, including use in the prevention or treat­
ment o f cancer.
[0003] The present invention also relates to aminopyrazine 
derivatives that are selective inhibitors o f the PI3-kinase fam­
ily o f enzymes (which is alternatively known as the phos- 
phatidylinositol-3-kinase family or PI3K family), particu­
larly of PI3K -a and ΡΙ3Κ-δ isoforms, and are, for example, 
useful for anti-tumour therapy.
[0004] In the area o f cancer it has in recent years been 
discovered that a cell may become cancerous by virtue of the 
transformation of a portion of its DNA into an oncogene, that 
is a gene which, on activation, leads to the formation o f 
malignant tumour cells (Bradshaw, Mutagenesis, 1986, I, 
91). Several such oncogenes give rise to the production o f 
peptides, which are Kinases, a class o f enzymes that are 
capable o f phosphorylating their protein or lipid substrates. 
There are several classes o f kinases.
[0005] Firstly, tyrosine kinases, which may be receptor 
tyrosine kinases or non receptor tyrosine kinases. Various 
classes o f receptor tyrosine kinases are known (Wilks, 
Advances in Cancer Research, 1993, 60, 43-73) based on 
families o f growth factors, that can bind to the extracellular 
surface o f different receptor tyrosine kinases; as an example 
the classification includes Class I receptor tyrosine kinases 
comprising the EGF family o f receptor tyrosine kinases. Non­
receptor tyrosine kinases are located intracellularly; various 
classes o f non-receptor tyrosine kinases are known including 
the Src family such as the Src, Lyn, Fyn and Yes tyrosine 
kinases.
[0006] Secondly, certain kinases belong to the class o f 
serine/threonine kinases which are also located intracellu­
larly. Serine/threonine kinase signalling pathways include the 
Raf-MEK-ERK cascade and those downstream of PI3-kinase 
such as PD K -I, AKT and mTOR (Blume-Jensen and Hunter, 
Nature, 2001,411,355).
[0007] It is also known that certain other kinases belong to 
the class o f lipid kinases, which are located intracellularly and 
are, as for the above mentioned kinases, involved in the trans­
mission o f biochemical signals such as those that influence 
tumour cell growth and invasiveness. Various classes o f lipid 
kinases are known including the aforementioned PI3-kinase 
family.
[0008] It is now well understood that deregulation o f onco­
genes and tumour-suppressor genes contributes to the forma­
tion o f malignant tumours, for example by way o f increased 
cell proliferation or increased cell survival. It is also now 
known that signalling pathways mediated by the PI3-kinase 
family have a central role in a number o f cell processes 
including proliferation and survival, and deregulation o f 
these pathways is a causative factor across a wide spectrum of 
human cancers and other diseases (Katso et ah, Annual Rev.
Cell Dev. Biol., 2001, 17: 615-617 and Foster et al., J  Cell 
Science, 2003, 116: 3037-3040).
[0009] The PI3-kinase family o f lipid kinases is a group of 
enzymes that phosphorylate the 3-position o f the inositol ring 
o f phosphatidylinositol (PI). Three major groups o f PI3-ki- 
nase enzymes are known which are classified according to 
their physiological substrate specificity (Vanhaesebroeck et 
al., Trends in Biol. Sci., 1997,22,267; Engleman eta\., Nature 
Review Genetics, 2006,7, 607). Class III PI3-kinase enzymes 
phosphorylate PI alone. In contrast, Class II PI3-kinase 
enzymes phosphorylate both PI and PI4-phosphate [abbrevi­
ated hereinafter to PI(4)P]. Class I PI3-kinase enzymes phos­
phorylate PI, PI(4)P and PI4,5-bisphosphate [abbreviated 
hereinafter to PI(4,5)P2], although only PI(4,5)P2 is believed 
to be the physiological cellular substrate. Phosphorylation of 
PI(4,5)P2 produces the lipid secondmessengerPI3,4,5-triph- 
osphate [abbreviated hereinafter to PI(3,4,5)P3]. More dis­
tantly related members o f this superfamily are Class IV 
kinases such as mTOR and DNA-dependent protein kinase 
that phosphorylate serine/threonine residues within protein 
substrates. The most studied and understood o f these lipid 
kinases are the Class I PI3-kinase enzymes.
[0010] Class I PI3-kinases are heterodimers consisting o f a 
p i 10 catalytic subunit and a regulatory subunit, and the fam­
ily is further divided into Class Ia and Class Ib enzymes on the 
basis o f regulatory partners and mechanism o f regulation 
(Engleman et al., Nature Review Genetics, 2006, 7, 607). 
Class Ia enzymes consist o f three distinct catalytic subunits 
(pi 10a, p i 10β and p i I OS, by nomenclature define the PI3- 
Kinase isoform as α, β or δ respectively) that dimerise with 
five distinct regulatory subunits (ρ85α, p55a, p50a, ρ85β 
and ρ55γ), with all catalytic subunits being able to interact 
with all regulatory subunits to form a variety of heterodimers. 
Class Ia PI3-kinase enzymes are generally activated in 
response to growth factor-stimulation o f receptor tyrosine 
kinases, via interaction of the regulatory subunit SH2 
domains with specific phospho-tyrosine residues o f the acti­
vated receptor or adaptor proteins such as IRS-1. B o thp l 10a 
and p 110β are widely expressed across cell types and tissues, 
whereas p i 10 δ expression is more restricted to leukocyte 
populations and some epithelial cells. In contrast, the single 
Class Ib enzyme consists o f a ρΙΙΟγ catalytic subunit that 
interacts with a p lO l regulatory subunit. Furthermore, the 
Class Ib enzyme is activated in response to G-protein coupled 
receptor (GPCR) systems as well as by the mechanisms 
described above.
[0011] There is now considerable evidence indicating that 
Class Ia PI3-kinase enzymes, contribute to tumourigenesis in 
a wide variety o f human cancers, either directly or indirectly 
(Vivanco and Sawyers, Nature Reviews Cancer, 2002, 2, 
489-501). In particular, the PIK3CA gene which encodes the 
p i 10a catalytic subunit of PI3-kinase is widely implicated in 
tumourigenesis. Activating point mutations, most frequently 
found in the helical or catalytic domains o f p i 10a, increase 
the PI3-kinase activity o f the holoenzyme and can transform 
cells. They have been reported, particularly, as somatically 
occurring mutations at significant frequencies across a wide 
range o f tumour types (Samuels et al., Science, 2004, 304, 
554; Samuels et al., Cancer Cell, 2005, 7, 561; Engleman et 
al., Nature Review Genetics, 2006,7, 607; Zhao L and Vogt P 
K, Oncogene 2008, 27 5486). Tumour-related mutations in 
p85a have also been identified in cancers such as those o f the 
ovary and colon (Philp et al., Cancer Research, 2001, 61, 
7426-7429). Furthermore, the p i 10a subunit is amplified in
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some tumours such as those of the ovary (Shayesteh et al., 
Nature Genetics, 1999, 21, 99-102) and cervix (Ma et al., 
Oncogene, 2000, 19, 2739-2744).
[0012] In addition to direct effects, it is believed that acti­
vation o f Class Ia PI-3 kinase contributes to tumourigenic 
events that occur upstream in signalling pathways, for 
example by way o f ligand-dependent or ligand-independent 
activation o f receptor tyrosine kinases, GPCR systems or 
integrins (Vara et al., Cancer Treatment Reviews, 2004, 30, 
193-204). Examples o f such upstream signalling pathways 
include over-expression o f the receptor tyrosine kinase Erb2 
in a variety o f tumours leading to activation o f PI 3-kinase- 
mediated pathways (Eiarari et al., Oncogene, 2000, 19, 6102- 
6114) and over-expression o f the oncogene Ras (Kauffmann- 
Zeh et al., Nature, 1997, 385, 544-548). In addition, Class Ia 
PI3-kinases may contribute to tumourigenesis caused by vari­
ous downstream signalling events. For example, loss o f the 
effect o f the PTEN tumour-suppressor phosphatase that 
catalyses conversion o f PI(3,4,5)P3 backto PI(4,5)P2 is asso­
ciated with a very broad range o f tumours via deregulation o f 
PI3-kinase-mediated production o f PI(3,4,5)P3 (Simpson 
and Parsons, Exp. CellRes., 2001, 264, 29-41). Furthermore, 
augmentation o f the effects o f other PI3-kinase-mediated sig­
nalling events is believed to contribute to a variety o f cancers, 
for example by activation o f Akt (Nicholson and Anderson, 
Cellular Signalling, 2002, 14, 381-395).
[0013] Fience the common deregulation o f PI3-kinase 
together with those o f upstream and downstream signalling 
pathways collectively make it one o f the most commonly 
deregulated pathways in human cancer (Fiennessey et al., 
Nature Reviews Drug Discovery, 2005, 4, 988).
[0014] In addition to a role in mediating proliferative and 
survival signalling in tumour cells, there is also good evi­
dence that Class Ia PI3 -kinase enzymes will also contribute to 
tumourigenesis via its function in tumour-associated stromal 
cells. For example, PI3-kinase signalling is known to play an 
important role in mediating angiogenic events in endothelial 
cells in response to pro-angiogenic factors such as VEGF 
(A bidetaL 5Arteno-Scfe?: Thromb. Vase. Biol., 2004, 24, 294- 
300). As Class I PI3-kinase enzymes are also involved in 
motility and migration (Sawyer, Expert Opinion Investig. 
Drugs, 2004, 13, 1-19), PI3-kinase inhibitors should provide 
therapeutic benefit via inhibition o f tumour cell invasion and 
metastasis.
[0015] In addition, Class I PI3-kinase enzymes play an 
important role in the regulation of immune cells with PI3- 
kinase activity contributing to pro-tumourigenic effects o f 
inflammatory cells (Coussens and Werb, Nature, 2002, 420, 
860-867). Indeed, the Class Ia PI3-kinase enzyme, PI3-ki- 
nase δ, is particularly implicated in tumourigenesis in hae- 
matological malignancies, such as Chronic Lymphoctyic 
Leukaemia (CLL), Acute Lymphoblastic Leukaemia (ALL) 
and Mantle Cell Lymphoma (MCL). Elevated-signalling o f 
PI3K (mainly p 110δ) is reported in a wide range o f malignant 
lymphoid cells (Flerman et al., Blood, 2010, 116.2078; Ikeda 
e ta l.,Blood, 2010, 116,1460; U d d in e ta l.,Blood, 2006, 108, 
4178; Rudelius et al., Blood  2006, 108, 1668; Garcia-Mar- 
imez., B r J  Cancer, 2011, 104, 1116; Renne etal., Leukemia, 
2007, 2, 780). This has led to the development o f agents 
targeting PI3-kinase δ, with promising initial clinical results 
in haematological malignancies. (Castillo et al., Expert Opin­
ion on Investigational D rugs, 2012, 21, 15).
[0016] These findings suggest that pharmacological inhibi­
tors o f Class I PI3-kinase enzymes should be o f therapeutic
value for treatment o f the various forms o f the disease of 
cancer comprising solid tumours such as carcinomas and 
sarcomas and the leukaemias and lymphoid malignancies.
[0017] Early studies, both pre-clinical and clinical, explor­
ing the physiological and pathological roles o f the PI3 -kinase 
enzyme, have largely used agents with limited kinase inhibi­
tion selectivity, either stretching across the wider kinase fami­
lies, across the PI3-kinase family, or across the PI3-kinase 
Class I family. Flence, there is a need for more selective 
pharmaceutical PI3-kinase Class I inhibitors to provide use­
ful therapeutic agents with potential to deliver an improved 
therapeutic margin over the initial agents that entered the 
clinic.
[0018] Generally, the compounds o f the present invention 
possess potent inhibitory activity against a subset o f Class I 
PI3-kinase enzymes, particularly against Class Ia PI3-ki- 
nase-α  and -δ isoforms, with relative sparing o f the -γ and 
particularly the -β isoform. The compounds are also selective 
against wider PI3-kinase family and the wider kinome. Such 
compounds possess sufficient potency against Class I PI3- 
kinase enzymes that they may be used in an amount sufficient 
to inhibit a subset o f Class IPI 3-kinase isoforms, particularly 
to inhibit Class Ia PI3-kinase enzymes-α  and -δ, whilst dem­
onstrating little activity against other kinases.
[0019] The understanding o f the deregulation o f PI3-kinase 
signalling in human cancer and other diseases offers the pros­
pect o f targeting a subset o f patients most likely to benefit 
from treatment o f the agents described in this patent, through 
a process known as Personalised Healthcare (PHC) or Per­
sonalised Medicine. For these agents, patients whose disease 
depends on elevated or otherwise altered PI3K -a signalling 
and/or ΡΙ3Κ-δ signalling may particularly benefit from treat­
ment. It is well known in the art that diagnostics can be used 
to provide a response-prediction biomarker readout. Such 
diagnostics could measure one or more readouts o f pathway 
deregulation such as, but not restricted to, mutation in the 
PIK3CA, PTEN or p85 (PIK3R) genes, amplification or 
increased copy number of the PIK3CA gene, overexpression 
or elevated activity o f the PI3K -a and/or -δ isoform, or use of 
a phosphobiomarker readout within the pathway such as 
phospho-RTK or phospho-AKT. In addition, the measure­
ment o f mutation status or activation status o f additional 
genes, such as Kras, a potential marker o f resistance in 
tumours with aberrant or deregulated PIK3CA or PI3K -a 
(Engelman et al., Nature Medicine, 2008 14, p 1351-1355; 
Ihle et al., Cancer Research, 2009, 69, p 143-160; Janku et. 
al., Molecular Cancer Therapeutics, 2011, 10, p558-564), 
could help increase the predictivity o f a Personalised Medi­
cine approach. Alternatively, in another targeted but less spe­
cific approach, the treatment could be focused in disease 
subsets where the deregulation o f the relevant PI3K isoforms 
is known to be most prevalent.
[0020] The compounds described could be used to target 
disease, either alone or in combination with another phara- 
maceutical agent or agents. Combining PI3-kinase inhibitors 
with other therapies may improve efficacy by overcoming 
resistance mechanisms, either innate, or induced in response 
to the PI3-kinase agent. There is substantial pre-clinical data 
to support such an approach (Courtney et al, J  Clin Oncol, 
2010, 28, 1075; Engleman et al., Nature Review Genetics, 
2006, 7, 607). One approach is ‘intra-pathway’ combinations 
with agents modulating other axes in the PI3-kinase signal­
ling pathways (e.g. mTOR, AKT, RTK, other PI3-kinase 
agent). A  second approach is ‘inter-pathway’ combinations
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where inhibition of more than one signalling pathway may be 
beneficial over inhibition of a single pathway (e.g. combined 
with MEK inhibitors, R af inhibitors, Bcl family modulators, 
RTK inhibitors or DNA damage signalling modulators such 
as PARP inhibitors). Other approaches include where the 
PI3 -kinase inhibitor is combined with agents or regimens that 
are already established in clinical practice, so called Standard 
o f Care (SoC) approaches, or combinations with agents tar­
geting non tumour cell mechanisms such as tumour stromal 
cell or via the immune system.
[0021] In addition to tumourigenesis, there is evidence that 
Class I PI3-kinase enzymes play a role in other diseases 
(Wymann et al., Trends in Pharmacological Science, 2003, 
24,366-376). BothClass IaPI3-kinase enzymes, particularly 
PI3K-6, and the single Class Ib enzyme (ΡΙ3Κ-γ) have impor­
tant roles in cells o f the immune system (Koyasu, Nature 
Immunology, 2003, 4, 313-319) and thus they are therapeutic 
targets for inflammatory and allergic indications. Inhibition 
o f PI3-kinase is also, as described earlier, useful to treat 
cardiovascular disease via anti-inflammatory effects or 
directly by affecting cardiac myocytes (Prasad et al., Trends 
in Cardiovascular Medicine, 2003, 13, 206-212). Thus 
inhibitors o f Class I PI3-kinase enzymes may be o f value in 
the prevention and treatment o f a wide variety o f diseases in 
addition to cancer.
[0022] The compounds, i.e. the aminopyrazine derivatives, 
o f the invention have been found to possess potent anti­
tumour activity, being useful in inhibiting the uncontrolled 
cellular proliferation which arises from malignant disease. 
Without wishing to imply that the compounds disclosed in the 
present invention possess pharmacological activity only by 
virtue o f an effect on a single biological process, it is believed 
that the compounds provide an anti-tumour effect by way o f 
inhibition of Class I PI3-kinase enzymes, particularly by way 
o f inhibition o f a subset o f the Class Ia PI3-kinase enzymes, 
more particularly by way o f inhibition o f the PI3K -a and -δ 
isoforms.
[0023] The compounds o f the present invention may also be 
useful in inhibiting the uncontrolled cellular proliferation 
which arises from various non-malignant diseases such as 
inflammatory diseases (for example rheumatoid arthritis and 
inflammatory bowel disease), fibrotic diseases (for example 
hepatic cirrhosis and lung fibrosis), glomerulonephritis, mul­
tiple sclerosis, psoriasis, benign prostatic hypertrophy 
(BPH), hypersensitivity reactions o f the skin, blood vessel 
diseases (for example atherosclerosis andrestenosis), allergic 
asthma, insulin-dependent diabetes, diabetic retinopathy and 
diabetic nephropathy.
[0024] Proline amides have been disclosed as selective 
PI3K -a selective agents by Novartis in International Patent 
Applications W 02009/080705, W 02010/029082 and 
W O2011/000905 Aminopyrazine containing ATR kinase 
inhibitors have been disclosed in W O2011/143426 and 
W 02010/071837 (Vertex).
[0025] According to one aspect o f the invention there is 
provided a compound o f the Formula (I)
(I)
wherein:
R 1 is methyl or ethyl; and
R2 is (C2-3)alkyl substituted by hydroxyl;
or a pharmaceutically-acceptable salt thereof
[0026] In another aspect o f the invention, there is provided 
a compound o f Formula (I) as defined above.
[0027] It will be understood that the term “(C2-3)alkyl 
substituted by hydroxy” includes both straight chain and 
branched alkyl groups, for example those illustrated as 
groups (i) to (xi) below:
(i)
(iii)
HO \
(iv)
OH
(viii)
OH
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-continued
(ix)
OH
(xi)
OH
[0028] It is to be understood that, insofar as certain o f the 
compounds of Formula (I) defined above may exist in opti­
cally active or racemic forms by virtue o f one or more asym­
metric carbon atoms, the invention includes in its definition 
any such optically active or racemic form which possesses 
PI3K -a and -δ inhibitory activity. The synthesis o f optically 
active forms may be carried out by standard techniques o f 
organic chemistry well known in the art, for example by 
synthesis from optically active starting materials or by reso­
lution o f a racemic form. Similarly, the above-mentioned 
activity may be evaluated using the standard laboratory tech­
niques.
[0029] A particular enantiomer o f a compound described 
herein may be more active that other enantiomers o f the same 
compound.
[0030] According to a further aspect o f the invention there 
is provided a compound o f the Formula (I), or a pharmaceu- 
tically-acceptable salt thereof, which is a single enantiomer 
being in an enantiomeric excess (% ee) o f >95, >98% or 
>99%. Conveniently, the single enantiomer is present in an 
enantiomeric excess (% ee) o f >99%.
[0031] According to a further aspect o f the invention there 
is provided a pharmaceutical composition, which comprises a 
compound o f the Formula (I), which is a single enantiomer 
being in an enantiomeric excess (% ee) o f >95, >98% or 
>99% or a pharmaceutically-acceptable salt thereof, in asso­
ciation with a pharmaceutically-acceptable diluent or carrier. 
Conveniently, the single enantiomer is present in an enantio­
meric excess (% ee) o f >99%.
[0032] Some compounds o f Formula (I) may be crystalline 
and may have more than one crystalline form. It is to be 
understood that the present invention encompasses any crys­
talline or amorphous form, or mixtures thereof, which form 
possesses properties useful in the inhibition o f PI3K -a and -δ 
activity, it being well known in the art how to determine 
efficacy o f a crystalline or amorphous form for the inhibition 
o f PI3K -a and/or -δ activity by the standard tests described 
hereinafter.
[0033] It is generally known that crystalline materials may 
be analysed using conventional techniques such as X-Ray 
PowderDiffraction (hereinafter XRPD) analysis, Differential 
Scanning calorimetry (hereinafter DSC), Thermal Gravimet­
ric Analysis (hereinafter TGA), Diffuse Reflectance Infrared 
Fourier Transform (DRIFT) spectroscopy, Near Infrared 
(NIR) spectroscopy, solution and/or solid state nuclear m ag­
netic resonance spectroscopy. The water content o f such crys­
talline materials may be determined by Karl Fischer analysis.
[0034] As an example, the compound o f Example I exhib­
its crystallinity and one crystalline form has been identified.
[0035] Accordingly, a further aspect o f the invention is 
Form A of l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol- 
2-yl)pyrazin-2-yl)-l-m ethyl-IH -1,2,4-triazol-3-yl)piperi- 
din-1 -yl)-3-hydroxypropan-l -one.
[0036] According to a further aspect o f the present inven­
tion, there is provided a crystalline form, Form A of I -(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-1 -methyl-1H -1,2,4-triazol-3 -yl)piperidin-1 -yl)-3 - 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with at least one specific peak at about 
2-theta=5.1°.
[0037] According to a further aspect o f the present inven­
tion, there is provided a crystalline form, Form A of I -(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-1 -methyl-1H -1,2,4-triazol-3 -yl)piperidin-1 -yl)-3 - 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with at least one specific peak at about 
2-theta=18.0°.
[0038] According to a further aspect o f the present inven­
tion, there is provided a crystalline form, Form A of I -(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-1 -methyl-1H -1,2,4-triazol-3 -yl)piperidin-1 -yl)-3 - 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with at least two specific peaks at about 
2-theta=5.1 and 18.0°.
[0039] According to a further aspect o f the present inven­
tion there is provided a crystalline form, Form A  o f 1-(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-1 -methyl-1H -1,2,4-triazol-3 -yl)piperidin-1 -yl)-3 - 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with specific peaks at about 2-theta=5.1,
18.0, 10.2, 11.7, 19.4, 18.5, 14.8, 26.7, 26.6, 17.8°.
[0040] According to the present invention there is provided 
crystalline form, Form A which has an X-ray powder diffrac­
tion pattern substantially the same as the X-ray powder dif­
fraction pattern shown in FIG. I.
[0041] According to a further aspect o f the present inven­
tion, there is provided a crystalline form, Form A of I -(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-1 -methyl-1H -1,2,4-triazol-3 -yl)piperidin-1 -yl)-3 - 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with at least one specific peak at about 
2-theta=5.1° plus or minus 0.2° 2-theta.
[0042] According to a further aspect o f the present inven­
tion, there is provided a crystalline form, Form A of I -(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-1 -methyl-1H -1,2,4-triazol-3 -yl)piperidin-1 -yl)-3 - 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with at least one specific peak at about 
2-theta=18.0° plus or minus 0.2° 2-theta.
[0043] According to a further aspect o f the present inven­
tion, there is provided a crystalline form, Form A of I -(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-1 -methyl-1H -1,2,4-triazol-3 -yl)piperidin-1 -yl)-3 - 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with at least two specific peaks at about 
2-theta=5.1 and 18.0° plus or minus 0.2° 2-theta.
[0044] According to a further aspect o f the present inven­
tion there is provided a crystalline form, Form A  o f 1-(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-
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yl)-l-m ethyl-lH-l,2,4-triazol-3-yl)piperidin-l-yl)-3- 
hydroxypropan-l-one, which has an X-ray powder 
diffraction pattern with specific peaks at about 2-theta=5.1,
18.0, 10.2, 11.7, 19.4, 18.5, 14.8, 26.7, 26.6, 17.8° plus or 
minus 0.2° 2-theta.
[0045] Example 3 is also crystalline and three forms (A, B 
and C) are described herein.
[0046] According to the present invention there is provided 
a crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at about 2-theta=4.8°.
[0047] According to the present invention there is provided 
a crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at about 2-theta=10.0°.
[0048] According to the present invention there is provided 
a crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least two 
specific peaks at about 2-theta=4.8° and 10.0°.
[0049] According to the present invention there is provided 
a crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with specific peaks at 
about 2-theta=4.8,10.0,14.6,5.2,19.9,10.4,25.4,23.6,24.4, 
16.2°.
[0050] According to the present invention there is provided 
crystalline form, Form A of I -(4-(5-(5-amino-6-(5-tert-butyl-
l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4-tria- 
zol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which has 
an X-ray powder diffraction pattern substantially the same as 
the X-ray powder diffraction pattern shown in FIG. 3.
[0051] According to the present invention there is provided 
crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert-bu- 
tyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at 2-theta=4.8° plus or minus 0.2° 2-theta.
[0052] According to the present invention there is provided 
a crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at 2-theta=10.0° plus or minus 0.2° 2-theta.
[0053] According to the present invention there is provided 
a crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least two 
specific peaks at 2-theta=4.8° and 10.0° wherein said values 
may be plus or minus 0.2° 2-theta.
[0054] According to the present invention there is provided 
a crystalline form, Form A, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with specific peaks at 
2-theta=4.8,10.0,14.6,5.2,19.9,10.4,25.4,23.6,24.4,16.2° 
wherein said values may be plus or minus 0.2° 2-theta.
[0055] According to the present invention there is provided 
a crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at about 2-theta=5.8°.
[0056] According to the present invention there is provided 
a crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at about 2-theta=10.9°.
[0057] According to the present invention there is provided 
a crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least two 
specific peaks at about 2-theta=5.8° and 10.9°.
[0058] According to the present invention there is provided 
a crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with specific peaks at 
about 2-theta=5.8, 10.9, 11.5, 25.9, 17.3, 24.0, 19.1, 12.9, 
24.7, 27.2°.
[0059] According to the present invention there is provided 
crystalline form, Form B o f I -(4-(5-(5-amino-6-(5-tert-butyl-
l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4-tria- 
zol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which has 
an X-ray powder diffraction pattern substantially the same as 
the X-ray powder diffraction pattern shown in FIG. 5.
[0060] According to the present invention there is provided 
crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert-bu- 
tyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at 2-theta=5.8° plus or minus 0.2° 2-theta.
[0061] According to the present invention there is provided 
a crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at 2-theta=10.9° plus or minus 0.2° 2-theta.
[0062] According to the present invention there is provided 
a crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least two 
specific peaks at 2-theta=5.8° and 10.9° wherein said values 
may be plus or minus 0.2° 2-theta.
[0063] According to the present invention there is provided 
a crystalline form, Form B, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with specific peaks at 
2-theta=5.8, 10.9, 11.5, 25.9, 17.3, 24.0, 19.1, 12.9, 24.7, 
27.2° wherein said values may be plus or minus 0.2° 2-theta.
[0064] According to the present invention there is provided 
a crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at about 2-theta=6.9°.
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[0065] According to the present invention there is provided 
a crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at about 2-theta=12.3°.
[0066] According to the present invention there is provided 
a crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least two 
specific peaks at about 2-theta=6.9° and 12.3°.
[0067] According to the present invention there is provided 
a crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with specific peaks at 
about 2-theta=6.9, 12.3, 10.5, 21.0, 24.6, 13.6, 16.4, 19.6, 
20.2, 22.5°.
[0068] According to the present invention there is provided 
crystalline form, Form C o f l-(4-(5-(5-amino-6-(5-tert-butyl-
l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4-tria- 
zol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which has 
an X-ray powder diffraction pattern substantially the same as 
the X-ray powder diffraction pattern shown in FIG. 7.
[0069] According to the present invention there is provided 
crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert-bu- 
tyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at 2-theta=6.9° plus or minus 0.2° 2-theta.
[0070] According to the present invention there is provided 
a crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least one 
specific peak at 2-theta=12.3° plus or minus 0.2° 2-theta.
[0071] According to the present invention there is provided 
a crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with at least two 
specific peaks at 2-theta=6.9° and 12.3° wherein said values 
may be plus or minus 0.2° 2-theta.
[0072] According to the present invention there is provided 
a crystalline form, Form C, o f l-(4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one which 
has an X-ray powder diffraction pattern with specific peaks at 
2-theta=6.9, 12.3, 10.5, 21.0, 24.6, 13.6, 16.4, 19.6, 20.2, 
22.5° wherein said values may be plus or minus 0.2° 2-theta.
[0073] W hen it is stated that the present invention relates to 
a crystalline form o f a compound o f the invention, such as 
Example I or Example 3, the degree of crystallinity is con­
veniently greater than about 60%, more conveniently greater 
than about 80%, preferably greater than about 90% and more 
preferably greater than about 95%. Most preferably the 
degree of crystallinity is greater than about 98%.
[0074] W hen it is stated that the present invention relates to 
a crystalline form o f a compound o f the invention, such as 
Example I or Example 3, the crystalline form is preferably 
substantially free o f other crystalline forms or amorphous 
form of the same compound. In this context, “substantially 
free” conveniently means greater than about 60%, more con­
veniently greater than about 80%, preferably greater than 
about 90%, more preferably greater than about 95%, still 
more preferable greater than about 98% and even more pref­
erably greater than about 99% pure single crystalline form. 
For example, Example 3 may be in the form o f Form A and 
substantially free o f forms B and C; alternatively, Example 3 
may be in the form of Form B and substantially free o f forms 
A  and C; alternatively Example 3 may be in the form o f Form 
C and substantially free of forms A and B . Similarly, Example
3 may be in the form o f Form B and substantially free of 
alternative crystalline or amorphous forms.
[0075] It will be understood that 2-theta values o f the X-ray 
powder diffraction patterns may vary slightly from one 
machine to another or from one sample to another, and so the 
values quoted are not to be construed as absolute.
[0076] It is known that an X-ray powder diffraction pattern 
may be obtained which has one or more measurement errors 
depending on measurement conditions (such as equipment or 
machine used). In particular, it is generally known that inten­
sities in an X-ray powder diffraction pattern may fluctuate 
depending on measurement conditions. Therefore it should 
be understood that the crystalline Forms o f the present inven­
tion described above, unless otherwise stated, are not limited 
to the crystals that provide X-ray powder diffraction patterns 
identical to the X-ray powder diffraction pattern shown in 
FIGS. I, 3, 5 and any crystals providing X-ray powder dif­
fraction patterns substantially the same as those shown in 
these Figures fall within the scope o f the present invention. A 
person skilled in the art o f X-ray powder diffraction is able to 
judge the substantial identity o f X-ray powder diffraction 
patterns.
[0077] Persons skilled in the art o f X-ray powder diffrac­
tion will also realise that the relative intensity o f peaks can be 
affected by, for example, grains above 30 microns in size and 
non-unitary aspect ratios, which may affect analysis o f 
samples. The skilled person will also realise that the position 
o f reflections can be affected by the precise height at which 
the sample sits in the diffractometer and the zero calibration 
o f the diffractometer. The surface planarity o f the sample may 
also have a small effect. Flence the diffraction pattern data 
presented are not to be taken as absolute values (see Jenkins, 
R & Snyder, R. L. ‘Introduction to X-Ray Powder Diffracto- 
metry’ JohnW iley & Sons 1996; Bunn, C. W. (1948), Chemi­
cal Crystallography, Clarendon Press, London; Klug, H. P. & 
Alexander, L. E. (1974), X-Ray Diffraction Procedures).
[0078] Generally, a measurement error o f a diffraction 
angle in an X-ray powder diffractogram is approximately plus 
or minus 0.2° 2-theta, and such degree of a measurement error 
should be taken into account when considering the X-ray 
powder diffraction data. Furthermore, it shouldbe understood 
that intensities might fluctuate depending on experimental 
conditions and sample preparation (preferred orientation).
[0079] Particular compounds o f the invention are each of 
the Examples, each o f which provides a further independent 
aspect o f the invention. Further particular compounds of the 
invention are pharmaceutically-acceptable salt(s) o f each of 
the Examples, each o f which provides a further independent 
aspect o f the invention.
[0080] According to a further aspect o f the invention there 
is provided a compound of the Formula (I), which is obtain­
able by following any o f the Examples as disclosed herein.
[0081] A further feature is any o f the scopes defined herein 
with the proviso that specific Examples, such as Example 1,3,
4 etc. are individually disclaimed.
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[0082] It will be appreciated by those skilled in the art that 
certain compounds o f Formula (I) contain asymmetrically 
substituted carbon atoms, and accordingly may exist in, and 
be isolated in, optically-active and racemic forms. Some com­
pounds o f Formula (I) may exhibit polymorphism. It is to be 
understood that the present invention encompasses any race­
mic, optically-active, polymorphic or stereoisomeric form, or 
mixtures thereof, which form possesses properties useful in 
the inhibition o f PI3K -a and -δ activity, it being well known 
in the art how to prepare optically-active forms (for example, 
by resolution of the racemic form by recrystallization tech­
niques, by synthesis from optically-active starting materials, 
by chiral synthesis, by enzymatic resolution, by biotransfor­
mation, or by chromatographic separation using a chiral sta­
tionary phase) and how to determine efficacy for the inhibi­
tion o f PI3K -a and -δ activity by the standard tests described 
hereinafter.
[0083] It is to be understood that certain compounds o f 
Formula (I) defined above may exhibit the phenomenon o f 
tautomerism. It is to be understood that the present invention 
includes in its definition any such tautomeric form, or a mix­
ture thereof, which possesses PI3K inhibitory activity and is 
not to be limited merely to any one tautomeric form utilised 
within the formulae drawings or named in the Examples. In 
general, just one o f any such tautomeric forms is named in the 
Examples that follow hereinafter or is presented in any rel­
evant formulae drawings that follow hereinafter.
[0084] The present invention is intended to include all iso­
topes o f atoms occurring in the present compounds. Isotopes 
will be understood to include those atoms having the same 
atomic number but different mass numbers. For example, 
isotopes o f hydrogen include tritium and deuterium. Isotopes 
o f carbon include 13C and 14C.
[0085] A suitable pharmaceutically-acceptable salt o f a 
compound o f the Formula (I) is, for example, an acid-addition 
salt o f a compound o f the Formula (I), for example an acid- 
addition salt with a strong inorganic or organic acid such as 
hydrochloric, hydrobromic, sulphuric or trifluoroacetic acid. 
A  further suitable pharmaceutically-acceptable salt o f a com­
pound of the Formula (I) is, for example, a salt formed within 
the human or animal body after administration o f a compound 
o f the Formula (I).
[0086] It is further to be understood that a suitable pharma­
ceutically-acceptable solvate o f a compound of the Formula 
(I) also forms an aspect o f the present invention. A  suitable 
pharmaceutically-acceptable solvate is, for example, a 
hydrate such as a hemi-hydrate, a mono-hydrate, a di-hydrate 
or a tri -hydrate or an alternative quantity thereof.
[0087] It is further to be understood that a suitable pharma­
ceutically-acceptable pro-drug o f a compound o f the Formula 
(I) also forms an aspect o f the present invention. Accordingly, 
the compounds of the invention may be administered in the 
form o f a pro-drug, which is a compound that is broken down 
in the human or animal body to release a compound of the 
invention. A  pro-drug may be used to alter the physical prop­
erties and/or the pharmacokinetic properties o f a compound 
o f the invention. A  pro-drug can be formed when the com­
pound o f the invention contains a suitable group or substitu­
ent to which a property-modifying group can be attached. 
Examples o f pro-drugs include in-vivo cleavable ester deriva­
tives that may be formed at a hydroxy group in a compound o f 
the Formula (I), and in-vivo cleavable amide derivatives that 
may be formed at an amino group in a compound o f Formula
(I)·
[0088] Accordingly, the present invention includes those 
compounds of the Formula (I) as defined hereinbefore when 
made available by oiganic synthesis and when made available 
within the human or animal body by way o f cleavage of a 
pro-drug thereof. Accordingly, the present invention includes 
those compounds o f the Formula (I) that are produced by 
oiganic synthetic means and also such compounds that are 
produced in the human or animal body by way o f metabolism 
o f a precursor compound, that is a compound o f the Formula
(I) may be a synthetically-produced compound or a metaboli- 
cally-produced compound.
[0089] A suitable pharmaceutically-acceptable pro-drug of 
a compound of the Formula (I) is one that is based on reason­
able medical judgement as being suitable for administration 
to the human or animal body without undesirable pharmaco­
logical activities and without undue toxicity.
[0090] Various forms o f pro-drug have been described, for 
example in the following documents:—
[0091] a) Methods in Enzymology, Vol. 42, p. 309-396, 
edited by K. Widder, et al. (Academic Press, 1985);
[0092] b) Design o f Pro-drugs, edited by H. Bundgaard, 
(Elsevier, 1985);
[0093] c) A  Textbook o f Drug Design and Development, 
edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 
“Design and Application o f Pro-drugs”, by H. Bundgaard 
p. 113-191 (1991);
[0094] d) H. Bundgaard, Advanced Drug Delivery Reviews, 
8, 1-38 (1992);
[0095] e) H. Bundgaard, et al., Journal o f  Pharmaceutical 
Sciences, 77, 285 (1988);
[0096] f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 
(1984);
[0097] g) T. Higuchi and V. Stella, “Pro-Drugs as Novel 
Delivery Systems”, A.C.S. Symposium Series5Volume 14; 
and
[0098] h) E. Roche (editor), “Bioreversible Carriers in 
Drug Design”, Pergamon Press, 1987.
[0099] A suitable pharmaceutically-acceptable pro-drug of 
a compound o f the Formula (I) that possesses a hydroxy 
group is, for example, an in vivo cleavable ester or ether 
thereof. An in vivo cleavable ester or ether o f a compound of 
the Formula (I) containing a hydroxy group is, for example, a 
pharmaceutically-acceptable ester or ether which is cleaved 
in the human or animal body to produce the parent hydroxy 
compound. Suitable pharmaceutically-acceptable ester form­
ing groups for a hydroxy group include inoiganic esters such 
as phosphate esters (including phosphoramidic cyclic esters). 
Further suitable pharmaceutically-acceptable ester forming 
groups for a hydroxy group include (I-10C)alkanoyl groups 
such as acetyl, benzoyl, phenylacefyl and substituted benzoyl 
and phenylacefyl groups, ( I - I OQalkoxycarbonyl groups 
such as ethoxycarbonyl, N,N-[di-(l-4C)alkyl]carbamoyl, 
2-dialkylaminoacefyl and 2-carboxyacetyl groups. Examples 
o f ring substituents on the phenylacefyl and benzoyl groups 
include aminomethyl, N-alkylaminomethyl, N,N-dialky- 
laminomethyl, morpholinomethyl, piperazin-l-ylmethyl and 
4-(l-4C)alkylpiperazin-l-ylmethyl. Suitable pharmaceuti- 
cally-acceptable ether forming groups for a hydroxy group 
include α -acyloxyalkyl groups such as acetoxymethyl and 
pivaloyloxymethyl groups.
[0100] A suitable pharmaceutically-acceptable pro-drug of 
a compound o f the Formula (I) that possesses an amino group 
is, for example, an in vivo cleavable amide derivative thereof. 
Suitable pharmaceutically-acceptable amides from an amino
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group include, for example an amide formed with (1-10C) 
alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and 
substituted benzoyl and phenylacetyl groups. Examples o f 
ring substituents on the phenylacetyl and benzoyl groups 
include aminomethyl, N-alkylaminomethyl, N,N-dialky- 
laminomethyl, morpholinomethyl, piperazin-l-ylmethyl and 
4-(l-4C)alkylpiperazin-l-ylmethyl.
[0101] The in vivo effects o f a compound of the F ormula (I) 
may be exerted in part by one or more metabolites that are 
formed within the human or animal body after administration 
o f a compound o f the Formula (I). As stated hereinbefore, the 
in vivo effects o f a compound o f the Formula (I) may also be 
exerted by way o f metabolism o f a precursor compound (a 
pro-drug).
[0102] Compounds o f Formula (I) contain a piperidine sub­
unit substituted by — C(O)R2, wherein R2 is (C2-3)alkyl sub­
stituted by hydroxyl. One potential route o f metabolism o f 
these compounds is by oxidation of the hydroxyl substituent 
on this group. These oxidised compounds generally retain 
some PI3K -a and -δ inhibitory activity.
[0103] Therefore, according to a further aspect o f the inven­
tion there is provided a compound o f the formula (A):
(A)
and Example 9 which is an identified metabolite o f Example 
3:
Example 9
HO·
NH-
[0105] Further potential metabolites o f Example 3 are two 
alternative oxidation products, shown below and further 
described in Examples 10 and 11:
N— N
NH-
wherein:
R 1j4 is methyl or ethyl; and
K2a is (Cl-2)alkyl substituted by carboxy;
or a pharmaceutically-acceptable salt thereof
[0104] Examples o f compounds of Formula (A) include 
Example 8, which is an identified metabolite o f Example I.
Example 8
HO·
NH-
HO
Example 10
HO
Example 11
[0106] Suitable pharmaceutically-acceptable salts o f com­
pounds o f formula (A) include for example an alkali or alka­
line earth metal salt such as a calcium or magnesium salt, or 
an ammonium salt, or a salt with an organic base such as
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methylamine, dimethylamine, trimethylamine, piperidine, 
morpholine or tris-(2-hydroxyethyl)amine.
[0107] For the avoidance o f doubt it is to be understood that 
where in this specification a group is qualified by ‘hereinbe­
fore defined’ or ‘defined hereinbefore’ the said group encom­
passes the first occurring and broadest definition as well as 
each and all o f the particular definitions for that group.
[0108] Particular novel compounds o f the invention 
include, for example, compounds o f the Formula (I), or phar­
maceutically-acceptable salts thereof, wherein, unless other­
wise stated, each o f R 1 and R2, has any of the meanings 
defined hereinbefore or in the following statements:
[0109] R 1 is methyl.
[0110] R 1 is ethyl.
[0111] R2 is any o f groups (i) to (xi) as hereinbefore 
defined.
[0112] R2 is groups (i) to (vi) as hereinbefore defined.
[0113] R2 is group (i).
[0114] A particular group of compounds o f the invention 
are compounds o f Formula (I) above wherein:—
R 1 is methyl or ethyl,
R2 is group (i):
(i)
HO
or a pharmaceutically-acceptable salt thereof
[0115] Particular compounds of the invention are, for 
example, the compounds o f the Formula (I) that are disclosed 
within the Examples that are set out hereinafter.
[0116] For example, a particular compound of the invention 
is a compound of the Formula (I) selected from any one of the 
following:—
[0117] l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol- 
2-yl)pyrazin-2-yl]-1 -methyl-1,2,4-triazol-3-yl]-1 -pip- 
eridyl]-3-hydroxy-propan-l-one (Example I and 2);
[0118] l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol- 
2-yl)pyrazin-2-yl] -1 -ethyl-1,2,4-triazol-3 -yl] -1 -pip- 
eridyl]-3-hydroxy-propan-l-one (Example 3);
[0119] (3R)-l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxa- 
diazol-2-yl)pyrazin-2-yl]-l-methyl-l,2,4-triazol-3-yl]-l- 
piperidyl]-3-hydroxy-butan-l-one (Example 4);
[0120] (3S)-1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxa- 
diazol-2-yl)pyrazin-2-yl]-l-methyl-l,2,4-triazol-3-yl]-l- 
piperidyl]-3-hydroxy-butan-l-one (Example 5);
[0121] (2R)-l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxa- 
diazol-2-yl)pyrazin-2-yl]-l-methyl-l,2,4-triazol-3-yl]-l- 
piperidyl]-3-hydroxy-2-methyl-propan-l -one (Example 
6);
[0122] l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-
2-yl)pyrazin -2-yl]-1 -methyl-1,2,4-triazol-3-yl]-1 -pip- 
eridyl]-2-hydroxy-2-methyl-propan-l-one (Example I).
[0123] Another aspect o f the present invention provides a 
process for preparing a compound o f the Formula (I), or a 
pharmaceutically-acceptable salt thereof. A  suitable process 
is illustrated by the following representative process variants 
in which, unless otherwise stated, R 1, R2 have any o f the 
meanings defined hereinbefore. Necessary starting materials 
may be obtained by standard procedures o f organic chemis­
try. The preparation o f such starting materials is described in 
conjunction with the following representative process vari­
ants and within the accompanying Examples. Alternatively, 
necessary starting materials are obtainable by analogous pro­
cedures to those illustrated which are within the ordinary skill 
o f an organic chemist.
[0124] Suitable process variants include, for example, the 
following:
(a) The reaction, conveniently in the presence o f a suitable 
activating reagent, o f a compound of the Formula II
Rl
N —  N
HN
wherein R 1 has any o f the meanings defined hereinbefore, 
with the carboxylic acid R2— COOFl except that any func­
tional group is protected if  necessary, in the presence o f a 
suitable base, whereafter any protecting group that is present 
is removed.
[0125] Suitable coupling agents forthis reaction include for 
example, 0 -(7 -azabenzotriazol-1 -yl)-N,N,N',N'-tetramethy- 
luronium hexafluorophosphate, TBTU (2-(UT-benzo[d][l,2,
3 ]triazol-l-y l)-l,1,3,3-tetramethylisouronium tetrafluorobo- 
rate) or l-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride ion the presence o f 2-hydroxy-pyridine N-ox- 
ide.
[0126] The reaction is conveniently carried out in the pres­
ence of a suitable base. A  suitable base is, for example, an 
oiganic amine base such as, for example, pyridine, 2,6-luti- 
dine, collidine, 4-dimethylaminopyridine, triethylamine, 
N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, 
diisopropylethyl amine, or, for example, an alkali or alkaline 
earth metal carbonate or hydroxide, for example sodium car­
bonate, potassium carbonate, calcium carbonate, sodium 
hydroxide or potassium hydroxide; preferably N-ethyl-N,N- 
diisopropylamine.
[0127] The reaction is conveniently carried out in the pres­
ence o f a suitable inert solvent such as for example, acetoni- 
trile, Ν,Ν-dimethylformamide, N-methylpyrrolidone, tet- 
rahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, 
toluene, xylene, methanol, ethanol, halogenated solvents 
such as dichloromethane, chloroform or carbon tetrachloride 
and at a temperature in the range, for example -50° C. to 100° 
C., preferably in the range 0° C. to 30° C.
[0128] Alternatively, the carboxylic acid R2— COOFl may 
be transformed into an activated species, which can then be 
reacted with a compound of the Formula II under conditions 
well known in the art.
[0129] A suitable protecting group for the hydroxyl group 
is the tetrahydropyran protecting group, as described in 
Example 2 and 3.
[0130] Suitable conditions for removing this group include 
mild acidic conditions in the presence of an alcohol as the 
solvent at temperature between 20 to 70° C., such as methanol 
or ethanol. A  typical mild acid used is pyridine p-toluene- 
sulfonate.
US 2014/0206700 Al
10
Jul. 24, 2014
[0131] A compound o f Formula II can be obtained from 
reaction o f compound o f Formula III:
III
N — N
P—
where P is a protecting group, such as tert-butoxycarbonyl, 
with an compound o f Formula R 1-L when L is a suitable 
leaving group such as for example, a halogeno group such as 
a bromo, iodo group (conveniently iodo), in the presence o f a 
suitable base, whereafter any protecting group that is present 
is removed.
[0132] A suitable base is, for example, an organic amine 
base, such as l,8-diazabicyclo[5.4.0]undec-7-ene.
[0133] The reaction is conveniently carried out in the pres­
ence of a suitable inert solvent such as for example 2-meth- 
yltetrahydrofuran, tetrahydrofuran, 1,4-dioxane, 1,2- 
dimethoxyethane, benzene, toluene, xylene, and at a 
temperature in the range, for example -50° C. to 60° C., 
preferably in the range -10° C. to 0° C.
[0134] Suitable conditions for deprotection o f the tert-bu- 
toxycarbonyl include acidic conditions such as trifluoroacetic 
acid in an inert solvent such as dichloromethane at approxi­
mately room temperature (20-25° C.).
[0135] Compound III canbe obtained from a coupling reac­
tion in the presence of a suitable activating reagent, o f com­
pound o f Formula IV
IV
with a compound o f Formula V
V
preferably in the presence of a suitable base, followed by a 
cyclisation reaction in the presence of a mild acid.
[0136] The coupling reaction can be carried out in the pres­
ence o f a suitable coupling agent such as, for example, 0 -(7- 
azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate or TBTU (2-(lFi-benzo[d][l,2,3]tria- 
zol-1 -y l)-l, 1,3,3-tetramethylisouronium tetrafluoroborate).
[0137] The coupling reaction is conveniently carried out in 
the presence o f a suitable base. A  suitable base is, for 
example, an organic amine base such as, for example, pyri­
dine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, tri- 
ethylamine, N-methylmorpholine, diazabicyclo[5.4.0]un- 
dec-7-ene, diisopropylethyl amine, or, for example, an alkali 
or alkaline earth metal carbonate or hydroxide, for example 
sodium carbonate, potassium carbonate, calcium carbonate, 
sodium hydroxide or potassium hydroxide; preferably 
N -ethy 1-N,N-dii sopropy lamine.
[0138] The coupling reaction is conveniently carried out in 
the presence o f a suitable inert solvent such as for example, 
N,N-dimethylacetamide, Ν ,Ν-dimethylformamide, N-meth- 
ylpyrrolidone, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxy- 
ethane, benzene, toluene, xylene, methanol, ethanol, haloge- 
nated solvents such as dichloromethane, chloroform or 
carbon tetrachloride and at a temperature in the range, for 
example -50° C. to 100° C., preferably in the range 0° C. to 
30° C.
[0139] The cyclisation conditions are carried out in the 
presence o f a mild acid, typically acetic acid. The reaction is 
conveniently carried out in the presence o f a suitable inert 
solvent such as for example, N,N-dimethylacetamide, Ν ,Ν- 
dimethylformamide, N-methylpyrrolidone, tetrahydrofuran,
1,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylene 
at a temperature in the range, for example 50° C. to 150° C., 
preferably in the range 80° C. to 100° C.
[0140] Compound IV can be obtained from a reaction of 
compound o f Formula VI with hydrazine.
VI
N —  N
[0141] This reaction is conveniently carried out in the pres­
ence o f a suitable inert solvent such as for example tetrahy­
drofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, tolu­
ene, xylene or an alcohol such as ethanol or isopropanol at a 
temperature in the range, for example 20° C. to 70° C., pref­
erably around 50° C .
[0142] CompoundVI can be obtained from a metal-cataly- 
sed reaction o f compound o f Formula VII with a source of 
cyanide such zinc (II) dicyanide.
VII
Br.
[0143] A suitable catalyst for the reaction includes, for 
example, a metallic catalyst such as palladium(O), for 
example tetrakis(triphenylphosphine)palladium(0); or a cata­
lyst formed in-situ from a palladium (II) salt, for example 
palladium(II) acetate, palladium(II) chloride, palladium(II) 
bromide, bis(triphenylphosphine)palladium(II) chloride, 
[l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium
(II), or tris(dibenzilideneacetone)dipalladium, and a phos- 
phine ligand, for example, dicyclohexyl(2',4',6'-triisopropyl-
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biphenyl-2-yl)phosphine. The reaction is conveniently 
carried out in a suitable solvent such as, N,N-dimethylaceta- 
mide, Ν ,Ν-dimethylformamide,tetrahydrofuran, 1,4-diox­
ane, 1,2-dimethoxyethane, benzene, toluene or xylene and at 
a temperature in the range, for example 20° C. to 150° C., 
preferably in the range 60° C. to 120° C. The reaction is also 
conveniently carried out in the presence o f additional metal, 
such as zinc.
[0144] Suitable reactions of this type are described in 
‘Metal-Catalyzed Cross-Coupling Reactions’, Second Edi­
tion, Edited by Armin Meijere, Francois Diederich, Wiley- 
VCH, 2004).
[0145] Syntheses o f Compound VII have been described in 
Examples I and 2.
[0146] Alternatively, a compound of Formula II can be 
obtained by metal-catalysed reaction of compound VIII, 
where R is a small alkyl and compound IX, where P is a 
protecting group, such as tert-butoxycarbonyl,
VIII
R1Sn
IX
P —  X
[0147] A suitable catalyst for the reaction includes, for 
example, a metallic catalyst such as palladium(O), for 
example tetrakis(triphenylphosphine)palladium(0); or a cata­
lyst formed in-situ from a palladium (II) salt, for example 
palladium(II) acetate, palladium(II) chloride, palladium(II) 
bromide, bis(triphenylphosphine)palladium(II) chloride, 
[ I , r-bis(diphenylphosphino)ferrocene]dichloropalladium 
(II), or tris(dibenzilideneacetone)dipalladium, and a phos- 
phine ligand, for example, dicyclohexyl(2',4',6'-triisopropyl- 
biphenyl-2-yl)phosphine.
[0148] The reaction is conveniently carried out in a suitable 
solvent such as, N,N-dimethylacetamide, Ν ,Ν-dimethylfor­
mamide,tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 
benzene, toluene or xylene or an alcohol such as 4-methyl-2- 
pentanol at a temperature in the range, for example 50° C. to 
180° C., preferably in the range 120° C. to 150° C.
[0149] The reaction is also conveniently carried out in the 
presence o f additional salt such as lithium chloride.
[0150] Suitable reactions of this type are described in 
‘Metal-Catalyzed Cross-Coupling Reactions’, Second Edi­
tion, Edited by Armin Meijere, Francois Diederich, Wiley- 
VCH, 2004).
[0151] A compound o f Formula VIII can be obtained from 
metal-catalysed reaction o f compound VII with a suitable 
hexa-alkyl distannane. A  suitable catalyst for the reaction 
includes, for example, a metallic catalyst such as palladium
(0), for example tetrakis(triphenylphosphine)palladium(0); 
or a catalyst formed in-situ from a palladium (II) salt, for 
example palladium(II) acetate, palladium(II) chloride, palla- 
dium(II) bromide, bis(triphenylphosphine)palladium(II) 
chloride, [l,l'-bis(diphenylphosphino)ferrocene]dichloro-
palladium(II), or tris(dibenzilideneacetone)dipalladium, and 
a phosphine ligand, for example, dicyclohexyl(2',4',6'-triiso- 
propy lbiphenyl -2 -y l)pho sphine.
[0152] The reaction is conveniently carried out in a suitable 
solvent such as, N,N-dimethylacetamide, Ν ,Ν-dimethylfor­
mamide, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxy­
ethane, benzene, toluene, xylene or an alcohol such as 4-me- 
thyl-2-pentanol at a temperature in the range, for example 50° 
C. to 100° C., preferably in the range 70° C. to 80° C.
[0153] Compound o f Formula IX can be obtained from 
commercially available material in a few steps, as illustrated 
in Example I (with R 1=Me and P=tert-butoxycarbonyl).
[0154] It is to be understood that other permutations of the 
process steps in the process variants described above are also 
possible.
[0155] It is to be understood that any compound o f Formula 
(I) obtained by any o f the processes described hereinbefore 
can be converted into another compound o f the Formula (I) if  
required.
[0156] W hen a pharmaceutically-acceptable salt o f a com­
pound o f the Formula (I) is required, for example an acid- 
addition salt, it may be obtained by, for example, reaction of 
said compound with a suitable acid.
[0157] W hen a pharmaceutically-acceptable pro-drug of a 
compound o f the Formula (I) is required, it may be obtained 
using a conventional procedure. For example, an in vivo 
cleavable ester o f compound of the Formula (I) may be 
obtained by, for example, reaction o f a compound o f the 
Formula (I) containing a hydroxy group with a pharmaceuti­
cally-acceptable carboxylic acid. Furtherinformation on pro­
drugs has been provided hereinbefore.
[0158] It will also be appreciated that, in some o f the reac­
tions mentioned hereinbefore, it may be necessary or desir­
able to protect any sensitive groups in the compounds. The 
instances where protection is necessary or desirable, and suit­
able methods for protection, are known to those skilled in the 
art. Conventional protecting groups may be used in accor­
dance with standard practice (for illustration see T.W. Green, 
Protective Groups in Organic Synthesis, John Wiley and 
Sons, 1991). Thus, if  reactants include groups such as amino, 
carboxy or hydroxy, it may be desirable to protect the group 
in some of the reactions mentioned herein.
[0159] A suitable protecting group for an amino or alky- 
lamino group is, for example, an acyl group, for example an 
alkanoyl group such as acetyl, an alkoxycarbonyl group, for 
example a methoxycarbonyl, ethoxycarbonyl or t-butoxycar­
bonyl group, an arylmethoxycarbonyl group, for example 
benzyloxycarbonyl, or an aroyl group, for example benzoyl. 
The deprotection conditions for the above protecting groups 
necessarily vary with the choice o f protecting group. Thus, 
for example, an acyl group such as an alkanoyl or alkoxycar­
bonyl group or an aroyl group may be removed for example, 
by hydrolysis with a suitable base such as an alkali metal 
hydroxide, for example lithium or sodium hydroxide. Alter­
natively an acyl group such as a t-butoxycarbonyl group may 
be removed, for example, by treatment with a suitable acid as 
hydrochloric, sulphuric or phosphoric acid or trifluoroacetic 
acid and an arylmethoxycarbonyl group such as a benzyloxy- 
carbonyl group may be removed, for example, by hydroge­
nation over a catalyst such as palladium-on-carbon, or by 
treatment with a Lewis acid for example boron tris(trifluoro- 
acetate). A  suitable alternative protecting group for a primary 
amino group is, for example, a phthaloyl group which may be
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removed by treatment with an alkylamine, for example dim- 
ethylaminopropylamine, or with hydrazine.
[0160] A suitable protecting group for a hydroxy group is, 
for example, an acyl group, for example an alkanoyl group 
such as acetyl, an aroyl group, for example benzoyl, or an 
arylmethyl group, for example benzyl. The deprotection con­
ditions for the above protecting groups will necessarily vary 
with the choice o f protecting group. Thus, for example, an 
acyl group such as an alkanoyl or an aroyl group may be 
removed, for example, by hydrolysis with a suitable base such 
as an alkali metal hydroxide, for example lithium or sodium 
hydroxide. Alternatively an arylmethyl group such as a ben­
zyl group may be removed, for example, by hydrogenation 
over a catalyst such as palladium-on-carbon.
[0161] A suitable protecting group for a carboxy group is, 
for example, an esterifying group, for example a methyl or an 
ethyl group which may be removed, for example, by hydroly­
sis with a base such as sodium hydroxide, or for example a 
t-butyl group which may be removed, for example, by treat­
ment with an acid, for example an organic acid such as trif- 
luoroacetic acid, or for example a benzyl group which may be 
removed, for example, by hydrogenation over a catalyst such 
as palladium-on-carbon.
[0162] The protecting groups may be removed at any con­
venient stage in the synthesis using conventional techniques 
well known in the chemical art.
[0163] Certain of the intermediates (for example, com­
pounds of the Formulae II, III, IV, VI, VII, VIII) defined 
herein are novel and these are provided as a further feature o f 
the invention.
Biological Assays—
[0164] The following assays were used to measure the 
effects of the compounds of the present invention as a) inhibi­
tors o f PI3-kinase enzymes in biochemical assays, b) as 
inhibitors o f other kinases in biochemical assays, c) as inhibi­
tors in vitro of phospho AKT (Thr308) in BT474 cells, d) as 
inhibitors in vitro o f phospho AKT (Ser473) in MDA-MB- 
468 cells, e) as inhibitors in vitro o f phospho AKT (Ser473) in 
JEKO cells, f) as inhibitors in vitro o f phospho Chkl (Ser345) 
in F1T29 cells, g) as inhibitors o f cell proliferation across a 
panel o f tumour cell lines, h  & i) as inhibitors in vivo o f 
phospho AKT (Ser473) or inhibitors in vivo o f tumour growth 
respectively, in SCID mice transplanted with the human 
breast adenocarcinoma cell line, MCF7.
Abbreviations Used in Assay Protocols:
[0165] PIP2: PI(4,5)P2, phosphatidyl inositol 4,5-bisphos- 
phate
[0166] s.c.: sub-cutaneously
[0167] ATP: Adenosine triphosphate
[0168] DMSO: Dimethyl sulphoxide
[0169] TRIS: Tris(Flydroxymethyl)aminomethane
[0170] CF1APS: 3-[(3-Cholamidopropyl)dimethylammo- 
nio] -1 -propanesulfonate
[0171] DTT: Dithiothreitol
[0172] FBS: Foetal bovine serum
[0173] DMEM: Dulbecco’s Modified Eagle Medium
[0174] EDTA: Ethylenediaminetetraacetic acid
[0175] EGTA: Ethylene glycol tetraacetic acid
[0176] BSA: Bovine Serum albumin
[0177] PBS: Phosphate buffered saline
[0178] F1RP: Florseradish peroxidase
[0179] RPMI: Roswell Park Memorial Institute 1640 
medium
[0180] 4NQO: 4-Nitroquinoline N-oxide
[0181] EMEM: Eagle’s Minimal Essential medium
[0182] CO2. Carbon dioxide
[0183] PBST: Phosphate buffered saline/Tween
[0184] Ab: Antibody
[0185] MTS reagent: [3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo- 
lium, inner salt; MTS] and an electron coupling reagent 
(phenazine methosulfate) PMS.
(a) InVitro Enzyme InhibitionAssay
[0186] The inhibition of ΡΙ3Κ-β, ΡΙ3Κ-α, ΡΙ3Κ-γ and 
ΡΙ3Κ-δ was evaluated in a Kinase Glo based enzyme activity 
assay using human recombinant enzymes. The assay platform 
indirectly measured the depletion o f ATP after incubation 
with enzyme, PIP2 substrate, ATP and compound.
[0187] After completion o f the enzyme reaction the 
remaining ATP was used in a secondary enzymatic reaction, 
where Luciferase converted beetle luciferin into oxyluciferin 
under the emission o f light. A  direct relationship existed 
between the luminescence measured and the ATP remaining 
in a completed kinase reaction. Therefore, the luminescence 
was inversely related to the kinase activity. Typically, twelve 
different compound concentrations were tested and raw data 
from the inhibition o f ΡΙ3Κ-β, ΡΙ3Κ-α, ΡΙ3Κ-γ or ΡΙ3Κ-δ 
were plotted versus inhibitor concentration.
Method Details:
[0188] Compounds in 100% DMSO were added to assay 
plates by acoustic dispensing. PI3K enzyme was added in a 
Tris buffer (50 mM Tris pH 7.4,0.05% CHAPS, 2.1 mM DTT, 
and 10 mM magnesium chloride) and allowed to preincubate 
with compound for 20 minutes prior to addition o f substrate 
solution containing PIP2 and ATP. The enzyme reaction was 
stopped after 80 minutes by the addition o f Kinase Glo detec­
tion solution containing Lucferin and Luciferase (from 
Kinase Glo(R) Plus Luminecent Kinase Assay kit (Promega 
#V3772). Plates were left for 30 minutes at room temperature 
then read on a Pherastar Instrument with a standard Lumines­
cence filter block. The final concentration of DMSO, ATP and 
PIP2 in the assay were, 1%, 8 μΜ, and 80 μΜ respectively.
Data Analysis
[0189] IC50 values were calculated using a log curve fitting 
to a non-linear regression fit. The IC50 value was the concen­
tration o f test compound that inhibited 50% o f enzyme activ­
ity.
(b) Evaluation o f Kinase Selectivity, Beyond PDKinase Class 
I Enzymes
[0190] Laigepanels o f kinase asssays are offered by a range 
o f commercial vendors such as Millipore, Invitrogen and 
ProQinase. Such panels allow for an assessment o f the overall 
kinase selectivity o f a given compound. The precise methods/ 
technologies will vary depending on the vendor.
[0191] Selectivity data for some o f the compounds 
described herein was generated using enzyme assays per­
formed at the MRC-Division of Signal Transduction Therapy 
(DSTT), MRC Protein Phosphorylation Unit, Dundee, UK. 
Protein kinase assays were carried using a Radiochemical 
format. Assays were performed in multidrop 384 well plates
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at room temperature in a total assay volume o f 25.5 μΐ. Com­
pounds were pre-incubated in the presence o f the enzyme and 
peptide/protein substrate for 5 minutes before initiation o f the 
reaction by addition o f 10 μΐ o f ATP (final concentration 
selected for each kinase at 5, 20 or 50 μΜ). Assays were run 
at room temperature before termination by the addition o f 5 μΐ 
orthophosphoric acid. The assay plate contents were then 
harvested onto W hatman-P81 -Unifilter Plates by a Packard 
Harvester (wash buffer was 50 mM orthophosphoric acid) 
and dried in air. The dry Unifilter plates were then sealed on 
the addition of MicroScint O and were counted in Packard 
Topcount NXT scintillation counters. This protocol captures 
the generic format suitable for the majority o f kinases in the 
panel, but modifications to the protocols were required for a 
small number o f kinases, as will be familiar to those skilled in 
the art.
[0192] Lipid kinase assays for -1 8  lipid kinases were also 
performed at DSTT. AU lipid kinase assays were carried out in 
384 well plates at room temperature in a total assay volume o f 
40 μΐ. The assay was performed according to the protocols 
provided with the ADP-GLO assay (Promega, #V9101). This 
protocol captures the generic format suitable for the majority 
o f kinases in the panel, but modifications to the protocols 
were required for a small number o f kinases, as will be famil­
iar to those skilled in the art.
[0193] Kinase selectivity was also evaluated using the 
KINOMEscan™ screening platform, available via Discov- 
erX. This employs an active site-directed competition binding 
assay to quantitatively measure interactions between test 
compounds and more than 450 human kinases and disease 
relevant mutant variants. KINOMEscan™ assays do not 
require ATP and thereby report true thermodynamic interac­
tion affinities, as opposed to IC50 values, which can depend 
on the ATP concentration. The methodology is based on com­
pounds that bind the kinase active site and directly (sterically) 
or indirectly (allosterically) preventing kinase binding to the 
immobilized ligand, thereby reducing the amount o f kinase 
captured onto a solid support. Conversely, test molecules that 
do not bind the kinase have no effect on the amount o f kinase 
captured on a solid support. Screening “hits” are identified by 
measuring the amount o f kinase captured in test versus con­
trol samples by using a quantitative qPCR method that detects 
the associated DNA label. In a similar manner, dissociation 
constants (Kds) for test compound-kinase interactions are 
calculated by measuring the amount o f kinase captured on the 
solid support as a function o f the test compound concentra­
tion.
(c) Protocol for Assay Measuring Phosphorylated AKT 
(Tyr308) in BT474 Cells
[0194] This assay was used to measure PI3K -a inhibition 
in cells. BT474 cells (human breast ductal carcinoma, ATCC 
HTB-20) were seeded into black 384 well plates (Costar, 
#3712) at a density o f 5600 cells/well in DMEM containing 
10% FBS and I % glutamine and allowed to adhere overnight.
[0195] The following morning compounds in 100% DMSO 
were added to assay plates by acoustic dispensing. After a 2 
hour incubation at 37° C. and 5% CO2, the medium was 
aspirated and the cells were lysed with a buffer containing 25 
mM Tris, 3 mM EDTA, 3 mM EGTA, 50 mM sodium fluo­
ride, 2 mM Sodium orthovanadate, 0.27M sucrose, 10 mM 
β-glycerophosphate, 5 mM  sodium pyrophosphate, 0.5%Tri- 
ton X-100 and complete protease inhibitor cocktail tablets 
(Roche #04 693 116 001, used I tab per 50 ml lysis buffer).
[0196] After 20 minutes, the cell lysates were transferred 
into ELISA plates (Greiner #781077) which had been pre­
coated with an anti total-AKT antibody in PBS buffer and 
non-specific binding was blocked with 1% BSA in PBS con­
taining 0.05% Tween 20. Plates were incubated over night at 
4° C. The next day the plates were washed with PBS buffer 
containing 0.05% Tween 20 and further incubated with a 
mouse monoclonal anti-phospho AKT T308 for 2 hours. 
Plates were washed again as above before addition o f a horse 
anti-mouse-HRP conjugated secondary antibody. Following 
a 2 hour incubation at room temperature, plates were washed 
and QuantaBlu substrate working solution (Thermo Scien­
tific #15169, prepared according to provider instruction) was 
added to each well. The developed fluorescent product was 
stopped after 60 minutes by addition o f Stop solution to the 
w ells. Plates were read using a Tecan Satire plate reader using 
325 nm excitation and 420 nm emission wavelengths respec­
tively. Except where specified, reagents contained in the Path 
Scan Phospho AKT (Thr308) sandwich ELISA kit from Cell 
Signalling (#7144) were used in this ELISA assay.
(d) Protocol for Detection o f Phospho AKT (Ser473) in 
MDA-MB-468 Cells as a Measure for PI3Kinase-Beta 
Inhibition.
[0197] Thisassay w asusedto measure ΡΙ3Κ-β inhibitionin 
cells, and was used, in conjunction with assay (c) above, to 
determine alpha vs beta selectivity in cells. MDA-MB-468 
cells (human breast adenocarcinoma #ATCC HTB 132) were 
seeded at 1500 cells/well in 40 μΐ o f DMEM containing 10% 
FBS and 1% glutamine into Greiner 384 well black flat- 
bottomed plates. Cell plates were incubated for 18 hours in a 
37° C. incubator before dosing with compounds in 100% 
DMSO using acoustic dispensing.
[0198] Compounds were dosed in a 12 point concentration 
range into a randomised plate map. Control wells were gen­
erated either by dosing o f 100% DMSO (max signal) or 
addition o f a reference compound (a ΡΙ3Κ-β inhibitor) that 
completely eliminated the pAKT signal (min control). Plates 
were incubated at 37° C. for 2 hours, cells were then fixed by 
the addition of 10 μΐ o f a 3.7% formaldehyde solution. After 
30 minutes the plates were washed with PBS using a Tecan 
PW384 plate washer. Wells were blocked and cells perme- 
abilised with the addition o f 40 μΐ o f PBS containing 0.5% 
Tween20 and 1% Marvel™ (dried milk powder) and incu­
bated for 60 minutes at room temperature. The plates were 
washed with PBS containing 0.5% (v/v) Tween20 and 20 μΐ 
rabbit anti-phospho AKT Ser473 (Cell Signalling Technolo­
gies, #3787) in same PBS-Tween+1% Marvel™ was added 
and incubated overnight at 4° C.
[0199] Plates were washed 3 times with PBS+0.05% 
Tween 20 using a Tecan PW384. 20 μΐ o f secondary antibody 
Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) 
diluted in PBS+0.05% Tween20 containing 1% Marvel™ 
was added to each well and incubated for I hour at room 
temperature. Plates were washed three times as before then 20 
μΐ PBS added to each well and plates sealed with a black plate 
sealer.
[0200] The plates were read on an Acumen plate reader as 
soon as possible, measuring green fluorescence after excita­
tion with 488 nm laser. Using this system IC50 values were 
generated and quality o f plates was determined by control 
wells. Reference compounds were run each time to monitor 
assay performance.
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(e) Protocol for Detection o f Phospho AKT (Ser473) in Jeko 
Cells
[0201] This assay was used to measure ΡΙ3Κ-δ inhibition in 
cells. Compounds at xlO final concentration in 10 μΐ o f 1% 
(v/v) DMSO were added to the wells o f a Greiner V-bottomed 
96 well plate (Sigma #M9686). Compounds were dosed in a 
10-point concentration range from top doseof I pM or 10μΜ, 
8 compounds were dosed on one plate. There were 8 maxi­
mum signal control wells per plate dosed with anti-IgM (Af- 
finiPure F(ab')2 Fragment Goat Anti-Fluman IgM (Stratech, 
#109-006-129) and vehicle, and 8 minimum signal control 
wells dosed with anti-IgM and a reference ΡΙ3Κ-δ inhibitor. 
Final vehicle concentration was 0.1% DMSO. A  full dose 
response curve for a ΡΙ3Κ-δ selective compound was 
included in each run. Jeko B cells (human mantle cell lym­
phoma, ATCC #CRL-3006) were seeded into the Greiner 96 
well V-bottomed plates containing compounds. Cells were 
seeded at 100,000 cell/well in 70 μΐ o f RPMI containing 1% 
glutamine.
[0202] Cell plates were incubated with compound for I 
hour in a 37° C. incubator. After this compound pre-incuba- 
tion time, the above described anti-IgM was added to the 
plates at x5 final concentration in 20 μΐ o f assay buffer (RPMI 
containing 1% glutamine). Final anti-IgM concentration was 
0.06 m/ml or an equivalent EC90 dose. Plates were incubated 
at 37° C. for 10 min, then plates were immediately placed on 
ice and centrifuged at 12000 rpm for 4 min. On ice, superna­
tants were carefully removed with a manual pipette and 40 μΐ 
lysis buffer added. Plates were incubated on ice for 5 min and 
stored at -80° C. until assayed in the phosphor (ser473)/total 
Akt whole cell lysate kit according to manufacturer’s instruc­
tions (Mesoscale Diagnostics, #K 11100D-3).
(f) Protocol for Detection o f Phospho C hkl (Ser345) inHT29 
Cells
[0203] ATR (Ataxia Telangiectasia+Rad3-related kinase) 
is a PI3-kinase-related kinase which phosphorylates multiple 
substrates on serine or threonine residues in response to DNA 
damage or replication blocks. C h k l, a downstream protein 
kinase o f ATR, plays a key role in DNA damage checkpoint 
control. Activation o f Chkl involves phosphorylation o f 
Ser317 and Ser345 (the latter regarded as the preferential 
target for phosphorylation/activation by ATR).
[0204] This was a cell based assay to measure inhibition o f 
ATR kinase, by measuring a decrease in phosphorylation o f 
Chkl (Ser 345) in HT29 cells, following treatment with com­
pound and the UV mimetic 4NQO (Sigma #N8141). HT29 
cells (ECACC #85061109) were seeded into 384 well assay 
plates (Costar #3712) at a density o f 6000 cells/well in 40 μΐ 
EMEM medium containing 1% L glutamine and 10% FBS 
and allowed to adhere overnight. The following morning 
compounds in 100% DMSO were added to assay plates by 
acoustic dispensing. After I hour incubation at 37° C. and 5% 
CO2, 40 nl o f 3 mM 4NQO in 100% DMSO was added to all 
wells by acoustic dispensing, except minimum control wells 
which were left untreated with 4NQO to generate a null 
response control. Plates were returned to the incubator for a 
further I hour. Then cells were fixed by adding 20 μΐ o f 3.7% 
formaldehyde in PBS solution and incubating for 20 mins at 
room temperature. Then 20 μΐ o f 0.1% Triton XlOO in PBS 
was added and incubated for 10 minutes at room temperature, 
to permeabalise cells. Then the plates were washed once with 
50 μΐ/well PBS, using a Biotek EL405 plate washer.
[0205] Phospho-Chkl Ser 345 antibody (Cell Signalling 
Technology #2348) was diluted 150 fold in PBS containing
0.05% polysorbate/Tween and 15 μΐ was added to each well 
and incubated over night at room temperature. The next 
morning plates were washed three times with 50 μΐ/well PBS, 
using a Biotek EL405 plate washer, and then 20 μΐ o f second­
ary Ab solution, containing 500 fold diluted Alexa Fluor 488 
Goat anti-rabbit IgG (Molecular Probes #A-11008) and 0.002 
mg/ml Hoeschst dye (Molecular Probes #H-3570), in PBST, 
was added. After 2 hours incubation at room temperature, the 
plates were washed three times with 50 μΐ/well PBS, using a 
Biotek EL405 plate washer, and plates were then sealed with 
black plate seals until read. Plates were read using an Array- 
ScanVTI instrument, using an XF53 filter with IOx objective. 
A  two laser set up was used to analyse nuclear staining with 
Hoeschst (405 nM) and secondary antibody staining of 
pChkl (488 nM).
(g) Cell ProliferationAssays in Tumour Cell Lines (Used to 
Demonstrate a Personalised Medicine Hypothesis)
[0206] The sensitivity o f a panel o f human cancer cell lines 
to the effects o f compounds was determined in a standard 
proliferation assay. Cell lines were sourced through the Astra­
Zeneca Cell Bank. The majority o f cell lines are also available 
through Cell Bank Repositories known to those working in 
the art, for example ATCC, ECACC, DMSZ, RIKEN, KCLB, 
JCRB (HSRRB), LBNL, CLS and ICLC.
[0207] Cells were plated in 96 well plates at densities o f 
1000-6000 cells per well in RPMI media containing 10% 
FBS. After incubation at 37° C. for 16 hours, various concen­
trations o f compound were added to the assay plates. After 
incubation for an additional 72 h, the viable cells were deter­
mined by the addition o f MTS reagent (Promega #3582) to 
each well for 2 h. MTS is a tetrazolium salt that is bioreduced 
by metabolically active cells in the presence o f an electron 
coupling reagent to formazan. The formazan product was 
then quantitated by absorbance at 490 nm, as an indicator o f 
the relative number o f live cells. In order to determine the 
GI50 (concentration at which growth o f cells was inhibited by 
50%) the relative number o f cells present at the time o f drug 
addition was determined by comparison with the MTS read­
out before the drug was added, and this value was subtracted 
from the 72 hr value o f untreated cells as a measure of cell 
growth during the assay.
[0208] Analysis o f this data, described below under ‘Per­
sonalised Healthcare/Personalised Medicine Examples’ illus­
trates how this data may be analysed to reveal that PI3K a 
inhibitors display selective growth inhibition of cell lines 
with PIK3CA gene mutation. This illustrates a Personalised 
Healthcare (PHC) or Personalised Medicine opportunity 
where a response prediction biomarker readout could be used 
to identify patients with tumours containing mutation in the 
PIK3CA gene and who would be more likely to respond to the 
compounds described herein.
[0209] Other potential markers o f response to the com­
pounds described herein include, but are not limited to, 
increased copy number, amplification or translocation o f the 
PIK3CA gene, and other genetic, genomic or proteomic 
changes which provide a measure o f PI33-Kinase pathway 
activation or dependency; for example but not limited to, 
activation o f one or more receptor tyrosine kinases, or muta­
tion or translocation in the PIK3R genes which encode the 
regulatory subunits (p85) of PI3-Kinase, or phosphorylation 
o f downstream signalling markers such as pAKT, pS6, or
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FOXO status. In addition, analysis o f further genes and/or the 
signalling o f their protein products, for example Kras, may 
help improve the predictivity o f a Personalised Medicine 
approach.
(h) Protocol for Detection of Phospho AKT (Ser473) from 
MCF-7 Tumours Grown in Male SCID Mice
[0210] This was a pharmacodynamic assay providing a 
measure o f PI3K -a inhibition in an animal m odel. Male SCID 
mice (AZ UK, also available from Charles River, UK) were 
transplanted sub-cutaneously (s.c.) with human breast adeno­
carcinoma cell line MCF7 (ICRF London, also available from 
ATCC # HTB-22)) to determine the inhibition o f phosphory­
lation of AKT with PI3-kinase inhibitors. Mice were 
implanted with a 0.5 mg 21 -day oestrogen pellet (Innovative 
Research o f America, #E121) 24 hours prior to cell implan­
tation. 5x10s cells in 50% matrigel (BD Bioscience) were 
injected s.c. on the left flank o f the animals. Animals were 
randomised into groups o f 8 control and 4 treatment when 
tumours reached a volume of 400 mm3 and dosing com­
menced the next day. Tumours were taken at selected time 
points, when blood samples were also taken for PK measure­
ments.
[0211] Tumours excised from mouse were placed into a 
Fast Prep tube (2 ml ridged tubes containing lysing matrix A, 
MP Biomedicals #6910-500) and immediately snap frozen. I 
ml of lysis buffer (25 mM Tris, 3 mM EDTA, 3 mM EGTA, 50 
mM sodium fluoride, 2 mM orthovanadate, 0.27M sucrose, 
10 mM beta-glycerophoshate, 5 mM pyrophosphate, 0.5% 
Tritonx-100) plus phosphatase inhibitors (Sigma #P2850 and 
Sigma #P5726, diluted 1:100) and protease inhibitors (Sigma 
#P8340, diluted 1:200) were added to each tube. The tumours 
were homogenised for I minute on a FastPrep-TM machine 
(MP Biomedicals #116004500) and then left on ice for 5 
minutes, followed by two further homogenisations steps, 
each followed by a 5 minutes incubation on ice. Samples were 
spun for 10 minutes at 13,000 rpm in a chilled centrifuge. 
Cleared lysates were then taken into fresh tubes and 10 μΐ 
used for a protein determination assay
[0212] The detection of total and phosphorylated AKT 
(ser473) was carried out using a MSD multi-spot assay kit 
(Meso ScaleDiscovery # K l 5 100D-3). Eachwell o f the plate 
contained 4 spots; two o f these were coated with mouse 
monoclonal antibodies provided with the kit; one was coated 
with a capture antibody for total AKT and one was coated 
with an antibody for phosphory lated AKT (ser473). The 
plates were blocked overnight in the cold room on a shaker 
with 150 μΐ o f blocking solution per well, which was made 
using 20 ml o f Ix  solution o f wash solution plus 600 mg 
Blocker A  supplied with the kit. Plates were washed three 
time with 0.3 ml per well o f wash solution. An aliquot o f the 
lysate was taken from each tumour and diluted to a concen­
tration o f 2 mg/ml with lysis buffer, 25 μΐ o f the diluted lysate 
was then added to each well giving a total amount o f 50 pg per 
well. The plates were placed on a shaker at room temperature 
for one hour before plates were washed three times. A detec­
tion antibody solution was prepared using a mix o f blocking 
and wash solution plus a I in 50 dilution o f the 50x SULFO- 
TAG-TM anti-total AKT antibody. The plates were placed on 
a shaker at room temperature for one hour before plates were 
washed three times. 150 μΐ o f read buffer supplied with the kit 
was diluted 1:4 with deionised water and added to each well 
and then the plate was read on MSD plate analyser. The read 
buffer gives the correct chemical environment for electro- 
chemiluminescence, so that when the plate reader applies a
voltage to the plate the electrodes on the base o f the plate 
cause the label bound to the detection antibody to emit light. 
The intensity o f light emitted is a quantitative measure o f the 
AKT, either total or phosphorylated, that is present. To cal­
culate the ratio o f phosphorylated to total AKT a calculation 
was applied as suggested by Meso Scale: two times phospho­
rylated signal divided by total plus phosphorylated signal 
then multiplied by 100 to give % phosphoprotein. The values 
were converted into Log 10, and then these values were used 
to calculate the Geomean for each group plus standard error. 
A  student T test was then applied using 2 tailed formula and 
unequal variance to check for significance. Studies showed 
that a control group o f 8 animals with 4 per treatment group 
were sufficient to power the study.
(i) Protocol for Detection o f Tumour Growth Inhibition in 
Human Breast Adenocarcinoma Cell Line MCF7 Trans­
planted into SCID Mice.
[0213] This method provides for assessment o f anti-tumour 
efficacy of PI3-kinase inhibitors in vivo, in a PI3K -a depen­
dent model. As for the PD studies, indicated above, male 
SCID mice were transplanted s.c. with human breast adeno­
carcinoma cell line, MCF7. Mice were implanted with a 0.5 
mg 21-day oestrogen pellet 24 hours prior to cell implanta­
tion. 5x10s cells in 50% matrigel were injected s.c. on the left 
flank o f the animals Animals were randomised into groups of 
10-15 when tumours reached a volume o f -200-300 mm3 and 
treatment commenced. Animals were dosed for 2-4 weeks by 
peroral, intravenous or intra-peritoneal routes with com­
pound in a vehicle suitable for dosing via the required route 
and consistent with welfare requirements (suspension for oral 
dosing in pH range 4-7, solution for ip/iv dosing in pH range
5.5-7.0) and at defined doses. Tumours were usually m ea­
sured twice weekly by caliper and volume of tumours calcu­
lated using elliptical formula (pi/6xwidthxwidthxlength).
[0214] Although the pharmacological properties o f the 
compounds of the Formula (I) vary with structural change as 
expected, in general activity possessed by compounds o f the 
Formula (I) may be demonstrated at the following concentra­
tions or doses in one or more o f the above tests (a) and (c):—
[0215] Test (a):— IC50 versus PI3K -a in the range, for 
example, I nM -100nM ;
[0216] Test (c):— IC50 versus cellular phospho AKT 
(Tyr308) in BT474 cells, in the range, for example, 10 
nM-1 μΜ;
[0217] Conveniently, particular compounds o f the inven­
tion possess activity at the following concentrations or doses 
in one or more o f the above tests (a) and (c):—
[0218] Test (a):— IC50 versus PI3K -a in the range, for 
example, I nM -100nM ;
[0219] Test (c):— IC50 versus cellular phospho AKT 
(Tyr308) in BT474 cells, in the range, for example, 10 
nM-1 μΜ;
[0220] Conveniently, particular compounds o f the inven­
tion possess activity at the following concentrations or doses 
in one or more o f the above tests (a), (c), (h) and (i):—
[0221] Test (a):— IC50 versus PI3K -a in the range, for 
example, I nM -100nM ;
[0222] Test (c):— IC50 versus cellular phospho AKT 
(Tyr308) in 13T474 cells, in the range, for example, 10 
nM-1 μΜ;
[0223] Test (h):— >50% inhibition of in vivo phospho 
AKT (ser473) in the range, for example, 1-200 mg/kg/ 
day;
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[0224] Test (i):— xenograft activity in the range, for 
example, 1-200 mg/kg/day.
[0225] The following data were generated for the 
Examples:
TABLEA
Example
number
PI3K-a
inhibition
IC50
(μΜ)*
PI3K-6
inhibition
IC50
(μΜ)*
ΡΙ3Κ-β
inhibition
IC50
(μΜ)*
PI3K-a cell
IC50
(μΜ)**
ATR cell
IC50
(μΜ)#
I 0.023 <0.014 2.24 0.36 >30
3 0.007 <0.010 0.57 0.09 >30
4 0.025 <0.012 2.91 0.31 >30
5 0.030 0.012 3.31 0.27 >30
6 0.032 <0.012 3.42 0.53 >30
7 0.037 0.014 6.26 0.42 >30
8 0.024 0.012 1.52 0.59 >30
9 <0.010 <0.010 0.640 0.33 —
10 — — — 0.085 —
11 — — — 0.11 —
*Test protocol a: these are m ean values calculated from  a num ber o f  replicates o f  the test. 
**Test protocol c: these are m ean values calculated from  a num ber o f  replicates o f  the test. 
#Test protocol f: one tes t replicate only  carried out.
Combination Studies 
Materials and Methods
[0226] MCF7 is an estrogen receptor positive breast 
tumour cell line carrying a mutation in the PIKC3CA gene 
(E545K). Male SCID mice (AZ UK) were transplanted sub- 
cutaneously (s.c.) with human breast adenocarcinoma cell 
line MCF7 (ICRF London) to determine anti-tumour activity 
o f PI3 kinase inhibitors. Mice were implanted with a 0.5 mg 
21 day oestrogen pellet (Innovative Research of America) 24 
hours prior to cell implantation. 5 x l0 6 cells in 50% matrigel 
(BD Bioscience) were injected s.c. on the left flank o f the 
animals.
[0227] BT474 is an estrogen receptor positive breast
tumour cell lines with elevated Fler2 expression and carries a 
mutation in the PIK3CA gene (K 11 IN). Female Swiss athy- 
mic nude mice (swiss nu/nu-AZUK) were transplanted sub- 
cutaneously with human epithelial breast ductal carcinoma 
cell line BT474c (derived inAZ from BT474-ATCC HTB-20) 
tumours passaged in mice. Mice were implanted with 0.36 
mg 60 day oestrogen pellet (Innovative Research o f America) 
24 hours prior to cell implantation. 5x106 cells in 50% matri­
gel (BD Bioscience) were injected s.c. on the left flank of the 
animals.
[0228] F1CC70 is breast tumour cell line which is deficient 
in PTEN gene expression. Female Swiss athymic nude mice 
(swiss nu/nu-AZUK) were transplanted subcutaneously with 
the breast ductal epithelial tumour cell line F1CC70 (ATCC- 
CRL2315) cells. Ix lO 6 cells in 50% matrigel (BD Bio­
science) were injected s.c. on the left flank o f the animals.
[0229] Animals were randomised into groups o f 10-15 
when tumours reached a volume o f -200-300 mm3 and treat­
ment commenced. Animals were dosed for 3-4 weeks by 
peroral route, with compound in a suitable vehicle at defined 
doses and schedules. Tumours were measured two-three 
times weekly by caliper and volume o f tumours calculated 
using elliptical formula (pi/6xwidthxwidthxlength).
[0230] W hen dosed alone, AZD5363 was formulated in 
10% DMSO, 25% Kleptose solution.
[0231] (Kleptose is sourced from Roquette— Pharma 
(Trademarked) Flydroxypropyl betacyclodextrin— suitable 
for in vivo use and formulations).
[0232] W hen co-dosed with Example 3, AZD5363 was for­
mulated in FIPMC/Tween (0.5% Methocel (hydroxypropyl 
methocellulose)/0.1% Polysorbate 80). The suspension was 
ball milled overnight.
[0233] Example 3 was formulated in FIPMC/Tween (0.5% 
Methocel (hydroxypropyl methocellulose)/0.1 % Polysorbate 
80).
[0234] A ZD 8186 was formulated in HPMC/Tween (0.5% 
Methocel (hydroxypropyl methocellulose)/0.1 % Polysorbate 
80).
[0235] W hen co-dosed with Example 3, A ZD 8186 was for­
mulated in FIPMC/Tween (0.5% Methocel (hydroxypropyl 
methocellulose)/0.1% Polysorbate 80). The suspension was 
ball milled overnight.
[0236] Olaparib was formulated in 10% DMSO/30% Klep­
tose solution.
Tumour Growth Inhibition by Example 3 in Combination 
with AKT Inhibitor (AZD5363)— Sequential Administration
[0237] Studies were performed in the BT474 xenograft 
model. Example 3 and AZD5363 were dosed twice daily 
(BID) 6-8 hours apart on a 2 days on/ 5 days off weekly cycle, 
in sequence such that AZD53 63 was dosed on days I a n d 2 o f 
the weekly cycle and Example 3 was dosed on days 3 and 4 of 
the weekly cycle. Example 3 was dosed at 50 mg/kg BID and 
AZD5363 was dosed at 170 mg/kg BID, in FIPMC/Tween 
and DMSO/Kleptose respectively.
[0238] The tumour growth curve (shown in FIG. 9) indi­
cates that intermittent dosing o f either Example 3 or 
AZD5363 partially inhibited tumour growth relative to 
vehicle only control (FIPMC/Tween). The combination of 
Example 3 plus AZD5363 induced tumour regression. 
Tumour Growth Inhibition by Example 3 in Combination 
with AKT Inhibitor (AZD5363)— Co-Administration
[0239] Studies were performed in the BT474 xenograft 
model. Example 3 and AZD5363 were dosed twice daily 
(BID) 6-8 hours apart and concomitantly on a 2 days on/5 
days off weekly cycle. Example 3 was dosed at 25 mg/kg BID 
and AZD5363 was dosed at 100 mg/kg BID, both in FIPMC/ 
Tween.
[0240] The tumour growth curve (shown in FIG. 10) indi­
cates that intermittent dosing o f either Example 3 or 
AZD5363 partially inhibited tumour growth relative to 
vehicle only control (FIPMC/Tween). The combination of 
Example 3 plus AZD5363 induced tumour regression during 
the dosing period, although followed by tumour re-growth 
during the dosing free period.
Tumour Growth Inhibition by Example 3 in Combination 
with PARP Inhibitor (Olaparib)
[0241] Studies were performed in the BT474 xenograft 
model. Example 3 and Olaparib were dosed on every day 
throughout the study, Example 3 twice daily (BID) 6-8 hours 
apart at 25 mg/kg each dose and Olaparib once daily (QD) at 
100 mg/kg I hour post first daily dose of Example 3. Both 
agents were dosed in FIPMC/Tween.
[0242] The tumour growth curve (FIG. 11) indicates that 
olaparib alone had no significant effect on tumour growth, 
example 3 alone partially inhibited growth, but the combina­
tion of Example 3 plus olaparib induced tumour regression.
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Tumour Growth Inhibition by Example 3 in Combination 
with PARP Inhibitor (Olaparib)
[0243] Studies were performed in the MCF7 xenograft 
model. Example 3 and Olaparib were dosed on every day 
throughout the study, Example 3 twice daily 6-8 hours apart at 
25 mg/kg each dose and Olaparib once daily (QD) at 100 
mg/kg I hour post first daily dose of Example 3. Both agents 
were dosed in HPMC/Tween.
[0244] The tumour growth curve (FIG. 12) indicates that 
olaparib alone had minimal effect on tumour growth, 
Example 3 alone caused some tumour regression, but the 
combination o f Example 3 plus olaparib induced stronger 
tumour regression.
Tumour Growth Inhibition by Example 3 in Combination 
with PI3Kbeta/Delta Inhibitor (AZD8186)
[0245] Studies were performed in the HCC70 xenograft 
model. Example 3 and AZD8186 were dosed on every day, 
twice daily (BID), throughout the study, Example 3 at 25 
mg/kg each dose and AZD8186 at 50 mg/kg each dose. Both 
agents were dosed in HPMC/Tween. The tumour growth 
curve (FIG. 13) indicates that AZD8186 partially inhibited 
tumour growth, Example 3 alone inhibited growth more 
strongly, but the combination o f Example 3 plus AZD8186 
induced tumour regression.
[0246] According to a further aspect o f the invention there 
is provided a pharmaceutical composition, which comprises a 
compound o f the Formula (I), or a pharmaceutically-accept- 
able salt thereof, as defined hereinbefore in association with a 
pharmaceutically-acceptable diluent or carrier.
[0247] Suitable pharmaceutically acceptable excipients for 
a tablet formulation include, for example, inert diluents, 
granulating and disintegrating agents, binding agents, lubri­
cating agents, preservative agents and anti-oxidants. Tablet 
formulations may be uncoated or coated either to modify their 
disintegration and the subsequent absorption of the active 
ingredient within the gastrointestinal tract, or to improve their 
stability and/or appearance, in either case, using conventional 
coating agents and procedures well known in the art.
[0248] Compositions for oral use may alternatively be in 
the form of hard gelatin capsules in which the active ingredi­
ent is mixed with an inert solid diluent, or as soft gelatin 
capsules in which the active ingredient is mixed with water or 
an oil.
[0249] Aqueous suspensions generally contain the active 
ingredient in finely powdered form together with one or more 
suspending agents, dispersing or wetting agents. The aqueous 
suspensions may also contain one or more preservatives, anti­
oxidants, colouring agents, flavouring agents, and/or sweet­
ening agents.
[0250] Oily suspensions may be formulated by suspending 
the active ingredient in a vegetable oil or in a mineral oil. The 
oily suspensions may also contain a thickening agent. Sweet­
ening agents such as those set out above, and flavouring 
agents may be added to provide a palatable oral preparation. 
These compositions may be preserved by the addition o f an 
anti-oxidant.
[0251] Dispersible powders and granules suitable for 
preparation o f an aqueous suspension by the addition o f water 
generally contain the active ingredient together with a dis­
persing or wetting agent, suspending agent and one or more 
preservatives. Additional excipients such as sweetening, fla­
vouring and colouring agents, may also be present.
[0252] The pharmaceutical compositions of the invention 
may also be in the form o f oil-in-water emulsions. The oily
phase may be a vegetable oil or a mineral oil or a mixture of 
any of these. The emulsions may also contain sweetening, 
flavouring and preservative agents.
[0253] Syrups and elixirs may be formulated with sweet­
ening agents, and may also contain a demulcent, preservative, 
flavouring and/or colouring agent.
[0254] Thepharmaceutical compositions may also be in the 
form of a sterile injectable aqueous or oily suspension, which 
may be formulated according to known procedures using one 
or more o f the appropriate dispersing or wetting agents and 
suspending agents, which have been mentioned above. A 
sterile injectable preparation may also be a sterile injectable 
solution or suspension in a non-toxic parenterally-acceptable 
diluent or solvent.
[0255] Compositions for administration by inhalation may 
be in the form o f a conventional pressurised aerosol arranged 
to dispense the active ingredient either as an aerosol contain­
ing finely divided solid or liquid droplets. Conventional aero­
sol propellants such as volatile fluorinated hydrocarbons or 
hydrocarbons may be used and the aerosol device is conve­
niently arranged to dispense a metered quantity o f active 
ingredient.
[0256] For further information on formulation the reader is 
referred to Chapter 25.2 in Volume 5 o f Comprehensive 
Medicinal Chemistry (Corwin Hansch; Chairman of Edito­
rial Board), Pergamon Press 1990.
[0257] The amount o f active ingredient that is combined 
with one or more excipients to produce a single dosage form 
will necessarily vary depending upon the host treated and the 
particular route o f administration. For example, oral admin­
istration to humans will generally require, for example, from 
I mg to 2 g o f active agent (more suitably from 100 mg to 2 g, 
for example from 250 mg to 1.8 g, such as from 500 mg to 1.8 
g, particularly from 500 mg to 1.5 g, conveniently from 500 
mg to I g) to be administered compounded with an appropri­
ate and convenient amount o f excipients which may vary 
from about 3 to about 98 percent by weight o f the total 
composition. It will be understood that, if  a large dosage is 
required, multiple dosage forms may be required, for 
example two or more tablets or capsules, with the dose of 
active ingredient divided conveniently between them. Con­
veniently, a single solid dosage form may contain between I 
and 300 mg o f active ingredient.
[0258] The size o f the dose for therapeutic or prophylactic 
purposes o f a compound o f the Formula (I) will naturally vary 
according to the nature and severity o f the disease state, the 
age and sex of the animal or patient and the route o f admin­
istration, according to well known principles o f medicine.
[0259] In using a compound of the Formula (I) for thera­
peutic or prophylactic purposes it will generally be adminis­
tered so that a daily dose in the range, for example, I mg/kg to 
100 mg/kg body weight is received, given if  required in 
divided doses. In general, lower doses will be administered 
when a parenteral route is employed. Thus, for example, for 
intravenous administration, a dose in the range, for example, 
I mg/kg to 25 mg/kg body weight will generally be used. 
Similarly, for administration by inhalation, a dose in the 
range, for example, I mg/kg to 25 mg/kg body weight will be 
used. Oral administration is however preferred, particularly 
in tablet form. Typically, unit dosage forms will contain about 
10 mg to 0.5 g of a compound o f this invention.
[0260] The compounds of the invention may be adminis­
tered daily or more than once daily. The compounds of the 
invention may also be administered in a suitable dosing
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schedule, for example the compounds o f the invention may be 
administered one or more times per day (for example once, 
twice or three times a day) for a certain number o f days, 
followed by a period o f days where no dose is given. This 
dosage cycle (consisting o f dosing days and no-dosing days) 
may then be repeated. Conveniently a dosage cycle is a period 
o f 5-14 days, such as 5, 7 ,10  or 14 days, more conveniently 7 
days. In one aspect, the compounds of formula (I) are dosed 
for I day or 2 or 3 consecutive days, followed by 3, 4, 5 or 6 
days with no dose in a dosage cycle.
[0261] In one aspect the compound of formula (I) is dosed 
for I day followed by no dose for 2, 3 or 4 days.
[0262] In another aspect the compound of formula (I) is 
dosed for 2 days followed by no dose for 4, 5 or 6 days.
[0263] In a further aspect the compound o f formula (I) is 
dosed for 3 days followed by no dose for 3, 4 or 5 days.
[0264] In another aspect the compound of formula (I) is 
dosed for 4 days followed by no dose for 2, 3 or 4 days.
[0265] In another aspect the compound of formula (I) is 
dosed for 5 days followed by no dose for I, 2 or 3 days.
[0266] In another aspect, the compound o f formula (I) is 
dosed every other day.
[0267] The above dosing schedules are conveniently
applied when the compounds o f the invention are used as
monotherapy. Furtherexamples o f potential dosing schedules 
for administration o f the compounds o f the invention as com­
bination therapy are described hereinafter.
[0268] As stated above, it is known that PI3K -a and -δ 
enzymes contribute to tumourigenesis by one or more o f the 
effects o f mediating proliferation o f cancer and other cells, 
mediating angiogenic events and mediating the motility, 
migration and invasiveness o f cancer cells. We have found 
that the compounds of the present invention possess potent 
anti-tumour activity which it is believed is obtained by way o f 
inhibition o f PI3K -a and -δ enzymes that are involved in the 
signal transduction steps which lead to the proliferation and 
survival o f tumour cells and the invasiveness and migratory 
ability o f metastasising tumour cells.
[0269] Accordingly, the compounds of the present inven­
tion are o f value as anti-tumour agents, in particular as selec­
tive inhibitors o f the proliferation, survival, motility, dissemi­
nation and invasiveness o f mammalian cancer cells leading to 
inhibition o f tumour growth and survival and to inhibition o f 
metastatic tumour growth. Particularly, the compounds of the 
present invention are o f value as anti-proliferative and anti- 
invasive agents in the containment and/or treatment o f solid 
tumour disease. Particularly, the compounds o f the present 
invention are expected to be useful in the prevention or treat­
ment o f those tumours which are sensitive to inhibition o f 
PI3K -a and/or -δ enzymes and that are involved in the signal 
transduction steps which lead to the proliferation and survival 
o f tumour cells and the migratory ability and invasiveness o f 
metastasising tumour cells. Further, the compounds of the 
present invention are expected to be useful in the prevention 
or treatment o f those tumours which are mediated alone or in 
part by inhibition o f PI3K -a and/or -δ enzymes, i.e. the com­
pounds may be used to produce a PI3K -a and/or -δ enzyme 
inhibitory effect in a warm blooded animal in need o f such 
treatment.
[0270] According to a further aspect o f the invention there 
is provided a compound o f the Formula (I), or a pharmaceu­
tically acceptable salt thereof, as defined hereinbefore for use 
as a medicament in a warm-blooded animal such as man.
[0271] According to a further aspect o f the invention, there 
is provided a compound o f the Formula (I), or a pharmaceu­
tically acceptable salt thereof, as defined hereinbefore for use 
in the production o f an anti-proliferative effect in a warm­
blooded animal such as man.
[0272] According to a further feature o f this aspect o f the 
invention there is provided a compound o f the Formula (I), or 
a pharmaceutically acceptable salt thereof, as defined herein­
before for use in a warm-blooded animal such as man as an 
anti-invasive agent in the containment and/or treatment o f 
solid tumour disease.
[0273] According to a further aspect o f the invention, there 
is provided the use o f a compound o f the Formula (I), or a 
pharmaceutically acceptable salt thereof, as defined herein­
before for the production of an anti-proliferative effect in a 
warm-blooded animal such as man.
[0274] According to a further feature o f this aspect o f the 
invention there is provided the use o f a compound o f the 
Formula (I), or a pharmaceutically acceptable salt thereof, as 
defined hereinbefore in the manufacture o f a medicament for 
use in the production o f an anti-proliferative effect in a warm­
blooded animal such as man.
[0275] According to a further feature o f this aspect o f the 
invention there is provided the use o f a compound o f the 
Formula (I), or a pharmaceutically acceptable salt thereof, as 
defined hereinbefore in the manufacture o f a medicament for 
use in a warm-blooded animal such as man as an anti-invasive 
agent in the containment and/or treatment o f solid tumour 
disease.
[0276] According to a further feature o f this aspect o f the 
invention there is provided a method for producing an anti­
proliferative effect in a warm blooded animal, such as man, in 
need of such treatment which comprises administering to said 
animal an effective amount o f a compound o f the Formula (I), 
or a pharmaceutically acceptable salt thereof, as defined here­
inbefore.
[0277] According to a further feature o f this aspect o f the 
invention there is provided a method for producing an anti- 
invasive effect by the containment and/or treatment o f solid 
tumour disease in a warm blooded animal, such as man, in 
need of such treatment which comprises administering to said 
animal an effective amount o f a compound o f the Formula (I), 
or a pharmaceutically acceptable salt thereof, as defined here­
inbefore.
[0278] According to a further aspect o f the invention, there 
is provided a compound o f the Formula (I), or a pharmaceu­
tically acceptable salt thereof, as defined hereinbefore for use 
in the prevention or treatment o f cancer in a warm blooded 
animal such as man.
[0279] According to a further aspect o f the invention there 
is provided the use o f a compound o f the Formula (I), or a 
pharmaceutically acceptable salt thereof, as defined herein­
before in the manufacture o f a medicament for use in the 
prevention or treatment o f cancer in a warm blooded animal 
such as man.
[0280] According to a further feature o f this aspect o f the 
invention there is provided a method for the prevention or 
treatment o f cancer in a warm blooded animal, such as man, 
in need of such treatment which comprises administering to 
said animal an effective amount o f a compound o f the For­
mula (I), or a pharmaceutically acceptable salt thereof, as 
defined hereinbefore.
[0281] According to a further aspect o f the invention, there 
is provided a compound o f the Formula (I), or a pharmaceu­
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tically acceptable salt thereof, as defined hereinbefore for use 
in the prevention or treatment o f solid tumour disease in a 
warm blooded animal such as man.
[0282] According to a further aspect o f the invention there 
is provided the use o f a compound o f the Formula (I), or a 
pharmaceutically acceptable salt thereof, as defined herein­
before in the manufacture o f a medicament for use in the 
prevention or treatment o f solid tumour disease in a warm 
blooded animal such as man.
[0283] According to a further feature o f this aspect o f the 
invention there is provided a method for the prevention or 
treatment o f solid tumour disease in a warm blooded animal, 
such as man, in need o f such treatment which comprises 
administering to said animal an effective amount o f a com­
pound o f the Formula (I), or a pharmaceutically acceptable 
salt thereof, as defined hereinbefore.
[0284] According to a further aspect o f the invention there 
is provided a compound o f the Formula (I), or a pharmaceu­
tically acceptable salt thereof, as defined hereinbefore for use 
in the prevention or treatment o f those tumours which are 
sensitive to inhibition of PI3K -a and/or -δ enzymes that are 
involved in the signal transduction steps which lead to the 
proliferation, survival, invasiveness and migratory ability o f 
tumour cells.
[0285] According to a further feature o f this aspect o f the 
invention there is provided the use o f a compound o f the 
Formula (I), or a pharmaceutically acceptable salt thereof, as 
defined hereinbefore in the manufacture o f a medicament for 
use in the prevention or treatment o f those tumours which are 
sensitive to inhibition of PI3K -a and/or -δ enzymes that are 
involved in the signal transduction steps which lead to the 
proliferation, survival, invasiveness and migratory ability o f 
tumour cells.
[0286] According to a further feature o f this aspect o f the 
invention there is provided a method for the prevention or 
treatment o f those tumours which are sensitive to inhibition o f 
PI3K -a and/or -δ enzymes that are involved in the signal 
transduction steps which lead to the proliferation, survival, 
invasiveness and migratory ability o f tumour cells which 
comprises administering to said animal an effective amount 
o f a compound o f the Formula (I), or a pharmaceutically 
acceptable salt thereof, as defined hereinbefore.
[0287] According to a further aspect o f the invention there 
is provided a compound o f the Formula (I), or a pharmaceu­
tically acceptable salt thereof, as defined hereinbefore for use 
in providing a PI3K -a and -δ enzyme inhibitory effect.
[0288] According to a further feature o f this aspect o f the 
invention there is provided the use o f a compound o f the 
Formula (I), or a pharmaceutically acceptable salt thereof, as 
defined hereinbefore in the manufacture o f a medicament for 
use in providing a PI3K -a and -δ enzyme inhibitory effect.
[0289] According to a further aspect o f the invention there 
is also provided a method for providing a PI3K -a and -δ 
enzyme inhibitory effect which comprises administering an 
effective amount o f a compound of the Formula (I), or a 
pharmaceutically acceptable salt thereof, as defined herein­
before.
[0290] As stated hereinbefore, certain compounds of the 
present invention possess substantially better potency against 
PI3K -a and -δ enzymes than against other PI3-kinase 
enzymes oro therkinases. Suchcompounds possess sufficient 
potency against PI3K -a and -δ enzymes that they may be 
used in an amount sufficient to inhibit PI3K -a and -δ enzymes 
whilst demonstrating little activity against the ΡΙ3Κ-β
enzyme and against most other kinase enzymes. Such com­
pounds are likely to be useful for the selective inhibition of 
PI3K -a and -δ enzymes and are likely to be useful for the 
effective treatment of, for example PI3K -a and/or -δ enzyme 
driven tumours.
[0291] According to this aspect o f the invention there is 
provided a compound o f the Formula (I), or a pharmaceuti­
cally acceptable salt thereof, as defined hereinbefore for use 
in providing a selective PI3K -a and -δ enzyme inhibitory 
effect.
[0292] According to a further feature o f this aspect o f the 
invention there is provided the use o f a compound o f the 
Formula (I), or a pharmaceutically acceptable salt thereof, as 
defined hereinbefore in the manufacture o f a medicament for 
use in providing a selective PI3K -a and -δ enzyme inhibitory 
effect.
[0293] According to a further aspect o f the invention there 
is also provided a method for providing a selective PI3K -a 
and -δ enzyme inhibitory effect which comprises administer­
ing an effective amount o f a compound o f the Formula (I), or 
a pharmaceutically acceptable salt thereof, as defined herein­
before.
[0294] By “a selective PI3K -a and -δ enzyme inhibitory 
effect” is meant that the compound o f the Formula (I) are 
more potent against PI3K -a and -δ enzymes than against 
other class I PI3-kinases, and generally display good selec­
tivity relative to other members o f the wider PI3-kinase fam­
ily and across the broader classes o f kinase enzymes com­
prising tyrosine and ser/thr kinases.
[0295] According to a further feature o f the invention there 
is provided a compound o f the Formula (I), or a pharmaceu­
tically acceptable salt thereof, as defined herein before for use 
in the treatment o f cancer o f the Breast, Stomach (Gastric) 
and Oesophagus cancers, Non Small Cell Lung Cancer 
(NSCLC) including squamous cell carcinomas (SCC) and 
adenocarcinoma, SCC o f the Fiead and Neck (Fi&N), Gynae­
cological cancers (including Endometrial, Ovarian and Cer­
vical) and o f Fiaematological cancers such as multiple 
myeloma, lymphomas and leukemias (including Chronic 
Lymphoctyic Leukaemia (CLL), Acute Lymphoblastic Leu­
kaemia (ALL) and Mantle Cell Lymphoma (MCL).
[0296] According to a further feature o f this aspect o f the 
invention there is provided a compound o f the Formula (I), or 
a pharmaceutically acceptable salt thereof, as defined herein 
before for use in the treatment o f cancer o f the Bladder, 
Brain/CNS, Colorectum, Lung (all other forms), Gallbladder 
and Bile duct, and Skin.
[0297] According to a further feature o f this aspect o f the 
invention there is provided a compound o f the Formula (I), or 
a pharmaceutically acceptable salt thereof, as defined herein 
before for use in the treatment o f cancer o f the Prostate, Bone, 
Kidney, Liver, Melanoma, Gastrointestinal tissue, Pancreas, 
Testes, Thyroid, Penile, Vulva, and other tumour types with a 
PI3-kinase dependency through mutation, amplification or 
other aberrations.
[0298] According to a further feature o f this aspect o f the 
invention there is provided a method for treating cancer o f 
Breast, Stomach (Gastric) and Oesophagus cancers, NSCLC 
including SCC and adenocarcinoma, SCC o f Fl&N, Gynae­
cological cancers (including Endometrial, Ovarian and Cer­
vical) and o f Flaematological cancers such as multiple 
myeloma, lymphomas and leukemias (including CLL, ALL 
and MCL) in a warm blooded animal such as man that is in 
need o f such treatment which comprises administering an
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effective amount o f a compound of the Formula (I), or a 
pharmaceutically acceptable salt thereof, as defined herein­
before.
[0299] According to a further feature o f this aspect o f the 
invention there is provided a method for treating cancer o f 
Bladder, Brain/CNS, Colorectum, Lung (all other forms), 
Gallbladder and Bile duct, and Skin in a warm blooded ani­
mal such as man that is in need o f such treatment which 
comprises administering an effective amount o f a compound 
o f the Formula (I), or a pharmaceutically acceptable salt 
thereof, as defined hereinbefore.
[0300] According to a further feature o f this aspect o f the 
invention there is provided a method for treating cancer o f 
Prostate, Bone, Kidney, Liver, Melanoma, Gastrointestinal 
tissue, Pancreas, Testes, Thyroid, Penile, Vulva, and other 
tumour types with a PI3-kinase dependency through muta­
tion, amplification or other aberrations, in a warm blooded 
animal such as man that is in need o f such treatment which 
comprises administering an effective amount o f a compound 
o f the Formula (I), or a pharmaceutically acceptable salt 
thereof, as defined hereinbefore.
[0301] According to a further feature of the invention there 
is provided the use o f a compound o f the Formula (I), or a 
pharmaceutically acceptable salt thereof, as defined herein 
before in the manufacture o f a medicament for use in the 
treatment o f cancer o f the Breast, Stomach (Gastric) and 
Oesophagus cancers, NSCLC including SCC and adenocar­
cinoma, SCC o f Fl&N, Gynaecological cancers (including 
Endometrial, Ovarian and Cervical) and of Flaematological 
cancers such as multiple myeloma, lymphomas and leuke­
mias (including CLL, ALL and MCL).
[0302] According to a further feature o f this aspect o f the 
invention there is provided the use o f a compound o f the 
Formula (I), or a pharmaceutically acceptable salt thereof, as 
defined herein before in the manufacture o f a medicament for 
use in the treatment o f cancer o f the Bladder, Brain/CNS, 
Colorectum, Lung (all other forms), Gallbladder and Bile 
duct, and Skin.
[0303] According to a further feature o f this aspect o f the 
invention there is provided the use o f a compound o f the 
Formula (I), or a pharmaceutically acceptable salt thereof, as 
defined herein before in the manufacture o f a medicament for 
use in the treatment o f cancer o f the o f Prostate, Bone, Kid­
ney, Liver, Melanoma, Gastrointestinal tissue, Pancreas, Tes­
tes, Thyroid, Penile, Vulva, and other tumour types with a 
PI3-kinase dependency through mutation, amplification or 
other aberrations.
[0304] In one feature o f the invention, the cancer to be 
treated is breast cancer. In a further aspect o f this feature, the 
breast cancer is Estrogen Receptor +ve. In one embodiment 
o f this aspect, the compound o f Formula (I), or a pharmaceu­
tically acceptable salt thereof, is dosed in combination with 
an anti-hormonal agent as defined herein. In another embodi­
ment o f this aspect, Example 3 is dosed in combination with 
an anti-hormonal agent as defined herein. In a further embodi­
ment o f this aspect, Example 3 is dosed in combination with 
olaparib, or a pharmaceutically-acceptable salt thereof, and 
optionally further in combination with an anti-hormonal 
agent as defined herein. In a further embodiment o f this 
aspect, Example 3 is dosed in combination with AZD5363, or 
a pharmaceutically-acceptable salt thereof, and optionally 
further in combination with an anti-hormonal agent as 
defined herein.
[0305] In one aspect where the treatment o f cancer is indi­
cated, it is to be understood that this may refer to the preven­
tion o f metastases and the treatment o f metastases, i.e. cancer 
spread. Therefore the compounds o f the present invention 
might be used to treat a patient who has no metastases to stop 
them occurring, or to lengthen the time period before they 
occur, and to a patient who already has metastases to treat the 
metastases themselves. Furthermore the treatment o f cancer 
may refer to treatment o f an established primary tumour or 
tumours and developing primary tumour or tumours. There­
fore, in one aspect the treatment o f cancer relates to the 
prevention o f metastases. In another aspect o f the invention 
the treatment o f cancer relates to the treatment o f metastases. 
In another aspect o f the invention the treatment o f cancer 
relates to treatment o f an established primary tumour or 
tumours or developing primary tumour or tumours.
[0306] As stated hereinbefore, the in vivo effects o f a com­
pound of the Formula (I) may be exerted in part by one or 
more metabolites (such as compounds o f formula A  as 
defined hereinbefore) that are formed within the human or 
animal body after administration o f a compound o f the For­
mula (I).
[0307] Particular compounds o f the invention possess bet­
ter potency against PI3-kinase-a and -δ than against other 
class I PI3-kinase isoforms such as -β an d -γ. Inoneaspectthe 
compounds of the invention are selective for PI3K -a and -δ 
compared to ΡΙ3Κ-β or -γ.
[0308] The present invention therefore also contemplates a 
method for inhibiting PI3-kinase-a in a patient, comprising 
administering to a patient an amount o f the compound of 
Formula (I), or a pharmaceutically acceptable salt thereof, 
effective in inhibiting the phosphoinositide 3-kinase-a in the 
patient.
[0309] The present invention therefore also contemplates a 
method for inhibiting PI3-kinase-a and -δ in a patient, com­
prising administering to a patient an amount o f the compound 
o f Formula (I), or a pharmaceutically acceptable salt thereof, 
effective in inhibiting the PI3-kinase-a and -δ in the patient.
[0310] The compound of Formula (I), or a pharmaceuti­
cally acceptable salt thereof, being an inhibitor o f PI3-kinase, 
also has potential therapeutic uses in a variety o f other disease 
states. For example, PI3-kinase plays an important role in 
promoting smooth muscle proliferation in the vascular tree,
i.e. vascular smooth muscle cells (Thyberg, European Jour­
nal o f  Cell Biology, 1998, 76(1), 33-42), and in the lungs 
(airway smooth muscle cells), Krymskaya, V. P., BioDrugs, 
2007, 21(2), 85-95. Excessive proliferation o f vascular 
smooth muscle cells plays an important role in the formation 
o f atherosclerotic plaques and in the development o f neoin- 
timal hyperplasia following invasive vascular procedures 
(Scwartz et ah, Progress in Cardiovascular Disease, 1984, 
26, 355-372; Clowes et ah, Laboratory Investigations, 1978, 
39, 141-150. Moreover, excessive proliferation o f airway 
smooth muscle cells leads to the development o f COPD in the 
setting of asthma and chronic bronchitis Inhibitors o f PI3- 
kinase activity therefore may be used to prevent vascular 
restenosis, atherosclerosis, and COPD.
[0311] PI3-kinase also plays an important role in leukocyte 
function (Fuller et ah, The Journal o f  Immunology, 1999, 
162(11), 6337-6340; Eder et al., The Journal o f  Biological 
Chemistry, 1998, 273(43), 28025-31) and lymphocyte func­
tion (Vicente-Manzanares et al., The Journal o f  Immunology, 
1999, 163(7), 4001-4012). For example, leukocyte adhesion 
to inflamed endothelium involves activation o f endogenous
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leukocyte integrins by a PI3-kinase-dependent signalling 
process. Furthermore, oxidative burst (Nishioka et al., FEBS  
Letters, 1998, 441(1), 63-66 and Condliffe, A. M., et al., 
Blood, 2005, 106(4), 1432-40) and cytoskeletal reorganiza­
tion (Kirsch et al., Proceedings National Academy o f  Sci­
ences USA, 1999, 96(11), 6211-6216) in neutrophils appears 
to involve PI3-kinase signalling. Neutrophil migration and 
directional movement are also dependent on PI3-kinase activ­
ity (Camps, M., et al., Nat Med, 2005, 11(9), 936-43 and 
Sadhu, C. et a l,  J Immunol, 2003, 170(5), 2647-54). Thus, 
inhibitors o f PI3-kinase may be useful in reducing leukocyte 
adhesion and activation at sites o f inflammation and therefore 
may be used to treat acute and/or chronic inflammatory dis­
orders. PI3-kinase also plays an important role in lymphocyte 
proliferation and activation, Fruman et a l ,  Science, 1999,283 
(5400), 393-397. In particular, ΡΙ3Κ-δ is essential for B cell 
development and function, including IgM-specific antibody- 
induced B-cell proliferation (Okkenhaug K et a l,  Science, 
2002,297(5583), 1031-1034), B-cell-receptor-induced DNA 
synthesis and proliferation, and IL-4-induced survival (Bilan- 
cio A  et a l ,  Blood, 2006, 107, 642-650). These observations 
indicate that ΡΙ3Κ-δ has a crucial and non-redundant role in 
B-cell function that is not compensated by other class I 
PI3Ks. Given the important role o f lymphocytes in auto­
immune diseases, an inhibitor o f PI3-kinase activity may be 
used in the treatment o f such disorders (Rommel C, Camps M 
and Ji Tl, Nat Rev Immunol, 2007, 1038, 191-201).
[0312] The anti-cancer treatment defined hereinbefore may 
be applied as a sole therapy or may involve, in addition to the 
compound o f the invention, conventional surgery or radio­
therapy or chemotherapy. Such chemotherapy may include 
one or more of the following categories o f anti-tumour 
agents:—
(i) antiproliferative/antineoplastic drugs and combinations 
thereof, as used in medical oncology, such as alkylating 
agents (for example cis-platin, oxaliplatin, carboplatin, 
cyclophosphamide, nitrogen mustard, melphalan, chloram­
bucil, busulphan, temozolamide and nitrosoureas); antime­
tabolites (for example gemcitabine and antifolates such as 
fluoropyrimidines like 5-fluorouracil andtegafur, raltitrexed, 
methotrexate, cytosine arabinoside, and hydroxyurea); anti­
tumour antibiotics (for example anthracyclines like adriamy- 
cin, bleomycin, doxorubicin, daunomycin, epirubicin, idaru- 
bicin, mitomycin-C, dactinomycin and mithramycin); 
antimitotic agents (for example vinca alkaloids like vincris­
tine, vinblastine, vindesine and vinorelbine and taxoids like 
taxol and taxotere and polokinase inhibitors); and topoi- 
somerase inhibitors (for example epipodophyllotoxins like 
etoposide and teniposide, amsacrine, topotecan and camp- 
tothecin);
(ii) antihormonal agents such as antioestrogens (for example 
tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene 
and iodoxyfene), antiandrogens (for example bicalutamide, 
flutamide, nilutamide and cyproterone acetate), LFlRFl 
antagonists or LFlRFl agonists (for example goserelin, Ieu- 
prorelin and buserelin), progestagens (for example megestrol 
acetate), aromatase inhibitors (for example as anastrozole, 
letrozole, vorazole and exemestane) and inhibitors o f 5a-re- 
ductase such as finasteride;
(iii) inhibitors o f growth factor function and their downstream 
signalling pathways: included are Ab modulators o f any 
growth factor or growth factor receptor targets, reviewed by 
S tem et al. Critical Reviews in Oncology/Haematology, 2005, 
54, pp 11-29); also included are small molecule inhibitors o f
such targets, for example kinase inhibitors— examples 
include the anti-erbB2 antibody trastuzumab [Flerceptin™], 
the anti-EGFR antibody panitumumab, the anti-EGFR anti­
body cetuximab [Erbitux, C225] and tyrosine kinase inhibi­
tors including inhibitors o f the erbB receptor family, such as 
epidermal growth factor family receptor (EGFR/erbBl) 
tyrosine kinase inhibitors such as gefitinib or erlotinib, erbB2 
tyrosine kinase inhibitors such as lapatinib, and mixed erbl/2 
inhibitors such as afatanib; similar strategies are available for 
other classes o f growth factors and their receptors, for 
example inhibitors o f the hepatocyte growth factor family or 
their receptors including c-met and ron; inhibitors o f the 
insulin and insulin growth factor family or their receptors 
(IGFR, IR) inhibitors o f the platelet-derived growth factor 
family or their receptors (PDGFR), and inhibitors o f signal­
ling mediated by other receptor tyrosine kinases such as c-kit, 
AnLK, and CSF-1R;
also included are modulators which target signalling proteins 
in the wider PI3-kinase signalling pathway, for example, 
inhibitors o f other PI3-kinase isoforms such as ΡΙ3Κ-β, and 
ser/thr kinases such as AKT, mTOR, PDK, SGK, PI4K or 
PIP5K;
also included are inhibitors o f serine/threonine kinases not 
listed above, for example ra f inhibitors such as vemurafenib, 
M EKinhibitors such as selumetinib (AZD6244), A bl inhibi­
tors such as imatinib or nilotinib, Btk inhibitors such as ibru- 
tinib, Syk inhibitors such as fostamatinib, aurora kinase 
inhibitors (for example A ZD l 152), inhibitors o f other ser/thr 
kinases such as JAKs, STATs and IRAK4, and cyclin depen­
dent kinase inhibitors;
iv) modulators o f DNA damage signalling pathways, for 
example PARP inhibitors (e.g. Olaparib), ATR inhibitors or 
ATM inhibitors;
v) modulators o f apoptotic and cell death pathways such as 
Bcl family modulators (e.g. ABT-263/Navitoclax, ABT-199);
(vi) antiangiogenic agents such as those which inhibit the 
effects o f vascular endothelial growth factor, [for example the 
anti-vascular endothelial cell growth factor antibody bevaci- 
zumab (Avastin™) and for example, a VEGF receptor 
tyrosine kinase inhibitor such as sorafenib, axitinib, pazo- 
panib, sunitinib and vandetanib (and compounds that work by 
other mechanisms (for example linomide, inhibitors o f inte- 
grin ανβ3 function and angiostatin)];
(vii) vascular damaging agents, such as Combretastatin A4;
(viii) anti-invasion agents, for example c-Src kinase family 
inhibitors like (dasatinib, J  Med. Chem., 2004, 47, 6658- 
6661) and bosutinib (SKI-606), and metalloproteinase inhibi­
tors like marimastat, inhibitors o f urokinase plasminogen 
activator receptor function or antibodies to Fleparanase];
(ix) immunotherapy approaches, including for example ex- 
vivo and in-vivo approaches to increase the immunogenicity 
o f patient tumour cells, such as transfection with cytokines 
such as interleukin 2, interleukin 4 or granulocyte-macroph- 
age colony stimulating factor, approaches to decrease T-cell 
anergy, approaches using transfected immune cells such as 
cytokine-transfected dendritic cells, approaches using cytok­
ine-transfected tumour cell lines and approaches using anti- 
idiotypic antibodies. Specific examples include monoclonal 
antibodies targeting PD-I (e.g. BMS-936558) or CTLA4 
(e.g. ipilimumab and tremelimumab);
(x) Antisense or RNAi based therapies, for example those 
which are directed to the targets listed.
(xi) gene therapy approaches, including for example 
approaches to replace aberrant genes such as aberrant p53 or
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aberrant BRCAl orBRCA2, GDEPT (gene-directed enzyme 
pro-drug therapy) approaches such as those using cytosine 
deaminase, thymidine kinase or a bacterial nitroreductase 
enzyme and approaches to increase patient tolerance to che­
motherapy or radiotherapy such as multi-drug resistance gene 
therapy.
[0313] According to this aspect o f the invention there is 
provided a combination suitable for use in the treatment o f 
cancer comprising a compound o f Formula (I) as defined 
hereinbefore or a pharmaceutically acceptable salt thereof 
and another anti-tumour agent, in particular any one o f the 
anti tumour agents listed under (i)-(xi) above. In particular, 
the anti-tumour agent listed under (i)-(xi) above is the stan­
dard o f care for the specific cancer to be treated; the person 
skilled in the art will understand the meaning o f “standard of 
care” .
[0314] Therefore in a further aspect o f the invention there is 
provided a compound o f Formula (I) or a pharmaceutically 
acceptable salt thereof in combination with another anti-tu­
mour agent, in particular an anti-tumour agent selected from 
one listed under (i)-(xi) herein above.
[0315] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with another anti-tumour agent, in 
particular an anti-tumour agent selected from one listed under
(i) above.
[0316] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and any one 
o f the anti tumour agents listed under (i) above.
[0317] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and a tax- 
oid, such as for example taxol or taxotere, conveniently taxo- 
tere.
[0318] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with another anti-tumour agent, in 
particular an anti-tumour agent selected from one listed under
(ii) herein above.
[0319] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and any one 
o f antihormonal agents listed under (ii) above, for example 
any one o f the anti-oestrogens listed in (ii) above.
[0320] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with an mTOR inhibitor, such as 
those disclosed in W 02008/023161, for example
-continued
OH
[0321] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and an 
mTOR inhibitor, such as those disclosed in W 02008/023161, 
for example
N
OH
N . .N 1
[0322] In particular, the mTOR inhibitor is AZD2014, 
which has the following structure:
[0323] In one aspect, the above combination of the com­
pound o f formula (I) and AZD2014 is suitable for use in the
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treatment o f ER+ve breast cancer, optionally in combination 
with standard o f care hormonal therapy.
[0324] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with an inhibitor o f ΡΙ3Κ-β.
[0325] The combination o f a compound of formula (I) with 
an inhibitor o f ΡΙ3Κ-β may be particularly useful in the treat­
ment o f tumours, for example, prostate, breast (for example 
triple negative breast), squamous cell NSCLC and renal can­
cer, with a background o f PTEN loss.
[0326] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and an 
inhibitor o f ΡΙ3Κ-β.
[0327] In one aspect, the inhibitors o f ΡΙ3Κ-β described 
herein also have some ΡΙ3Κ-δ inhibitory activity.
[0328] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with an inhibitor o f ΡΙ3Κ-β, such 
as any one o f the examples in International patent application 
W O2011/051704.
[0329] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and an 
inhibitor o f ΡΙ3Κ-β, such as anyone o f the examples in Inter­
national patent application W02011/051704.
[0330] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with an inhibitor o f ΡΙ3Κ-β and 
ΡΙ3Κ-δ, such as 8-((lR)-l-(3,5-difluorophenylamino)ethyl)- 
N,N-dimethyl-2-morpholino-4-oxo-4Fl-chromene-6-car- 
boxamide (example 3.06b in International patent application 
W O2011/051704, also known as AZD8186) or a pharmaceu­
tically-acceptable salt thereof:
NH
[0331] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and an 
inhibitor o f ΡΙ3Κ-β and ΡΙ3Κ-δ, such as 8-((lR)-l-(3,5-dif- 
luoropheny lamino)ethyl)-N,N-dimethyl -2 -morpholino -4 - 
oxo-4Fl-chromene-6-carboxamide (example 3.06b in Inter­
national patent application W 02011/051704, also known as 
AZD8186) or a pharmaceutically-acceptable salt thereof:
NH
[0332] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with an inhibitor o f AKT kinase, 
such as (S)-4-amino-N-(l-(4-chlorophenyl)-3-hydroxypro- 
pyl)-l-(7Fl-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-car- 
boxamide (AZD5363) or a pharmaceutically-acceptable salt 
thereof (see for example W 02009/047563).
[0333] The combination of a compound o f Formula (I) and 
an AKT inhibitor may be particularly useful in treating 
tumours with a higher prevalence of mutation in PIK3CA 
gene, such as ER+ve breast cancer, endometrial, ovarian, 
squamous cell NSCLC, gastric, bladder and biliary tract can­
cer.
[0334] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and an 
inhibitor o f AKT kinase, such as (5)-4-amino-N-(l-(4-chlo- 
rophenyl)-3-hydroxypropyl)-l-(7Fl-pyrrolo[2,3-d]pyrimi- 
din-4-yl)piperidine-4-carboxamide (AZD5363) or a pharma­
ceutically-acceptable salt thereof (see for example W 02009/ 
047563).
[0335] In a further aspect o f the invention there is provided 
a compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with olaparib (4-[3-(4-cyclopro- 
panecarbonyl-piperazine-l-carbonyl)-4-fluoro-benzyl]-2Fl- 
phthalazin-l-one) or a pharmaceutically-acceptable salt 
thereof.
[0336] The combination of a compound o f Formula (I) and 
olaparib may be particularly useful both in triple negative 
breast cancer, either BRCA wild type or deficient, and in 
estrogen receptor positive (ER+ve) breast cancer, particularly 
those with mutations in the PIK3CA gene.
[0337] In a further aspect o f the invention there is provided 
a combination suitable for use in the treatment o f cancer 
comprising a compound o f Formula (I) as defined hereinbe­
fore or a pharmaceutically acceptable salt thereof and ola­
parib (4-[3-(4-cyclopropanecarbonyl-piperazine-1 -carbo- 
nyl)-4-fluoro-benzyl]-2Fl-phthalazin-l-one) or a 
pharmaceutically-acceptable salt thereof.
[0338] Particular combinations o f the invention comprise 
any one o f the compounds o f the Examples herein (or a 
pharmaceutically acceptable salt thereof) and an mTOR 
inhibitor, ΡΙ3Κβ inhibitor, inhibitor o f AKT kinase or ola­
parib as described hereinabove. Further particular combina­
tions o f the invention comprise Example 3 (or a pharmaceu­
tically acceptable salt thereof) and an mTOR inhibitor, ΡΙ3Κβ 
inhibitor, inhibitor o f AKT kinase or olaparib as described 
hereinabove. Furtherparticularcombinations ofthe invention
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comprise Example 3 (or a pharmaceutically acceptable salt 
thereof) and a ΡΙ3Κβ inhibitor, inhibitor o f AKT kinase or 
olaparib (or a pharmaceutically-acceptable salt o f any one o f 
these three), as described hereinabove. Still further particular 
examples o f combinations o f the invention comprise 
Example 3 (or a pharmaceutically acceptable salt thereof) and 
any one o f AZD8186, AZD5363 and olaparib (or a pharma­
ceutically-acceptable salt o f any one o f these three). Another 
example o f a combination o f the invention comprises 
Example 3 and AZD2014.
[0339] In all o f the above combinations, it will be under­
stood that the combination may also be dosed with standard o f 
care treatment, as understood by the skilled person, such as 
other treatments from (i) to (xi) hereinbefore. For example, 
when it is intended to use any o f the above combinations for 
the treatment o f ER+ve breast cancer, standard o f care hor­
monal therapy (such as those agents listed under (ii) above) 
may be used in conjunction with the combination o f the 
invention. In other aspects, suitably the standard of care may 
be selected from (i) above.
[0340] Therefore in a further aspect o f the invention, there 
is provided a triple combination suitable for use in the treat­
ment o f cancer
[0341] a) a compound o f formula (I) (such as Example 3) 
or a pharmaceutically-acceptable salt thereof;
[0342] b) an mTOR inhibitor, ΡΙ3Κβ inhibitor, inhibitor 
o f AKT kinase or olaparib or a pharmaceutically-accept­
able salt thereof; and
[0343] c) standard o f care therapy for the cancer to be 
treated.
[0344] Suitably standard o f care therapy may be dosed 
according to its usual dosing regimen, as understood by the 
skilled person.
[0345] According to a further aspect o f the invention there 
is provided a pharmaceutical composition which comprises a 
compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with an anti-tumour agent 
selected from one listed under (i)-(xi) herein above, in asso­
ciation with a pharmaceutically acceptable diluent or carrier.
[0346] According to a further aspect o f the invention there 
is provided a pharmaceutical composition which comprises 
Example 3 or a pharmaceutically acceptable salt thereof in 
combination with an anti-tumour agent selected from one 
listed under (i)-(xi) herein above, in association with a phar­
maceutically acceptable diluent or carrier.
[0347] According to a further aspect o f the invention there 
is provided a pharmaceutical composition which comprises 
Example 3 or a pharmaceutically acceptable salt thereof in 
combination with AZD5363, AZD8186 or olaparib, (or a 
pharmaceutically-acceptable salt o f any one o f these three) in 
association with a pharmaceutically acceptable diluent or 
carrier.
[0348] According to a further aspect o f the invention there 
is provided a pharmaceutical composition which comprises a 
compound o f Formula (I) or a pharmaceutically acceptable 
salt thereof in combination with an anti-tumour agent 
selected from one listed under (i)-(xi) herein above, in asso­
ciation with a pharmaceutically acceptable diluent or carrier 
for use in treating cancer.
[0349] According to a further aspect o f the invention there 
is provided a pharmaceutical composition which comprises 
Example 3 or a pharmaceutically acceptable salt thereof in 
combination with an anti-tumour agent selected from one
listed under (i)-(xi) herein above, in association with a phar­
maceutically acceptable diluent or carrier for use in treating 
cancer.
[0350] According to a further aspect o f the invention there 
is provided a pharmaceutical composition which comprises 
Example 3 or a pharmaceutically acceptable salt thereof in 
combination with AZD5363, AZD8186 or olaparib, (or a 
pharmaceutically-acceptable salt o f any one o f these three) in 
association with a pharmaceutically acceptable diluent or 
carrier for use in treating cancer.
[0351] According to another feature o f the invention there 
is provided the use o f a compound o f the Formula (I) or a 
pharmaceutically acceptable salt thereof in combination with 
an anti-tumour agent selected from one listed under (i)-(xi) 
herein above, in the manufacture o f a medicament for use in 
cancer in a warm-blooded animal, such as man.
[0352] According to another feature o f the invention there 
is provided the use o f Example 3 or a pharmaceutically 
acceptable salt thereof in combination with an anti-tumour 
agent selected from one listed under (i)-(xi) herein above, in 
the manufacture o f a medicament for use in cancer in a warm­
blooded animal, such as man.
[0353] According to another feature o f the invention there 
is provided the use o f Example 3 or a pharmaceutically 
acceptable salt thereof in combination with AZD5363, 
AZD8186 or olaparib, (or a pharmaceutically-acceptable salt 
o f any one o f these three) in the manufacture o f a medicament 
for use in cancer in a warm-blooded animal, such as man.
[0354] Therefore in an additional feature o f the invention, 
there is provided a method of treating cancer in a warm­
blooded animal, such as man, in need o f such treatment which 
comprises administering to said animal an effective amount 
o f a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in combination with an anti-tumour agent 
selected from one listed under (i)-(xi) herein above.
[0355] Therefore in an additional feature o f the invention, 
there is provided a method of treating cancer in a warm­
blooded animal, such as man, in need o f such treatment which 
comprises administering to said animal an effective amount 
o f Example 3 or a pharmaceutically acceptable salt thereof in 
combination with an anti-tumour agent selected from one 
listed under (i)-(xi) herein above.
[0356] Therefore in an additional feature o f the invention, 
there is provided a method of treating cancer in a warm­
blooded animal, such as man, in need o f such treatment which 
comprises administering to said animal an effective amount 
o f Example 3 or a pharmaceutically acceptable salt thereof in 
combination with AZD5363, AZD8186 or olaparib (or a 
pharmaceutically-acceptable salt o f any one o f these three).
[0357] According to a further aspect o f the present inven­
tion there is provided a kit comprising a compound o f For­
mula (I) or a pharmaceutically acceptable salt thereof in com­
bination with an anti-tumour agent selected from one listed 
under (i)-(xi) herein above.
[0358] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an anti-tumour agent selected from one listed under (i)-(xi) 
herein above in a second unit dosage form; and
c) container means for containing said first and second dosage 
forms.
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[0359] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound of Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an anti-tumour agent selected from one listed under (i)-(xi) 
herein above in a second unit dosage form;
c) container means for containing said first and second dosage 
forms; and optionally
d) instructions for use.
[0360] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound of Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an mTOR inhibitor, such as those disclosed in W 02008/ 
023161, for example
OH
N . ,N
in a second unit dosage form; and
c) container means for containing said first and second dosage 
forms.
[0361] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound of Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an inhibitor of ΡΙ3Κ-β, such as any one o f the examples in 
International patent application WO2011/051704, or a phar­
maceutically acceptable salt thereof in a second unit dosage 
form; and
c) container means for containing said first and second dosage 
forms.
[0362] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound of Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an inhibitor of ΡΙ3Κ-β, such as any one o f the examples in 
International patent application WO2011/051704, or a phar­
maceutically acceptable salt thereof in a second unit dosage 
form;
c) container means for containing said first and second dosage 
forms; and optionally
d) instructions for use.
[0363] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an inhibitor o f ΡΙ3Κ-β and ΡΙ3Κ-δ which is 8-((lR )-l-(3 , 
5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-
4-oxo-4Fl-chromene-6-carboxamide (example 3.06b in 
International patent application W O2011/051704, also 
known as AZD8186), or a pharmaceutically acceptable salt 
thereof in a second unit dosage form; and
c) container means for containing said first and second dosage 
forms.
[0364] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an inhibitor o f ΡΙ3Κ-β and ΡΙ3Κ-δ which is 8-((lR )-l-(3 ,
5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino- 
4-oxo-4Fl-chromene-6-carboxamide (example 3.06b in 
International patent application W O2011/051704, also 
known as AZD8186), or a pharmaceutically acceptable salt 
thereof in a second unit dosage form;
c) container means for containing said first and second dosage 
forms; and optionally
d) instructions for use.
[0365] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an inhibitor o f AKT kinase, such as (5)-4-amino-N-(l -(4- 
chlorophenyl)-3-hydroxypropyl)-l-(7Fl-pyrrolo[2,3-d]pyri- 
midin-4-yl)piperidine-4-carboxamide or a pharmaceutically- 
acceptable salt thereof (AZD5363, see for example W 02009/ 
047563), in a second unit dosage form;
c) container means for containing said first and second dosage 
forms; and optionally
d) instructions for use.
[0366] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an inhibitor o f AKT kinase, such as (5)-4-amino-N-(l -(4- 
chlorophenyl)-3-hydroxypropyl)-l-(7Fl-pyrrolo[2,3-d]pyri- 
midin-4-yl)piperidine-4-carboxamide or a pharmaceutically- 
acceptable salt thereof (AZD5363, see for example W 02009/ 
047563), in a second unit dosage form; and
c) container means for containing said first and second dosage 
forms.
[0367] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) an inhibitor o f AKT kinase, such as (5)-4-amino-N-(l -(4- 
chlorophenyl)-3-hydroxypropyl)-l-(7Fl-pyrrolo[2,3-d]pyri- 
midin-4-yl)piperidine-4-carboxamide or a pharmaceutically- 
acceptable salt thereof (AZD5363, see for example W 02009/ 
047563), in a second unit dosage form;
c) container means for containing said first and second dosage 
forms; and optionally
d) instructions for use.
[0368] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound o f Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
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b) olaparib (4-[3-(4-cyclopropanecarbonyl-piperazine-l-car- 
bonyl)-4-fluoro-benzyl]-2H-phthalazin-l-one) or a pharma­
ceutically acceptable salt thereof, in a second unit dosage 
form; and
c) container means for containing said first and second dosage 
forms.
[0369] According to a further aspect o f the present inven­
tion there is provided a kit comprising:
a) a compound of Formula (I) or a pharmaceutically accept­
able salt thereof in a first unit dosage form;
b) olaparib (4-[3-(4-cyclopropanecarbonyl-piperazine-l-car- 
bonyl)-4-fluoro-benzyl]-2Fi-phthalazin-l-one) or a pharma­
ceutically acceptable salt thereof, in a second unit dosage 
form;
c) container means for containing said first and second dosage 
forms; and optionally
d) instructions for use.
[0370] In all o f the above combinations, uses, methods o f 
treatment and kits, AZD5363, A ZD 8186 and olaparib m aybe 
in the form of free bases or in the form o f a pharmaceutically- 
acceptable salt. Therefore in one embodiment AZD5363 is in 
the form of a free base; in a further embodiment AZD5363 is 
in the form o f a pharmaceutically-acceptable salt. In another 
embodiment AZD8186 is in the form o f a free base; in a 
further embodiment AZD8186 is in the form o f a pharmaceu­
tically-acceptable salt. In another embodiment olaparib is in 
the form o f a free base; in a further embodiment olaparib is in 
the form o f a pharmaceutically-acceptable salt.
[0371] Although the compounds o f the Formula (I) are 
primarily o f value as therapeutic agents for use in warm­
blooded animals (including man), they are also useful when­
ever it is required to inhibit the effects o f PI3-kinase-a and -δ. 
Thus, they are useful as pharmacological standards for use in 
the development o f new biological tests and in the search for 
new pharmacological agents.
[0372] Fierein, where the term “combination” is used it is to 
be understood that this refers to simultaneous, separate or 
sequential administration. In one aspect o f the invention 
“combination” refers to simultaneous administration. In 
another aspect o f the invention “combination” refers to sepa­
rate administration. In a further aspect o f the invention “com­
bination” refers to sequential administration. Where the 
administration is sequential or separate, the delay in admin­
istering the second component should not be such as to lose 
the beneficial effect.
[0373] In one embodiment sequential treatment involves 
administration o f each component o f the combination within 
a period o f 11 days. In another embodiment this period is 10 
days. In another embodiment this period is 9 days. In another 
embodiment this period is 8 days. In another embodiment this 
period is 7 days. In another embodiment this period is within 
6 days. In another embodiment this period is within 5 days. In 
another embodiment this period is within 4 days. In another 
embodiment this period is within 3 days. In another embodi­
ment this period is within 2 days. In another embodiment this 
period is within 24 hours. In another embodiment this period 
is within 12 hours.
[0374] Sequential and co-administration are both exempli­
fied herein in the combination experiments with Example 3 
and AZD5363 in BT474 model. In this example, sequential 
administration is illustrated by dosing AZD5363 for 2 days 
followed by Example 3 for 2 days, then 3 days with no dose o f 
either agent before the pattern is repeated (“dosage cycle”). 
Co-administration is illustrated with a dosing regimen where
both AZD5363 and Example 3 are dosed for 2 days, followed 
by 5 days with no dose o f either agent. In these two examples, 
sequential administration appears to be more effective in 
causing tumour regression, illustrating the potential impor­
tance of optimising the regimen. Further potential co-dosing 
regimens include:
1) a dosage cycle where both AZD5363 and Example 3 are 
dosed for 2 days, followed by 3 days with no dose o f either 
agent;
2) a dosage cycle where both AZD5363 and Example 3 are 
dosed for 3 days, followed by 4 days with no dose o f either 
agent;
3) a dosage cycle where both AZD5363 and Example 3 are 
dosed for 4 days, followed by 3 days with no dose o f either 
agent;
4) a dosage cycle where both AZD5363 and Example 3 are 
dosed for 5 days, followed by 2 days with no dose o f either 
agent
5) a dosage cycle where AZD5363 and Example 3 are dosed 
every other day
6) a dosage cycle where AZD5363 and Example 3 are dosed 
every three days
7) a dosage cycle where AZD5363 and Example 3 on dosed 
on a weekly schedule with 3 and 4 day gaps between dosing 
(e.g. Monday/Thursday)
8) a dosage cycle where AZD5363 and Example 3 are dosed 
on a weekly schedule with 2 and 3 days gaps between dosing 
(e.g. Monday/Wednesday/Friday)
[0375] Combinations o f compounds o f formula (I), particu­
larly Example 3, with an mTOR inhibitor, such as AZD2014 
or a ΡΙ3Κ-β inhibitor (such as the β/δ inhibitor A ZD 8186) 
may suitably be dosed in a similar regimen to those described 
above for the combination o f Example 3 and AZD5363.
[0376] A combination o f a compound of formula (I) and 
olaparib may be dosed according to a regimen where olaparib 
is dosed daily and the compound o f formula (I) is dosed 
according to an intermittent dosing schedule (such as for 
example 2 days dosing followed by 3 to 5 days with no dose).
[0377] Each o f these illustrative dosing regimes comprise a 
further aspect o f the invention. Each o f these illustrative dos­
ing regimes may also be applied to combinations with other 
anti-tumour agents listed in (i) to (xi) above.
[0378] It may be advantageous, within a given dosage 
cycle, to administer one specific component o f the combina­
tion before the other— i.e. sequential dosing.
[0379] Therefore, in one embodiment the sequential 
administration comprises the sequential administration of the 
compound o f formula (I) (particularly Example 3) prior to the 
administration o f the other anti-tumour agent listed in (i) to
(xi) above, particularly an anti-tumour agent selected from 
AZD5363, AZD8186 and olaparib, within a dosage cycle.
[0380] In another embodiment the sequential administra­
tion comprises the sequential administration o f the anti-tu­
mour agent listed in (i) to (xi) above, particularly an anti­
tumour agent selected from AZD5363, AZD8186 and 
olaparib, prior to the administration o f compound of formula 
(I) (particularly Example 3) within a dosage cycle.
[0381] In one embodiment, the anti-tumour agent listed in
(i) to (xi) above and the compound o f formula (I) are dosed up 
to 2 days apart. In another embodiment, the anti-tumour agent 
listed in (i) to (xi) above and the compound of formula (I) are 
dosed up to I day apart. In another embodiment, the anti­
tumour agent listed in (i) to (xi) above and the compound of 
formula (I) are dosed up to 18 hours apart. In another embodi­
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ment, the anti-tumour agent listed in (i) to (xi) above and the 
compound of formula (I) are dosed up to 12 hours apart. In 
another embodiment, the anti-tumour agent listed in (i) to (xi) 
above and the compound of formula (I) are dosed up to 6 
hours apart. In another embodiment, the anti-tumour agent 
listed in (i) to (xi) above and the compound o f formula (I) are 
dosed up to 3 hours apart.
[0382] In further embodiments the dosage cycle may be 
from 5 to 10 days in length.
[0383] In further embodiments the dosage cycle may be 
from 6 to 10 days in length.
[0384] In further embodiments the dosage cycle may be 
from 7 to 9 days in length.
[0385] In further embodiments the dosage cycle may be 
from 6 to 8 days in length.
[0386] In further embodiments the dosage cycle may be 10 
days in length.
[0387] In further embodiments the dosage cycle may be 9 
days in length.
[0388] In further embodiments the dosage cycle may be 8 
days in length.
[0389] In further embodiments the dosage cycle may be 7 
days in length.
[0390] In further embodiments the dosage cycle may be 6 
days in length.
[0391] In further embodiments the dosage cycle may be 5 
days in length.
[0392] In further embodiments the dosage cycle may 
involve the compound o f formula (I) (particularly Example 3) 
being dosed for 2-4 consecutive days and not being dosed for 
the other days within a dosage cycle o f 6 to 9 days in length.
[0393] In further embodiments the dosage cycle may 
involve the compound o f formula (I) (particularly Example 3) 
being dosed for 3-4 consecutive days and not being dosed for 
the other days within a dosage cycle o f 6 to 9 days in length; 
(for example, 7 days in length).
[0394] In further embodiments the dosage cycle may 
involve the compound o f formula (I) (particularly Example 3) 
being dosed for 3-5 consecutive days and not being dosed for 
the other days within a dosage cycle o f 7 to 10 days in length.
[0395] In further embodiments the dosage cycle may 
involve the compound o f formula (I) (particularly Example 3) 
being dosed for 5 consecutive days and not being dosed for 
the other days within a dosage cycle o f 6 to 9 days in length.
[0396] In further embodiments the dosage cycle may 
involve the compound o f formula (I) (particularly Example 3) 
being dosed for 4 consecutive days and not being dosed for 
the other days within a dosage cycle o f 6 to 9 days in length; 
(for example, 7 days in length).
[0397] In further embodiments the dosage cycle may 
involve the compound o f formula (I) (particularly Example 3) 
being dosed for 3 consecutive days and not being dosed for 
the other days within a dosage cycle o f 6 to 9 days in length.
[0398] Dosage cycles may be separated by a number o f 
days where none o f the active combination components are 
administered.
[0399] Combination therapy as described above may be 
added on top o f standard o f care therapy typically carried out 
according to its usual prescribing dosage schedule.
Personalised Elealthcare
[0400] Another aspect o f the present invention is based on 
identifying a link between the status o f the gene encoding 
phosphoinositide-3-kinase, catalytic, alpha polypeptide
(PIK3CA) and susceptibility to treatment with a compound of 
Formula (I). This therefore provides opportunities, methods 
and tools for selecting patients for treatment with a compound 
o f Formula (I), particularly cancer patients, and/or avoiding 
treatment o f patients less likely to respond therapeutically to 
the treatment thus avoiding unnecessary treatment and any 
side effects that may be associated with such ineffective treat­
ment.
[0401] The present invention relates to patient selection 
tools and methods (including personalised medicine). The 
selection is based on whether the tumour cells to be treated 
possess wild-type or mutant PIK3CA gene. The PIK3CA 
gene status can therefore be used as a biomarker o f suscepti­
bility to treatment with a PI3K -a and -δ inhibitor.
[0402] There is a clear need for biomarkers that will enrich 
for or select patients whose tumours will respond to treatment 
with a PI3K -a and -δ inhibitor, such as a compound o f For­
mula (I). Patient selection biomarkers that identify the 
patients most likely to respond to an agent are ideal in the 
treatment o f cancer, since they reduce the unnecessary treat­
ment o f patients with non-responding tumours to the potential 
side effects o f such agents.
[0403] A biomarker can be described as “a characteristic 
that is objectively measured and evaluated as an indicator o f 
normal biologic processes, pathogenic processes, or pharma­
cologic responses to a therapeutic intervention”. A  biomarker 
is any identifiable and measurable indicator associated with a 
particular condition or disease where there is a correlation 
between the presence or level o f the biomarker and some 
aspect o f the condition or disease (including the presence of, 
the level or changing level of, the type of, the stage of, the 
susceptibility to the condition or disease, or the responsive­
ness to a drug used for treating the condition or disease). The 
correlation may be qualitative, quantitative, or both qualita­
tive and quantitative. Typically a biomarker is a compound, 
compound fragment or group o f compounds. Such com­
pounds may be any compounds found in or produced by an 
organism, including proteins (and peptides), nucleic acids 
and other compounds.
[0404] Biomarkers may have a predictive power, and as 
such may be used to predict or detect the presence, level, type 
or stage of particular conditions or diseases (including the 
presence or level o f particular microorganisms or toxins), the 
susceptibility (including genetic susceptibility) to particular 
conditions or diseases, or the response to particular treat­
ments (including drug treatments). It is thought that biomar­
kers will play an increasingly important role in the future of 
drug discovery and development, by improving the efficiency 
o f research and development programs. Biomarkers can be 
used as diagnostic agents, monitors o f disease progression, 
monitors o f treatment and predictors o f clinical outcome. For 
example, various biomarker research projects are attempting 
to identify markers o f specific cancers and o f specific cardio­
vascular and immunological diseases. It is believed that the 
development o f new validated biomarkers will lead both to 
significant reductions in healthcare and drug development 
costs and to significant improvements in treatment for a wide 
variety o f diseases and conditions.
[0405] In order to optimally design clinical trials and to 
gain the most information from these trials, a biomarker may 
be required. The marker may be measurable in surrogate and 
tumour tissues. Ideally these markers will also correlate with 
efficacy and thus could ultimately be used for patient selec­
tion.
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[0406] Thus, the technical problem underlying this aspect 
o f the present invention is the identification o f means for 
stratification o f patients for treatment with a compound o f 
Formula (I). The technical problem is solved by provision of 
the embodiments characterized in the claims and/or descrip­
tion herein.
[0407] As detailed in the examples herein, it was found that 
cells that possess a mutation in the PIK3CA are generally 
more susceptible to growth inhibition by the compound o f 
Formula (I).
[0408] The invention provides a method of determining 
sensitivity o f cells to a compound o f Formula (I). The method 
comprises determining the status o f PIK3CA gene in said 
cells. The cells are identified as likely to be sensitive to a 
compound o f Formula I if  the cells possess a mutated 
PIK3CA gene. Those patients with a mutated PIK3CA gene 
are therefore predicted to be particularly susceptible to treat­
ment with a compound o f Formula (I). A  cell is defined as 
sensitive to a compound of Formula (I) if  it inhibits the 
increase in cell number in a cell growth assay (either through 
inhibition o f cell proliferation and/or through increased cell 
death). Methods o f the invention are useful for predicting 
which cells are more likely to respond to a compound o f 
Formula (I) by growth inhibition.
[0409] The present invention is further based, in part, on 
methods that can be used to determine a patient’s responsive­
ness to a compound of Formula (I) including determining 
whether to administer a compound o f Formula (I). Specifi­
cally the methods o f the present invention include the deter­
mination of the gene status o f PIK3CA. The presence o f a 
mutated PIK3CA gene indicates that the tumour cells are 
more likely to respond by growth inhibition when contacted 
with a compound o f Formula (I). The PIK3CA gene status can 
therefore be used to select patients for treatment with a com­
pound o f Formula (I).
[0410] Furthermore an in vitro method for the identification 
o f a patient likely to be sensitive to a compound o f Formula (I) 
is disclosed. Also disclosed are uses o f an oligo- or polynucle­
otide primers or probes capable o f detecting the mutation 
status o f PIK3CA gene is provided. Also disclosed are use o f 
‘kits for the detection o f PIK3CA mutations, including but 
not limited to, the PIK3CA mutation detection kits marketed 
by diagnostic companies including Qiagen and Roche 
Molecular Systems. In another embodiment, the invention 
pertains to an in vitro method for determining whether a 
patient suffering from cancer is likely to be a responder to a 
pharmaceutical treatment with a compound o f Formula (I), 
said method comprising the steps of: (i) obtaining a sample 
representative of the tumour that was previously collected 
from said patient; and, (ii) determining whether the PIK3CA 
genes contain a mutation in said sample. A  mutation in 
PIK3CA gene is indicative o f increased likelihood o f a 
response to treatment with a compound o f Formula (I). As a 
single gene biomarker test, identification o f tumours that 
contain a PIK3CA mutation will enrich for response to a 
compound of Formula (I). Individual tumours that contain a 
PIK3CA mutation have the greatest likelihood o f responding 
to a compound o f Formula (I).
[0411] A sample “representative o f the tumour” can be the 
actual tumour sample isolated, or may be a sample that has 
been further processed, e.g. a sample of PCR amplified 
nucleic acid from the tumour sample.
DEFINITIONS
[0412] In this Personalised Flealthcare section:
[0413] “Allele” refers to a particular form o f a genetic 
locus, distinguished from other forms by its particular nucle­
otide or amino acid sequence.
[0414] “Amplification reactions” are nucleic acid reactions 
which result in specific amplification of target nucleic acids 
over non-taiget nucleic acids. The polymerase chain reaction 
(PCR) is a well known amplification reaction.
[0415] “Cancer” is used herein to refer to neoplastic growth 
arising from cellular transformation to a neoplastic pheno­
type. Such cellular transformation often involves genetic 
mutation.
[0416] “Gene” is a segment o f DNA that contains all the 
information for the regulated biosynthesis o f an RNA prod­
uct, including a promoter, exons, introns, and other sequence 
elements which may be located within 5' or 3' flanking 
regions (not within the transcribed portions o f the gene) that 
control expression.
[0417] “Gene status” refers to whether the gene is wild type 
or not (i.e. mutant).
[0418] “Label” refers to a composition capable o f produc­
ing a detectable signal indicative o f the presence o f the taiget 
polynucleotide in an assay sample. Suitable labels include 
radioisotopes, nucleotide chromophores, enzymes, sub­
strates, fluorescent molecules, chemiluminescent moieties, 
magnetic particles, bioluminescent moieties, and the like. As 
such, a label is any composition detectable by spectroscopic, 
photochemical, biochemical, immunochemical, electrical, 
optical or chemical means.
[0419] “Non-synonymous variation” refers to a variation 
(variance) in or overlapping the coding sequence o f a gene 
that result in the production o f a distinct (altered) polypeptide 
sequence. These variations may or may not affect protein 
function and include missense variants (resulting in substitu­
tion of one amino acid for another), nonsense variants (result­
ing in a truncated polypeptide due to generation of a prema­
ture stop codon) and insertion/deletion variants.
[0420] “Synonymous variation” refers to a variation (vari­
ance) in the coding sequence o f a gene that does not affect 
sequence of the encoded polypeptide. These variations may 
affect protein function indirectly (for example by altering 
expression o f the gene), but, in the absence o f evidence to the 
contrary, are generally assumed to be innocuous.
[0421] “Nucleic acid” refers to single stranded or double 
stranded DNA and RNA molecules including natural nucleic 
acids found in nature and/or modified, artificial nucleic acids 
having modified backbones or bases, as are known in the art.
[0422] “Primer” refers to a single stranded DNA oligo­
nucleotide sequence capable o f acting as a point o f initiation 
for synthesis o f a primer extension product which is comple­
mentary to the nucleic acid strand to be copied. The length 
and sequence o f the primer must be such that they are able to 
prime the synthesis o f extension products. A  typical primer 
contains at least about 7 nucleotides in length o f a sequence 
substantially complementary to the target sequence, but 
somewhat longerprimers are preferred. Usually primers con­
tain about 15-26 nucleotides, but longer or shorter primers 
may also be employed.
[0423] “Polymorphic site” is a position within a locus at 
which at least two alternative sequences are found in a popu­
lation.
[0424] “Polymorphism” refers to the sequence variation 
observed in an individual at a polymorphic site. Polymor­
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phisms include nucleotide substitutions, insertions, deletions 
and microsatellites and may, but need not, result in detectable 
differences in gene expression or protein function. In the 
absence o f evidence of an effect on expression or protein 
function, common polymorphisms, including non-synono- 
mous variants, are generally considered to be included in the 
definition of wild-type gene sequence. A  catalog o f human 
polymorphisms and associated annotation, including valida­
tion, observed frequencies, and disease association, is main­
tained by NCBI (dbSNP: http://www.ncbi.nlm.nih.gov/ 
projects/SNP/). Please note that the term “polymorphism” 
when used in the context o f gene sequences should not be 
confused with the term “polymorphism” when used in the 
context o f solid state form of a compound, that is the crystal­
line or amorphous nature o f a compound. The skilled person 
will understand the intended meaning by its context.
[0425] “Probe” refers to single stranded sequence-specific 
oligonucleotides which have a sequence that is exactly 
complementary to the taiget sequence o f the allele to be 
detected.
[0426] “Response” is defined by measurements taken 
according to Response Evaluation Criteria in Solid Tumours 
(RECIST) involving the classification of patients into two 
main groups: those that show a partial response or stable 
disease and those that show signs o f progressive disease.
[0427] “Stringent hybridisation conditions” refers to an 
overnight incubation at 42° C. in a solution comprising 50% 
formamide, 5xSSC (750 mM NaCl, 75 mM trisodium cit­
rate), 50 mM sodium phosphate (pEl 7.6), 5xDenhardt’s solu­
tion, 10% dextran sulphate, and 20 pg/ml denatured, sheared 
salmon sperm DNA, followed by washing the filters in 0.1 x 
SSC at about 65° C.
[0428] “ Survival” encompasses a patients’ overall survival
and progression-free survival.
[0429] “Overall survival” (OS) is defined as the time from 
the initiation o f drug administration to death from any cause. 
“Progression-free survival” (PFS) is defined as the time from 
the initiation of drug administration to first appearance o f 
progressive disease or death from any cause.
[0430] According to one aspect o f the invention there is 
provided a method for selecting a patient for treatment with a 
compound o f Formula (I), the method comprising providing 
a tumour cell containing sample from a patient; determining 
whether the PIK3CA gene in the patient’s tumour cell con­
taining sample is wild type or mutant; and selecting a patient 
for treatment with a compound o f Formula (I) based thereon.
[0431] The method may include or exclude the actual 
patient sample isolation step. Thus, according to one aspect o f 
the invention there is provided a method for selecting a patient 
for treatment with a compound o f Formula (I), the method 
comprising determining whether the PIK3CA gene in a 
tumour cell containing sample previously isolated from the 
patient is wild type or mutant; and selecting a patient for 
treatment with a compound o f Formula (I) based thereon.
[0432] In one embodiment, the patient is selected for treat­
ment with a compound o f Formula (I) if  the tumour cell DNA 
has a mutant PIK3CA gene. In other embodiments, a patient 
whose tumour cell DNA possesses a wild type PIK3CA gene 
is not selected for treatment with a compound o f Formula (I).
[0433] According to another aspect o f the invention there is 
provided a method for predicting a patient’s responsiveness 
to a compound of Formula (I), the method comprising deter­
mining whether the PIK3CA gene in the patient’s tumour
cells is wild type or mutant and based thereon, predicting a 
patient’s responsiveness to treatment with a compound of 
Formula (I).
[0434] According to another aspect o f the invention there is 
provided a method for determining the likelihood o f effec­
tiveness o f treatment with a compound o f formula I in a 
human patient affected with cancer comprising: determining 
whether the PIK3CA gene(s) in the patient’s tumour cells is 
wild type or mutant and based thereon, predicting a patient’s 
responsiveness to treatment with a compound o f Formula (I).
[0435] For the purpose o f this invention, a gene status o f 
wild-type is meant to indicate normal or appropriate expres­
sion o f the gene and normal function o f the encoded protein. 
In contrast, mutant status is meant to indicate abnormal or 
inappropriate gene expression, or expression of a protein with 
altered function, consistent with the known roles o f mutant 
PIK3CA in cancer (as described herein). Any number of 
genetic or epigenetic alterations, including but not limited to 
mutation, amplification, deletion, genomic rearrangement, or 
changes in methylation profile, may result in a mutant status. 
Flowever, if  such alterations nevertheless result in appropriate 
expression of the normal protein, or a functionally equivalent 
variant, then the gene status is regarded as wild-type. 
Examples o f variants that typically would not result in a 
functional mutant gene status include synonomous coding 
variants and common polymorphisms (synonymous or non- 
synonymous). As discussed below, gene status can be 
assessed by a functional assay, or it may be inferred from the 
nature o f detected deviations from a reference sequence.
[0436] In certain embodiments the wild-type or mutant sta­
tus o f the PIK3CA gene is determined by the presence or 
absence of non-synonymous nucleic acid variations in the 
genes. Observed non-synonymous variations corresponding 
to known common polymorphisms with no annotated func­
tional effects do not contribute to a gene status o f mutant.
[0437] Other variations in the PIK3CA gene that signify 
mutant status include splice site variations that decrease rec­
ognition of an intron/exon junction during processing o f pre- 
mRNA to mRNA. This can result in exon skipping or the 
inclusion o f normally intronic sequence in spliced mRNA 
(intron retention or utilization o f cryptic splice junctions). 
This can, in turn, result in the production o f aberrant protein 
with insertions and/or deletions relative to the normal protein. 
Thus, in other embodiments, the gene has a mutant status if  
there is a variant that alters splice site recognition sequence at 
an intron/exon junction.
[0438] In addition, the measurement o f mutation status or 
activation status o f additional genes, such as Kras, a potential 
marker o f resistance in tumours with aberrant or deregulated 
PIK3CA or PI3K-a, could help increase the predictivity o f a 
Personalised Medicine approach.
[0439] In a survey we conducted at AstraZeneca on breast 
cancers (based on COSMIC database (Welcome Trust Sanger 
Institute, September 2011), >55 different mutations in the 
PIK3CA gene were identified from across a dataset covering 
>5K human tumours. The majority o f mutations occurred at 
<1% frequency, 3 occurred at 1-3% frequency, but 4 muta­
tions accounted for -88%  of total PIK3CA mutations. These 
were kinase domain missense mutations in the C terminal 
kinase domain, H1047R (55%) and H1047L (5%), and the 
helical domain residues, E545K (18%) and E542K (11%). A 
longer list o f other prevalent breast cancer mutations, 
although not intended to be exhaustive, encompasses R38H, 
R38C, R88Q, N345K, C420R, E453Q, P539R, E542K,
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E545K, E545A, Q546K, Q546P, M1043I , M1043V, 
H1047R, H1047L, H1047Y. EIence diagnostic assays can be 
built that focus on detection of the most common mutations, 
thereby allowing identification of the majority o f PIK3CA 
mutations. For example the Cobas (TM) PIK3CA Mutation 
Test from Roche Molecular Systems is designed to detect 17 
mutations in exons I, 4, 7, 9 and 20 o f the PIK3CA gene 
(E542K, E545A, E545G, E545K, E545D, Q546K, Q546R, 
Q546E, Q546L, N345K, C420R, R88Q, H1047L, H1047R, 
H1047Y, G1049R and M 1043I) in DNA isolated from for­
malin-fixed paraffin-embedded tumour samples. This kit is 
capable o f picking up to -95%  o f mutations in ER+ve breast 
cancer. The distribution o f mutations differs across other 
tumour types and the diagnostic strategy may be adapted 
accordingly. For example, in endometrial cancer, there is a 
more even distribution o f mutations spread throughout the 
PIK3CA gene coding sequence and with larger number o f 
mutations in the N terminal region of the protein (communi­
cated by Douglas A. Levine, M. D, TCGA 2nd Annual Sym­
posium, Nov. 28, 2012), compared with breast cancers.
[0440] For PIK3CA, reference sequences are available for 
the gene (GenBank accession number: NG 012113), mRNA 
(GenBank accession number: NM 006218), and protein
(GenBank accession number: NP 006209 or Swiss-Prot
accession: P42336). The reference gene (genomic region) 
sequences include 5000 bases o f upstream sequence and 2000 
bases o f downstream sequence. Mutations within PIK3CA 
are well known (COSMIC database— Welcome Trust Sanger 
Institute), and the person o f skill in the art will be able to 
determine the PIK3CA gene status, i.e. whether a particular 
PIK3CA gene is wild type or mutant, based on comparison o f 
DNA or protein sequence with wild type.
[0441] It will be apparent that the gene and mRNA 
sequences disclosed for PIK3CA and the p i 10a catalytic 
subunit o f PI3-kinase alpha protein sequence are each a rep­
resentative sequence. In normal individuals there are two 
copies o f each gene, a maternal and paternal copy, which will 
likely have some sequence differences, moreover within a 
population there will exist numerous allelic variants o f the 
gene sequence. Other sequences regarded as wild type 
include those that possess one or more synonymous changes 
to the nucleic acid sequence (which changes do not alter the 
encoded protein sequence), non-synonymous common poly­
morphisms (e.g. germ-line polymorphisms) which alter the 
protein sequence but do not affect protein function, and 
intronic non-splice-site sequence changes.
[0442] According to another aspect o f the invention there is 
provided a method for determining the likelihood o f effec­
tiveness o f treatment with a compound of Formula (I) in a 
human patient affected with cancer comprising: detecting the 
presence or absence o f at least one non-synonymous nucleic 
acid variance in the PIK3CA gene o f said patient relative to 
the wild type gene, wherein the presence o f at least one 
somatic non-synonymous nucleic acid variance in the 
PIK3CA gene indicates that treatment with the compound of 
Formula (I) is likely to be effective.
[0443] According to another aspect o f the invention there is 
provided a method for assessing the susceptibility o f an indi­
vidual to treatment with a compound o f Formula (I), which 
method comprises:
[0444] (i) determining the non-synonymous mutation
status o f the PIK3CA gene in tumour cell DNA from the 
individual; and,
[0445] (ii) determining the likely susceptibility o f the 
individual to treatment with a compound o f Formula (I) 
by reference to the non-synonymous mutation status o f 
the PIK3CA gene in the tumour cells.
[0446] There are numerous techniques available to the per­
son skilled in the art to determine the gene status o f PIK3CA. 
The gene status can be determined by determination o f the 
nucleic acid sequence. This could be via direct sequencing of 
the full-length gene or analysis o f specific sites within the 
gene, e.g. commonly mutated sites.
[0447] An alternative means for determining whether or not 
the PIK3CA gene is wild type or mutant is to assess the 
function o f the transcribed gene. Functional mutation o f this 
PIK3CA gene produces a protein that has increased lipid 
kinase activity resulting in increased downstream signalling 
o f the pathway in cells, including, but not limited to, activa­
tion o f Akt and S6 kinase. The assays to assess the functional 
status o f PIK3CA variants when expressed in cells include 
but are not limited to:
(i) increased production o f the product o f the kinase activity 
o f the PIK3CA gene, phosphatidylinositol-trisphosphate (PI 
(3,4,5)P3);
(ii) increased levels o f phosphorylated Akt or S6 kinase;
(iii) increased focus and colony formation of NIH-3T3 cells 
transfected with the variant o f PIK3CA; (Ikenoue T et al., 
CancerRes., 2005 65, 4562-4567).
Samples
[0448] The patient’s sample to be tested for the gene status 
can be any tumour tissue or tumour-cell containing sample 
obtained or obtainable from the individual. The test sample is 
conveniently a sample o f blood, mouth swab, biopsy, or other 
body fluid or tissue obtained from an individual. Particular 
examples include: circulating tumour cells, circulating DNA 
in the plasma or serum, cells isolated from the ascites fluid o f 
ovarian cancer patients, lung sputum for patients with 
tumours within the lung, a fine needle aspirate from a breast 
cancer patient, urine, peripheral blood, a cell scraping, a hair 
follicle, a skin punch or a buccal sample.
[0449] It will be appreciated that the test sample may 
equally be a nucleic acid sequence corresponding to the 
sequence in the test sample, that is to say that all or a part o f 
the region in the sample nucleic acid may firstly be amplified 
using any convenient technique e.g. polymerase chain reac­
tion (PCR), before analysis. The nucleic acid may be genomic 
DNA or fractionated or whole cell RNA. In particular 
embodiments the RNA is whole cell RNA and is used directly 
as the template for labelling a first strand cDNA using random 
primers or poly A primers. The nucleic acid or protein in the 
test sample may be extracted from the sample according to 
standard methodologies (see Green & Sambrook, Eds., 
Molecular Cloning: A  Laboratory Manual, (2012,4th edition, 
Vol. 1-3, ISBN 9781936113422), Cold Spring Harbor Labo­
ratory Press, Cold Spring Harbor, N.Y.).
[0450] The diagnostic methods o f the invention can be 
undertaken using a sample previously taken from the indi­
vidual or patient. Such samples may be preserved by freezing 
or fixed and embedded in formalin-paralfin or other media. 
Alternatively, a fresh tumour cell containing sample may be 
obtained and used.
[0451] The methods o f the invention can be applied using 
cells from any tumour. Suitable tumours for treatment with a 
compound o f Formula (I) have been described hereinbefore.
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[0452] Mutations in PIK3CA are found broadly in clinical 
tumours, but the prevalence of mutations in each gene varies 
significantly by tumour tissue type. For example, PIK3CA 
mutations are relatively common in breast cancer but rela­
tively rare in kidney tumours.
TABLE I
Tissue
PIK3CA 
mutation prevalence (%)
Penis 29
Endometrium 26
Breast 26
Small_intestine 20
Urinary tract 17
Skin 13
Large intestine 12
Stomach 9
Biliary_tract 9
Ovary 9
Cervix 8
Oesophagus 6
Liver 6
Upper aerodigestive tract 6
CNS 5
NS 5
Lung 4
Thyroid 4
Pituitary 3
Soft_tissue 3
Pancreas 3
Kidney 2
Prostate 2
Meninges I
Eye I
Autonomic ganglia I
Haematopoietic/lymphoid I
Adrenal_gland 0
Bone 0
Lallopian_tube 0
Gastrointestinal_tract_(site_indeterminate) 0
Peritoneum 0
Salivary_gland 0
Testis 0
Thymus 0
Vagina 0
Table I : P revalence o f  P IK 3C A  m utations in clinical sam ples. Source for P IK 3C A  infor­
m ation is the CO SM IC  database (release v62). The patien t selection m ethods o f  the inven­
tion m ay  be particularly  useful in the disease (tissue) segm ents w here there is a high 
incidence o f  PEK.3CA m utations (e.g. breast, u rinary  tract, endom etrium , large intestine, 
cervix etc.).
[0453] As will be evident to anyone skilled in the art, this 
frequency data is continually being refined and updated as 
new and more comprehensive data emerges from Fluman 
Cancer Genome profiling consortia such as the TCGA (The 
Cancer Genome Atlas) and ICGC (International Cancer 
Genome Consortium). Flence additional tumour types with 
PIK3CA dependency may be identified and be eligible for 
treatment with the compounds described herein.
Methods for Detection o f Nucleic Acids
[0454] The detection of mutant PIK3CA nucleic acids can 
be employed, in the context o f the present invention, to pre­
dict the response to drug treatment. Since mutations in these 
genes occur at the DNA level, the methods o f the invention 
can be based on detection of mutations or variances in 
genomic DNA, as well as transcripts and proteins themselves. 
It can be desirable to confirm mutations in genomic DNA by 
analysis o f transcripts and/or polypeptides, in order to ensure 
that the detected mutation is indeed expressed in the subject. 
It will be apparent to the person skilled in the art that there are 
a large number o f analytical procedures which may be used to
detect the presence or absence o f variant nucleotides at one or 
more positions in a gene. In general, the detection o f allelic 
variation requires a mutation discrimination technique, 
optionally an amplification reaction (such as one based on 
polymerase chain reaction) and optionally a signal generation 
system. There are a multitude o f mutation detection tech­
niques available in the art and these may be used in combi­
nation with a signal generation system, of which there are 
numerous available in the art. Many methods for the detection 
o f allelic variation are reviewed by Nollau et al., Clin. Chem., 
1997,43,1114-1120; Anderson S M. Expert Rev M ol Diagn., 
2011,11, 635-642; M eyersonM. et al., N atR ev Genet., 2010, 
11, 685-696; and in standard textbooks, for example “Labo­
ratory Protocols fo r  Mutation Detection”, Ed. by U. Lande- 
gren, Oxford University Press, 1996 and “PCR”, 2nd Edition 
by Newton & Graham, BIOS Scientific Publishers Limited, 
1997.
[0455] As noted above, determining the presence or 
absence o f a particular variance or plurality o f variances in the 
PIK3CA gene in a patient with cancer can be performed in a 
variety o f ways. Such tests are commonly performed using 
DNA or RNA collected from biological samples, e.g., tissue 
biopsies, urine, stool, sputum, blood, cells, tissue scrapings, 
breast aspirates or other cellular materials, and can be per­
formed by a variety o f methods including, but not limited to, 
PCR, hybridization with allele-specific probes, enzymatic 
mutation detection, chemical cleavage o f mismatches, mass 
spectrometry or DNA sequencing, including minisequenc­
ing.
[0456] Suitable mutation detection techniques include 
amplification refractory mutation system (ARMS™), ampli­
fication refractory mutation system linear extension 
(ALEX™) competitive oligonucleotide priming system 
(COPS), Taqman, Molecular Beacons, restriction fragment 
length polymorphism (RFLP), and restriction site based PCR 
and fluorescence resonance energy transfer (FRET) tech­
niques.
[0457] In particular embodiments the method employed for 
determining the nucleotide(s) within a biomarker gene is 
selected from: allele-specific amplification (allele specific 
PCR)— such as amplification refractory mutation system 
(ARMS), sequencing, allelic discrimination assay, hybridisa­
tion, restriction fragment length polymorphism (RFLP) or 
oligonucleotide ligation assay (OLA).
[0458] In particular embodiments, hybridization with allele 
specific probes can be conducted by: (I) allele specific oligo­
nucleotides bound to a solid phase (e.g. glass, silicon, nylon 
membranes) with the labelled sample in solution, for example 
as in many DNA chip applications; or, (2) bound sample 
(often cloned DNA or PCR amplified DNA) and labelled 
oligonucleotides in solution (either allele specific or short so 
as to allow sequencing by hybridization). Diagnostic tests 
may involve a panel o f variances, often on a solid support, 
which enables the simultaneous determination o f more than 
one variance. Such hybridization probes are well known in 
the art (see, e.g., Green & Sambrook, Eds., Molecular Clon­
ing: A  Laboratory Manual, (2012,4th edition, Vol. I -3, ISBN 
9781936113422), Cold Spring Flarbor Laboratory Press, 
Cold Spring Flarbor, N.Y.) and may span two or more vari­
ance sites.
[0459] Thus, in one embodiment, the detection of the pres­
ence or absence o f at least one mutation provides for contact­
ing PIK3CA nucleic acid containing a putative mutation site 
with at least one nucleic acid probe. The probe preferentially
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hybridizes with a nucleic acid sequence including a variance 
site and containing complementary nucleotide bases at the 
variance site under selective hybridization conditions. 
Hybridization can be detected with a detectable label using 
labels known to one skilled in the art. Such labels include, but 
are not limited to radioactive, fluorescent, dye, and enzymatic 
labels.
[0460] In another embodiment, the detection o f the pres­
ence or absence o f at least one mutation provides for contact­
ing PIK3CA nucleic acid containing a putative mutation site 
with at least one nucleic acid primer. The primer preferen­
tially hybridizes with a nucleic acid sequence including a 
variance site and containing complementary nucleotide bases 
at the variance site under selective hybridization conditions.
[0461] Oligonucleotides used as primers for specific ampli­
fication may carry the complementary nucleotide base to the 
mutation o f interest in the centre o f the molecule (so that 
amplification depends on differential hybridization; see, e.g., 
Gibbs, et al., 1989. Nucl. Acids Res., 17, 2437-248) or at the 
extreme 3'-terminus o f one primer where, under appropriate 
conditions, mismatch can prevent, or reduce polymerase 
extension (see, e.g., Prossner, 1993, Tibtech, 11 238).
[0462] In yet another embodiment, the detection o f the 
presence or absence of at least one mutation comprises 
sequencing at least one nucleic acid sequence and comparing 
the obtained sequence with the known wild type nucleic acid 
sequence.
[0463] Alternatively, the presence or absence o f at least one 
mutation comprises mass spectrometric determination of at 
least one nucleic acid sequence.
[0464] In one embodiment, the detection of the presence or 
absence of at least one nucleic acid variance comprises per­
forming a polymerase chain reaction (PCR). The target 
nucleic acid sequence containing the hypothetical variance is 
amplified and the nucleotide sequence o f the amplified 
nucleic acid is determined Determining the nucleotide 
sequence of the amplified nucleic acid comprises sequencing 
at least one nucleic acid segment. Alternatively, amplification 
products can be analyzed using any method capable o f sepa­
rating the amplification products according to their size, 
including automated and manual gel electrophoresis, and the 
like.
[0465] Mutations in genomic nucleic acid are advanta­
geously detected by techniques based on mobility shift in 
amplified nucleic acid fragments. For instance, Chen et al., 
Anal Biochem  1996, 23961-9, describe the detection o f 
single-base mutations by a competitive mobility shift assay. 
Moreover, assays based on the technique o f Marcelino et al., 
BioTechniques 1999, 26, 1134-1148 are available commer­
cially.
[0466] In a particular example, capillary heteroduplex 
analysis may be used to detect the presence o f mutations 
based on mobility shift o f duplex nucleic acids in capillary 
systems as a result o f the presence of mismatches.
[0467] Generation o f nucleic acids for analysis from 
samples generally requires nucleic acid amplification. Many 
amplification methods rely on an enzymatic chain reaction 
(such as a polymerase chain reaction, a ligase chain reaction, 
or a self-sustained sequence replication) or from the replica­
tion o f all or part o f the vector into which it has been cloned. 
Preferably, the amplification according to the invention is an 
exponential amplification, as exhibited by for example the 
polymerase chain reaction.
[0468] Many taiget and signal amplification methods have 
been described in the literature, for example, general reviews 
o f these methods in Landegren, U., et al., Science, 1988 242, 
229-237 and Lewis, R., Genetic Engineering News 1990, 10, 
54-55. These amplification methods can be used in the meth­
ods of our invention, and include polymerase chain reaction 
(PCR), PCR in situ, ligase amplification reaction (LAR), 
ligase hybridisation, Q3 bacteriophage replicase, transcrip­
tion-based amplification system (TAS), genomic amplifica­
tion with transcript sequencing (GAWTS), nucleic acid 
sequence-based amplification (NASBA) and in situ hybridi­
sation. Primers suitable for use in various amplification tech­
niques can be prepared according to methods known in the 
art.
[0469] Polymerase Chain Reaction (PCR) PCR is a nucleic 
acid amplification method described inter alia in U.S. Pat. 
Nos. 4,683,195 and 4,683,202. PCR consists o f repeated 
cycles o f DNA polymerase generated primer extension reac­
tions. The target DNA is heat denatured and two oligonucle­
otides, which bracket the target sequence on opposite strands 
o f the DNA to be amplified, are hybridised. These oligonucle­
otides become primers for use with DNA polymerase. The 
DNA is copied by primer extension to make a second copy of 
both strands. By repeating the cycle o f heat denaturation, 
primer hybridisation and extension, the target DNA can be 
amplified a million fold or more in about two to four hours. 
PCR is a molecular biology tool, which must be used in 
conjunction with a detection technique to determine the 
results o f amplification. An advantage o f PCR is that it 
increases sensitivity by amplifying the amount o f target DNA 
by I million to I billion fold in approximately 4 hours. PCR 
can be used to amplify any known nucleic acid in a diagnostic 
context (Mok et al., Gynaecologic Oncology, 1994, 52: 247- 
252,).
[0470] An allele specific amplification technique such as 
Amplification Refractory Mutation System (ARMS™) 
(Newton e ta l .,Nucleic Acids Res., 1989, 17, 2503-2516) can 
also be used to detect single base mutations. Under the appro­
priate PCR amplification conditions a single base mismatch 
located at the 3'-end of the primer is sufficient for preferential 
amplification o f the perfectly matched allele (Newton et al., 
1989, supra), allowing the discrimination o f closely related 
species. The basis o f an amplification system using the prim­
ers described above is that oligonucleotides with a m is­
matched 3'-residue will not function as primers in the PCR 
under appropriate conditions. This amplification system 
allows genotyping solely by inspection of reaction mixtures 
after agarose gel electrophoresis.
[0471] Analysis o f amplification products can be per­
formed using any method capable o f separating the amplifi­
cation products according to their size, including automated 
and manual gel electrophoresis, mass spectrometry, and the 
like.
[0472] The methods o f nucleic acid isolation, amplification 
and analysis are routine for one skilled in the art and examples 
o f protocols can be found, for example, Green & Sambrook, 
Eds., Molecular Cloning: A  Laboratory Manual, (2012, 4th 
edition, Vol. 1-3, ISBN 9781936113422), Cold Spring Har­
bor Laboratory Press, Cold Spring Harbor, N.Y.) Particularly 
useful protocol source for methods used in PCR amplification 
is PCR  (Basics: From Background to Bench) by M. J. 
McPherson, S. G. Mailer, R. Beynon, C. Howe, Springer 
Verlag; 1st edition (Oct. 15, 2000), ISBN: 0387916008.
US 2014/0206700 Al
33
Jul. 24, 2014
[0473] The present invention also provides predictive and 
diagnostic kits comprising degenerate primers to amplify a 
target nucleic acid in the PIK3CA gene and instructions com­
prising; amplification protocol and analysis of the results. The 
kit may alternatively also comprise buffers, enzymes, and 
containers for performing the amplification and analysis o f 
the amplification products. The kit may also be a component 
o f a screening, or diagnostic kit comprising other tools such 
as DNA microarrays, or other supports. Preferably, the kit 
also provides one or more control templates, such as nucleic 
acids isolated from normal tissue sample, and/or a series o f 
samples representing different variances in the reference 
genes.
[0474] In one embodiment, the kit provides two or more 
primer pairs, each pair capable of amplifying a different 
region of the reference (PIK3CA) gene (each region a site o f 
potential variance) thereby providing a kit for analysis o f 
expression o f several gene variances in a biological sample in 
one reaction or several parallel reactions.
[0475] Primers in the kits may be labelled, for example 
fluorescently labelled, to facilitate detection o f the amplifica­
tion products and consequent analysis o f the nucleic acid 
variances. The kit may also allow for more than one variance 
to be detected in one analysis. A  combination kit will there­
fore comprise o f primers capable o f amplifying different 
segments o f the reference gene. The primers may be differ­
entially labelled, for example using different fluorescent 
labels, so as to differentiate between the variances.
[0476] Also disclosed are use o f ‘kits for the detection o f 
PIK3CA mutations, including but not limited to, the PIK3CA 
mutation detection kits marketed by diagnostic companies 
including Qiagen and Roche Molecular Systems.
[0477] In another aspect, the invention provides a method 
o f treating a patient suffering from cancer comprising: deter­
mining the mutant or wild type status o f the PIK3CA gene in 
the patient’s tumour cells and if  the PIK3CA gene is mutant, 
administering to the patient an effective amount o f a com­
pound o f Formula (I).
[0478] As used herein, the terms “effective” and “effective­
ness” includes both pharmacological effectiveness and physi­
ological safety. Pharmacological effectiveness refers to the 
ability o f the treatment to result in a desired biological effect 
in the patient. Physiological safety refers to the level o f tox­
icity, or other adverse physiological effects at the cellular, 
organ and/or organism level (often referred to as side-effects) 
resulting from administration o f the treatment. “Less effec­
tive” means that the treatment results in a therapeutically 
significant lower level o f pharmacological effectiveness and/ 
or a therapeutically greater level o f adverse physiological 
effects.
[0479] According to another aspect o f the invention there is 
provided the use o f a compound of Formula (I) to treat a 
cancer patient whose tumour cells have been identified as 
possessing a mutant PIK3CA gene.
[0480] According to another aspect o f the invention there is 
provided a compound o f Formula (I) for treating cancers with 
tumour cells identified as harbouring mutant PIK3CA gene.
[0481] In still further embodiments, the invention relates to 
pharmaceutical composition comprising a compound o f For­
mula (I) for use in the prevention and treatment o f cancer with 
tumour cells identified as harbouring a mutant PIK3CA gene.
[0482] For all the aspects above, mutant forms of PIK3CA 
determined/identified are at all positions across the gene.
[0483] For all the aspects above, using tumours such as 
breast cancer as an example, particular mutant forms of 
PIK3CA determined/identified are those at positions R38, 
R88, N345, C420, E453, P539, E542K, E545K, Q546, 
M1043, M l043 and H1047R,
[0484] For all the aspects above, using tumours such as 
breast cancer as an example, particular mutant forms of 
PIK3CA determined/identified are those at positions E542, 
E545 and H1047.
Personalised Healthcare/Personalised Medicine Examples
Cell ProliferationAssay in Tumour Cell Lines
[0485] The sensitivity o f a panel o f human cancer cell lines 
to the effects o f compounds was determined in a standard 
proliferation assay. Assay protocol details are captured under 
Biological assays (g), above.
Mutation CorrelationAnalysis
Methods
[0486] Pharmacology data measuring cell growth inhibi­
tion in response to treatment with Example 3 was obtained for 
a collection of 209 cancer cell lines from a variety o f tissues 
and from multiple sources. Each cell line was classified as 
sensitive (GI50<=1.0 μΜ), or resistant (GI50>1.0 μΜ).
[0487] Mutation status for genes in each cell line was 
obtained by integrating results from internal (AstraZeneca) 
and public sources. Public data included all cell line data from 
the Genomics o f Drug Sensitivity in Cancer Project release 3 
(Garnett M J, et al. Nature, 2012, March 483, 570-5), Cancer 
Cell Line Encyclopedia project (Barretina J, et al., Nature 
2012,483, 603-7) and the Catalogue o f Somatic Mutations In 
Cancer (COSMIC) database (release v6 1; http://www.sanger. 
ac.uk/genetics/CGP/cosmic/; Forbes S A, et al. NucleicAcids 
Res, 2011, 39 (Database issue):D945-50; Forbes S A, et al., 
Curr Protoc Hum Genet. 2008; Chapter 10:Unit 10.11.), and 
selectedjoumal articles. Silent coding region mutations (syn­
onymous variants) and non-synonymous polymorphisms 
were excluded, and, for the purpose o f this analysis, the 
zygosity o f mutations was ignored. For each combination of 
cell line and gene, status was summarized as mutant (MUT), 
wild-type (WT) or inconsistent (INCON). Some initially 
inconsistent cases (independent WT and MUT observations 
for the same gene in the same cell line) were resolved by 
weighting internal observations and those for the Cancer Cell 
line Project (CCLP) subset o f COSMIC, or by selecting a 
status after manual review. In cases where inconsistent obser­
vations could not be resolved, the INCON label was retained 
and the gene status was regarded as unknown during analysis.
[0488] Associations between mutation status and response 
were identified by constructing contingency tables for each 
gene and determining corresponding odd-ratios and two- 
tailed Fisher’s exact test p-values. The cell lines classified as 
marginal for response were excluded from the initial analyses 
to identify candidate biomarkers. For mutation status, MUT 
or WT findings were counted and Genes with fewer than 4 
WT or 4 MUT cell lines were also excluded.
Results and Discussion
[0489] Associations between mutation status and response 
were identified as described in Methods. The cell line
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response to Example 3 and the corresponding genetic status 
for the PIK3CA gene is shown in Table 3.
TABLE 3
The pharmacology data, response classification and the mutation status
o f the PIK3CA gene for the cell lines used in this study.
Cell Line Category Tissue GI50 μΜ PIK3C2
RS411 Sensitive Blood/lymph 9.03E-02 WT
T47D Sensitive Breast 0.1982 MUT
H596 Sensitive Lung 0.3018 MUT
MCF7 Sensitive Breast 0.3094 MUT
MV411 Sensitive Blood/lymph 0.3816 WT
HRA19 Sensitive Rectum 0.3926 MUT
IM95M Sensitive Stomach 0.4359 MUT
MDAMB453 Sensitive Breast 0.4564 MUT
JEKOl Sensitive Blood/lymph 0.4994 WT
SNU601 Sensitive Stomach 0.5063 MUT
HCC1187 Sensitive Breast 0.5088 WT
SW48 Sensitive Colon 0.5131 MUT
H1703 Sensitive Lung 0.5144 WT
THPl Sensitive Blood/lymph 0.5281 WT
LK2 Sensitive Lung 0.5884 WT
HUPT4 Sensitive Pancreas 0.6408 WT
L363 Sensitive Blood/lymph 0.6812 MUT
TCCSUP Sensitive Bladder 0.7237 MUT
VMCUBl Sensitive Bladder 0.7319 MUT
RERFLCSQ1 Sensitive Lung 0.7711 MUT
HCC1419 Sensitive Breast 0.7799 WT
LNCAPC ASRES Sensitive Prostate 0.7924 WT
CCK81 Sensitive Colon 0.8031 MUT
HCC1954 Sensitive Breast 0.8794 MUT
SW948 Sensitive Colon 0.9111 MUT
PANC0203 Sensitive Pancreas 0.9628 WT
BFTC905 Sensitive Bladder 0.9662 WT
REH Resistant Blood/lymph 1.047 WT
SNU216 Resistant Stomach 1.072 WT
SKCOl Resistant Colon 1.128 WT
SUM52PE Resistant Breast 1.145 WT
RT11284 Resistant Bladder 1.171 WT
OVCAR3 Resistant Ovary 1.179 WT
MOLM13 Resistant Blood/lymph 1.22 WT
C99 Resistant Colon 1.224 WT
CALU3 Resistant Lung 1.296 WT
N87 Resistant Stomach 1.301 WT
2313287 Resistant Stomach 1.339 WT
PAMC 82 Resistant Stomach 1.366 WT
HCC1569 Resistant Breast 1.369 WT
AGS Resistant Stomach 1.414 MUT
JIMTl Resistant Breast 1.46 MUT
HGC27 Resistant Stomach 1.501 MUT
MKNl Resistant Stomach 1.579 MUT
SKB R3 Resistant Breast 1.588 WT
SNU368 Resistant Liver 1.597 WT
PANC89 Resistant Pancreas 1.618 WT
ASPCl Resistant Pancreas 1.74 WT
SNU484 Resistant Stomach 1.785 WT
H2085 Resistant Lung 1.835 WT
HARA Resistant Lung 1.906 WT
AZ521 Resistant Duodenum 2.063 WT
HPAC Resistant Pancreas 2.162 WT
NOMOl Resistant Blood/lymph 2.167 WT
PNTlA Resistant Prostate 2.17 WT
H1975 Resistant Lung 2.262 MUT
OCUMl Resistant Stomach 2.332 WT
BT20 Resistant Breast 2.36 MUT
HCT8 Resistant Colon 2.51 MUT
COLO320DM Resistant Colon 2.512 WT
PANC1005 Resistant Pancreas 2.607 WT
SW403 Resistant Colon 2.61 MUT
MONOMAC6 Resistant Blood/lymph 2.622 WT
HPAFII Resistant Pancreas 2.63 WT
HT1197 Resistant Bladder 2.8 MUT
LNCAPCLONEFGC Resistant Prostate 3.007 WT
HCC95 Resistant Lung 3.107 WT
SNU620 Resistant Stomach 3.144 WT
TABLE 3-continued
The pharmacology data, response classification and the mutation status
o f the PIK3CA gene for the cell lines used in this study.
Cell Line Category Tissue GI50 μΜ PIK3C2
MOLP8 Resistant Blood/lymph 3.289 WT
H2291 Resistant Lung 3.291 WT
DMSl 14 Resistant Lung 3.294 WT
MHCC97L Resistant Liver 3.353 WT
CFPACl Resistant Pancreas 3.384 WT
HS766T Resistant Pancreas 3.467 WT
ZR751 Resistant Breast 3.558 WT
PC3 Resistant Prostate 3.833 WT
22RV1 Resistant Prostate 4.144 MUT
RKO Resistant Colon 4.323 MUT
977 Resistant Bladder 4.42 WT
MOLMl 6 Resistant Blood/lymph 4.601 WT
H358 Resistant Lung 4.642 WT
LUDLUl Resistant Lung 4.646 WT
QGPl Resistant Pancreas 4.865 WT
OE19 Resistant Esophagus 5.129 WT
SW1710 Resistant Bladder 5.339 WT
PANCl Resistant Pancreas 5.344 WT
SNU449 Resistant Liver 5.41 WT
647V Resistant Bladder 5.464 WT
HT29 Resistant Colon 5.483 MUT
SNU354 Resistant Liver 5.604 WT
HS746T Resistant Stomach 5.978 WT
H1869 Resistant Lung 6.044 WT
UMUC3 Resistant Bladder 6.217 WT
PANC0403 Resistant Pancreas 6.468 WT
KGl Resistant Blood/lymph 6.588 WT
H520 Resistant Lung 6.619 WT
HEP3B Resistant Liver 6.687 WT
HCT15 Resistant Colon 7.268 MUT
H1793 Resistant Lung 7.329 WT
U937 Resistant Blood/lymph 7.345 WT
H2170 Resistant Lung 7.644 WT
PANC0327 Resistant Pancreas 8.025 WT
BEL7405 Resistant Liver 8.11 WT
HT1376 Resistant Bladder 8.199 WT
SNU638 Resistant Stomach 8.221 WT
H322 Resistant Lung 8.227 WT
DU145 Resistant Prostate 8.239 WT
EBCl Resistant Lung 8.566 WT
JURKAT Resistant Blood/lymph 8.691 WT
COLO205 Resistant Colon 8.934 WT
RT4 Resistant Bladder 8.936 WT
KATOIII Resistant Stomach 9.155 WT
MDAMB468 Resistant Breast 9.325 WT
5637 Resistant Bladder 9.627 WT
OE33 Resistant Esophagus 9.856 WT
LS180 Resistant Colon 9.942 MUT
HCCC9810 Resistant Bile duct 10.02 WT
H226 Resistant Lung 10.1 WT
A549 Resistant Lung 10.15 WT
QGY7703 Resistant Liver 11.07 WT
H647 Resistant Lung 11.34 WT
MGHU3 Resistant Bladder 11.5 WT
H23 Resistant Lung 12.3 WT
SCABER Resistant Bladder 12.4 WT
H2126 Resistant Lung 12.91 WT
HUPT3 Resistant Pancreas 13.39 WT
SW620 Resistant Colon 13.4 WT
CAPAN2 Resistant Pancreas 13.42 WT
J82 Resistant Bladder 13.42 MUT
HLE Resistant Liver 13.47 WT
BXPC3 Resistant Pancreas 14.08 WT
MCF7MDR+ Resistant Breast 14.45 WT
BEL7404 Resistant Liver 14.9 WT
SNUl Resistant Stomach 14.97 WT
KP4 Resistant Pancreas 15.05 WT
CAMAl Resistant Breast 15.47 WT
HCA7 Resistant Colon 15.49 WT
SNU668 Resistant Stomach 15.51 WT
H522 Resistant Lung 15.55 WT
SNU886 Resistant Liver 15.6 WT
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TABLE 3-continued
The pharmacology data, response classification and the mutation status 
o f the PIK3CA sene for the cell lines used in this study.
Cell Line Category Tissue GI50 μΜ PIK3CA
SW480 Resistant Colon 15.9 WT
HUH7 Resistant Liver 15.97 WT
CALUl Resistant Lung 16.03 WT
SNU878 Resistant Liver 16.06 WT
HCC1806 Resistant Breast 16.71 WT
SNUl 6 Resistant Stomach 16.76 WT
GTL16 Resistant Stomach 17.38 WT
BT549 Resistant Breast 17.44 WT
NAMALWA Resistant Blood/lymph 17.55 WT
WSUDLCL2 Resistant Blood/lymph 17.71 WT
SU8686 Resistant Pancreas 17.97 WT
H460DNP53 Resistant Lung 17.98 WT
SNU761 Resistant Liver 18.49 WT
LOVO Resistant Colon 18.64 WT
SW780 Resistant Bladder 19.23 WT
SKMESl Resistant Lung 19.54 WT
H2286 Resistant Lung 20.03 WT
SNU5 Resistant Stomach 21.19 WT
HCC1395 Resistant Breast 21.81 WT
HUHl Resistant Liver 22.34 WT
MDAMB231 Resistant Breast 23.61 WT
NUGC3 Resistant Stomach 24.15 WT
MIAPACA2 Resistant Pancreas 24.2 WT
SNU739 Resistant Liver 25.91 WT
CALU6 Resistant Lung 26.15 WT
AMOl Resistant Blood/lymph 26.93 WT
SW1990 Resistant Pancreas 28.28 WT
CMK Resistant Blood/lymph 28.91 WT
1A6 Resistant Bladder 30 WT
A2058 Resistant Skin 30 WT
ARH77 Resistant Blood/lymph 30 WT
CAPANl Resistant Pancreas 30 WT
CC20 Resistant Colon 30 WT
H1299 Resistant Lung 30 WT
H1437 Resistant Lung 30 WT
H460 Resistant Lung 30 MUT
H526 Resistant Lung 30 WT
H838 Resistant Lung 30 WT
HCC15 Resistant Lung 30 WT
HCC1937 Resistant Breast 30 WT
HCTl 16 Resistant Colon 30 MUT
HEL9217 Resistant Blood/lymph 30 INCON
HEPG2 Resistant Liver 30 WT
HLF Resistant Liver 30 WT
HX147 Resistant Lung 30 WT
IM9 Resistant Blood/lymph 30 WT
JJN3 Resistant Blood/lymph 30 WT
JVM3 Resistant Blood/lymph 30 WT
K562 Resistant Blood/lymph 30 WT
KU1919 Resistant Bladder 30 WT
MDAMB157 Resistant Breast 30 WT
MDAMB436 Resistant Breast 30 WT
MECl Resistant Blood/lymph 30 WT
MKN74 Resistant Stomach 30 WT
NUGC4 Resistant Stomach 30 WT
OCIAML2 Resistant Blood/lymph 30 WT
OCILYl 9 Resistant Blood/lymph 30 WT
PC9 Resistant Lung 30 WT
RAJI Resistant Blood/lymph 30 WT
RAMOS Resistant Blood/lymph 30 WT
RERFLCAI Resistant Lung 30 WT
RPM18226 Resistant Blood/lymph 30 WT
SCI Resistant Blood/lymph 30 WT
SKHEPl Resistant Liver 30 WT
SMMC7721 Resistant Liver 30 WT
SNU398 Resistant Liver 30 WT
SW900 Resistant Lung 30 WT
T24 Resistant Bladder 30 WT
YAPC Resistant Pancreas 30 WT
[0490] The gene for which mutations were most strongly 
correlated with sensitivity to Example 3 was PIK3CA. Only
12 o f 177 PIK3CA WT cell lines (7.7%) were sensitive to 
Example 3, whereas 15 o f 32 cell lines (46.9%) that are 
mutant for PIK3CA were sensitive, corresponding to an odds- 
ratio o f 12.1 and a p-value o f 1 .2xl0-7 (see Table 4).
TABLE 4
Contingency table for PIK3CA mutation status and response to 
Example 3.
Mutation Status Response
(PIK3CA) Sensitive Resistant
MUT 15 17
WT 12 165
Odds-Ratio: 12.1 
p-value: 1.2 x IO-7
[0491] As indicated herein, it has been reported that the 
measurement o f mutation status or activation status o f addi­
tional genes, such as KRAS, a potential marker o f resistance 
in tumours with aberrant or deregulated PIK3CA or PI3K-a, 
could help increase the predictivity o f a Personalised Medi­
cine approach.
[0492] We exemplified this for the above dataset by com­
paring the enrichment o f KRAS mutations in PIK3CA mutant 
cells with the cell line’s response to inhibition. Analysis was 
limited to cell lines containing ‘hotspot’ mutations o f the two 
genes (at codons E542, E545 and EU047 for PIK3CA and at 
codons K12, 13 and Q61 for KRAS). This demonstrated that 
in PIK3CA mutant cell lines, mutations in KRAS conferred 
resistance to inhibition by Example 3.
[0493] Twenty-eight cell lines contained activating muta­
tions in PIK3CA.
[0494] 6 o f 19 cell lines (31.6%) containing an activating 
PIK3CA mutation and a wild-type KRAS gene were resistant 
to Example 3.
[0495] 7 o f 9 PIK3CA mutant cell lines (77.8%) contained 
coexisting KRAS mutations and were resistant to Example 3 .
[0496] This translates into an odds-ratio o f 7.5 and a 
p-value of 0.042 (see Table 5).
TABLE 5
Contingency table for PIK3CA and KRAS mutation status and 
response to Example 3.
Mutation Response
Status Sensitive Resistant
KRAS AND 
PIK3CA MUT 
PIK3CA MUT 
and KRAS WT
2 7 
13 6
Odds Ratio: 7.5 
p-value: 0.042
EXAMPLES
[0497] The invention will now be illustrated in the follow­
ing Examples in which, generally:
[0498] (i) operations were carried out at ambient tempera­
ture, i.e. in the range 17 to 25° C. and under an atmosphere of 
an inert gas such as nitrogen unless otherwise stated;
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[0499] (ii) evaporations were carried out by rotary evapo­
ration or utilising Genevac equipment in vacuo and work-up 
procedures were carried out after removal o f residual solids 
by filtration;
[0500] (iii) Flash chromatography purifications were per­
formed on an automated Armen Glider Flash: Spot II U lti­
mate (Armen Instrument, Saint-Ave, France) using pre­
packed Merck normal phase Si60 silica cartridges 
(granulometry: 15-40 or 40-63 pm) obtained from Merck, 
Darmstad, Germany;
[0501] (iv) preparative chromatography was performed on 
a Waters instrument (600/2700 or 2525) fitted with a ZMD or 
ZQ ESCi mass spectrometers and a Waters X-Terra or a 
Waters X-Bridge or a Waters SunFire reverse-phase column 
(C-18,5 microns silica, 19 mm diameter, 100 mm length, flow 
rate o f 40 mL/minute) using decreasingly polar mixtures o f 
water (containing 0.2% ammonium carbonate) and acetoni- 
trile as eluent;
[0502] (v) yields, where present, are not necessarily the 
maximum attainable;
[0503] (vi) in general, the structures o f end-products o f the 
Formula I were confirmed by nuclear magnetic resonance 
(NMR) spectroscopy; NMR chemical shift values were mea­
sured on the delta scale [proton magnetic resonance spectra 
were determined using a Bruker Avance 500 (500 MHz) 
instrument]; measurements were taken at ambient tempera­
ture unless otherwise specified; the following abbreviations 
have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; dd, doublet o f doublets; ddd, doublet o f doublet of 
doublet; dt, doublet o f triplets; bs, broad signal;
[0504] (vii) in general, end-products o f the Formula I were 
also characterised by mass spectroscopy following liquid 
chromatography (LCMS); LCMS was carried out using an 
Waters Alliance HT (2790 & 2795) fitted with a Waters ZQ 
ESCi or ZMD ESCi mass spectrometer and an X Bridge 5 pm 
C -18 column (2.1x50 mm) at a flow rate o f 2.4 mL/min, using 
a solvent system o f 95% A+5% C to 95% B+5% C over 4 
minutes, where A=water, B=methanol, C = I: I methanokwa- 
ter (containing 0.2% ammonium carbonate);
[0505] (viii) intermediates were not generally fully charac­
terised and purity was assessed by thin layer chromato­
graphic, mass spectral, HPLC and/or NM R analysis;
[0506] (ix) X-ray powder diffraction spectra were deter­
mined (using a Bruker D4 Analytical Instrument) by mount­
ing a sample o f the crystalline material on a Bruker single 
silicon crystal (SSC) wafer mount and spreading out the 
sample into a thin layer with the aid o f a microscope slide. The 
sample was spun at 30 revolutions per minute (to improve 
counting statistics) and irradiated with X-rays generated by a 
copper long-fine focus tube operated at 40 kV and 40 mA with 
a wavelength o f 1.5418 angstroms. The collimated X-ray 
source was passed through an automatic variable divergence 
slit set at V20 and the reflected radiation directed through a
5.89 mm antiscatter slit and a 9.55 mm detector slit. The 
sample was exposed for 0.03 seconds per 0.00570° 2-theta 
increment (continuous scan mode) over the range 2 degrees to 
40 degrees 2-theta in theta-theta mode. The running time was 
3 minutes and 36 seconds. The instrument was equipped with 
a Position sensitive detector (Lynxeye). Control and data 
capture was by means o f a Dell Optiplex 686 NT 4.0 Work­
station operating with Diffrac+ software. Persons skilled in 
the art o f X-ray powder diffraction will realise that the relative 
intensity of peaks can be affected by, for example, grains 
above 30 microns in size and non-unitary aspect ratios that
may affect analysis o f samples. The skilled person will also 
realise that the position o f reflections can be affected by the 
precise height at which the sample sits in the diffractometer 
and the zero calibration o f the diffractometer. The surface 
planarity o f the sample may also have a small effect. Hence 
the diffraction pattern data presented are not to be taken as 
absolute values;
[0507] (x) Differential Scanning calorimetry was per­
formed using a TA Instruments Q 1000 DSC instrument. Typi­
cally less than 5 mg o f material contained in a standard 
aluminium pan fitted with a lid was heated over the tempera­
ture range 25° C. to 300° C. at a constant heating rate o f 10° 
C. per minute. A purge gas using nitrogen was used at a flow 
rate o f 50 mL per minute; and
[0508] (xi) the following abbreviations have been used:—
[0509] aq. aqueous
[0510] CDCl3 deutero-chloroform
[0511] CHCl3 chloroform
[0512] DBU l,8-diazabicyclo[5.4.0]undec-7-ene
[0513] DCM dichloromethane
[0514] DEA diethyl amine
[0515] DIPEA N-ethyl-N-isopropylpropan-2-amine
[0516] DMA N,N-dimethylacetamide
[0517] DMF NN-dimethylformamide
[0518] DMSO dimethyl sulphoxide
[0519] DSC Differential Scanning calorimetry
[0520]
late
DTAD (E)-di-tert-butyl diazene-l,2-dicarboxy-
[0521] EDCI I -(3-dimethylaminopropyl)-3-ethylcarbo-
diimide hydrochloride
[0522] Ether diethyl ether
[0523] EtOH ethanol
[0524] EtOAc ethyl acetate
[0525] % ee % enantiomeric excess
[0526] HOPO 2-hydroxy-pyridine N-oxide
[0527] HPLC high performance liquid chromatography
[0528] IPA isopropyl alcohol
[0529] MeCN acetonitrile
[0530] MeOH methanol
[0531] MIBK methyl isobutyl ketone
[0532] MTBE methyl tert-butyl ether
[0533] NMP I -methyl-2-pyrrolidone
[0534] rt room temperature
[0535] sat. saturated
[0536] sol. solution
[0537] THF tetrahydrofuran
[0538] TEA triethyl amine
[0539] TBTU 2-(lH -benzo[d][l,2 ,3]triazol-l-yl)-l,l,3 ,
3 -tetramethy Ii souronium tetrafluoroborate
[0540] v/v volume/volume
[0541] TFA trifluoroacetic acid
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Example I
l-(4-(5-(5-Amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl)-1 -methyl-1 H -1,2,4-triazol-3-yl) 
piperidin-1 -yl)-3 -hydroxypropan-1 -one
[0542]
O
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Example 1.1
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■continued
(A)
NH2
[0543] 3-Hydroxypropanoic acid (30% v/v soln in water) 
(200 pL, 47.0 mg, 0.52 mmol) was evaporated to dryness then 
azeotroped with the toluene. The acid was dissolved in NMP 
(I mL) and molecular sieves (100 mg, 0.26 mmol), N-ethyl- 
N-isopropylpropan-2-amine (0.136 mL, 0.78 mmol) were 
added followed by the addition of 2-(lH -benzo[d][l,2,3]- 
triazol-1 -yl)-l ,1,3,3-tetramethylisouronium tetrafluorobo- 
rate (209 mg, 0.65 mmol). After 30 minutes stirring, 3-(5-tert- 
butyl-1,3,4-oxadiazol-2-yl)-5-(l-methyl-3-(piperidin-4-yl)- 
lH-l,2,4-triazol-5-yl)pyrazin-2-amine (100 mg, 0.26 mmol) 
was added and the mixture was stirred for 2 hours. The reac­
tion mixture was purified by preparative HPLC using a 
Waters X-Bridge reverse-phase column (C-18, 5 microns 
silica, 19 mm diameter, 100 mm length, flow rate o f 40 
ml/minute) and decreasingly polar mixtures o f water (con­
taining 0.2% ammonium carbonate) and acetonitrile as elu­
ent.
[0544] The fractions containing the desired compound 
were evaporated to dryness to afford l-(4-(5-(5-amino-6-(5- 
tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1 -methyl-1H-
l,2,4-triazol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one 
(45.0 mg, 37.9%) as a clearyellow solid: 1H NMR Spectrum 
(CDC13) 1.52 (9H, s), 1.79-1.94 (2H, m), 2.07-2.15 (2H,m), 
2.58 (2H, t), 2.84-2.94 (1H, m,), 3.00-3.10 (I H, m), 3.17-3.26 
(1H, m), 3.53 (1H, t), 3.86-3.94 (3H, m), 4.30 (3H, s), 4.56- 
4.62 (1H, m), 9.02 (1H, s); Mass Spectrum [M+H]+=456.
[0545] 3-(5-tert-Butyl-l,3,4-oxadiazol-2-yl)-5-(l-methyl- 
3-(piperidin-4-yl)-lH-l,2,4-triazol-5-yl)pyrazin-2-amine 
(Example 1.1) was prepared as follows:
[0546] At 20° C., tert-butyl 4-carbamoylpiperidine-l-car- 
boxylate (47 g, 205.88 mmol) in dichloromethane (500 mL) 
was added dropwise to a stirred solution o f triethyloxonium 
hexafluorophosphate(V) (56.2 g, 226.47 mmol) in dichlo­
romethane (500 mL) over a period o f 45 minutes under nitro­
gen. The resulting solution was stirred at 20° C. overnight. A 
saturated aqueous solution OfNa2CO3 was then added until 
pH o f 8 was obtained. The phases were decanted and the 
aqueous phase was extracted again with 200 mL o f CH2Cl2 
then the organic phases were dried over MgSO4, filtered and 
concentrated to afford tert-butyl 4-(ethoxy(imino)methyl)pi- 
peridine-l-carboxylate (51.0 g, 97%) as a colourless liquid: 
1H NMR Spectrum; (CDCl3) 1.28 (3H, t), 1.46 (9H, s), 1.47
(2H, m), 1.79-1.93 (2H, m), 2.28 (1H, m), 2.73 (2H, m), 4.10 
(2H, q), 4.13-4.18 (2H, m); Mass Spectrum [M+H]+=no mass 
ion.
[0547] To a stirred solution o f tert-butyl 4-(ethoxy(imino) 
methyl)piperidine-1-carboxylate (51 g, 198.95 mmol) in 
dioxane (500 mL), was added formohydrazide (17.92 g, 298. 
43 mmol). This solution was left to stir at 40° C. overnight 
under N2 resulting in precipitation o f a white solid (hydrazide 
intermediate). The reaction mixture was then heated to 80° C. 
for 6 h, cooled to room temperature and concentrated. The 
residue was dissolved in 500 mL of CH2Cl2 and 300 mL of 
water was added. The phases were decanted and the organic 
phase was washed with brine, dried over MgSO4, filtered and 
concentrated to afford tert-butyl 4-(lH-l,2,4-triazol-3-yl)pi- 
peridine-1-carboxylate (46.0 g, 92%) as a white solid: 1H 
NMR Spectrum; (CDCl3) 1.47 (9H, s), 1.76 (2H, m), 1.98-2. 
11 (2H, m), 2.91 (2H, s), 2.97-3.08 (m, 1H), 4.06-4.23 (2H, 
m), 8.05 (1H, s); Mass Spectrum [M+H]+=no mass ion.
[0548] To a stirred solution o f tert-butyl 4-(lH -l,2,4-tria- 
zol-3-yl)piperidine-l-carboxylate (22 g, 87.19 mmol) in 
dichloromethane (250 mL) was added sodium hydroxide 2N 
(131 mL, 261.58 mmol). The reaction mixture was vigor­
ously stirred with mechanical stirring and a solution of ben- 
zyltrimethylammonium tribromide (37.4 g, 95.91 mmol) in 
dichloromethane (250 mL) was then added dropwise, keep­
ing temperature around 15° C. The reaction mixture was left 
to stir at room temperature for I h  and 2N HCl was added to 
give a pH o f 5 (keeping temperature around 15° C.). The 
phases were decanted and the organic phase was washed with 
H2O (2x I L), dried over MgSO4, filtered and concentrated to 
afford tert-butyl 4-(5-bromo-lH-l,2,4-triazol-3-yl)piperi- 
dine-1-carboxylate (25.00 g, 87%) as an off-white solid: 1H 
NMR Spectrum; (CDCl3) 1.46 (9H, s), 1.67-1.84 (2H, m),
1.90-2.13 (2H, m), 2.77-2.96 (2H, m), 2.98-3.10 (1H, m), 
3.94-4.35 (2H, m); Mass Spectrum [M+H]+=no mass ion.
[0549] To a stirred suspension o f tert-butyl 4-(5-bromo- 
lH-l,2,4-triazol-3-yl)piperidine-l-carboxylate (26 g, 78.50 
mmol) in toluene (200 mL) and methanol (50 mL) was added 
dropwise (diazomethyl)trimethylsilane 2M solution in hex­
ane (43.2 mL, 86.35 mmol) under N2, keeping temperature 
around 20° C.: gas evolution and a small exotherm were 
observed. The yellow solution obtained was stirred at room
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temperature for I h. The solvent were evaporated and the 
resulting oil was purified on silica, eluting with 40% EtOAc in 
petroleum ether to afford tert-butyl 4-(5-bromo-l-methyl- 
lH-l,2,4-triazol-3-yl)piperidine-l-carboxylate (15.00 g, 
55.3%) as an oil: 1H NMR Spectrum; (CDCl3) 1.46 (9H, s), 
1.65-1.78 (2H, m), 1.90-2.01 (2H, m), 2.68-3.02 (3H, m),
3.83 (3H, s), 3.94-4.31 (2H, m); Mass Spectrum [M+H]+=no 
mass ion.
[0550] Hydrazine monohydrate (34 mL, 1094.95 mmol) 
was added portionwise to a stirred suspension o f methyl
3-aminopyrazine-2-carboxylate (21.3 g, 139.09 mmol) in 
ethanol (65 mL) at r.t. The resulting slurry was stirred at 60° 
C. for 2 hours, cooled to room temperature and filtered. The 
solid was washed with cold ethanol (2x25 ml) and dried to a 
constant weight to afford 3-aminopyrazine-2-carbohydrazide 
(20.75 g, 97%) as a beige solid: 1H NMR Spectrum; (DMSO- 
d6) 4.49 (2H, d), 7.46 (2H, br s,), 7.78 (1H, d), 8.17 (1H, d), 
9.79 (1H, t); Mass Spectrum [M+H]+=154.
[0551] 2-(lH -benzo[d][l,2,3]triazol-l-yl)-l,l,3,3-tetram - 
ethylisouroniumtetrafluoroborate (47.7 g, 148.69 mmol) was 
added portionwise over 15 minutes to a stirred suspension of 
N-ethyl-N-isopropylpropan-2-amine (70.6 mL, 405.51 
mmol), pivalic acid (17.08 mL, 148.69 mmol) and 3-ami- 
nopyrazine-2-carbohydrazide (20.7 g, 135.17 mmol) in 
acetonitrile (350 mL) and the reaction mixture was stirred at 
80° C. for 20 minutes (a solution was obtained). The reaction 
mixture was cooled to 0° C. andN-ethyl-N-isopropylpropan-
2-amine (70.6 mL, 405.51 mmol), followed by 4-methylben- 
zene-l-sulfonyl chloride (77 g, 405.51 mmol) were added 
over a period o f 15 minutes. The reaction mixture (yellow 
suspension) was brought to reflux (solubilisation) and then 
allowed to stir at room temperature for 14 hours affording a 
dark orange solution. The solution was concentrated. The 
residue was diluted with dichloromethane, washed with 
water, brine, dried over magnesium sulfate and concentrated. 
The crude product was purified by flash chromatography on 
silica gel eluting with 0 to 40% ethyl acetate in dichlo­
romethane. The solvent was evaporated to dryness. The 
resulting mixture was triturated with ether (100 mL), filtered, 
washed with the minimum of ether and dried to afford 3-(5- 
tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-amine (20.8 g, 
70.2%) as a pale yellow soild: 1H NMR Spectrum; (CDCl3)
1.53 (9H, s), 1.58-1.68 (2H, m), 6.67 (2H, s), 8.13 (2H, dt); 
Mass Spectrum [M+H]+=220.
[0552] l-Bromopyrrolidine-2,5-dione (18.57 g, 104.36 
mmol) was added portionwise to a solution o f 3-(5-tert-butyl-
l,3,4-oxadiazol-2-yl)pyrazin-2-amine (20.8 g, 94.87 mmol) 
in THF (320 mL) and the solution was stirred at room tem­
perature for 16 hours. The reaction mixture was concentrated 
and the residue was dissolved in dichloromethane (300 mL), 
washed with water (2xl50m L ), brine, dried over magnesium 
sulfate and concentrated. The solvent was evaporated and the 
crude product was purified by flash chromatography on silica 
gel, eluting with 0 to 10% ethyl acetate in dichloromethane. 
The solvent was evaporated to dryness to afford 5-bromo-3- 
(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-amine (25.5 g, 
90%) as a beige solid: 1H NMR Spectrum; (CDCl3) 1.52 (9H, 
s), 8.23 (1H, s); Mass Spectrum [M+H]+=300.
[0553] To a suspension of 5-bromo-3-(5-tert-butyl-l,3,4- 
oxadiazol-2-yl)pyrazin-2-amine (45 g, 150.94 mmol) in tolu­
ene (450 mL) were added 1,1,1,2,2,2-hexamethyldistannane 
(37.6 mL, 181.12 mmol) and bis(triphenylphosphine) palla­
dium (II) chloride (5.30 g, 7.55 mmol). The reaction mixture 
was degassed with argon and heated at 80° C. for 2 hours.
(solubilisation upon heating, orange solution then reprecipi­
tation and turned black indicating reaction is complete.) The 
reaction mixture was cooled down, concentrated and the resi­
due was dissolved in CH2Cl2 and filtered on Decalite to 
remove the insoluble impurities. The filtrate was concen­
trated and purified on silica eluting with 0 to 10% EtOAc in 
CH2Cl2. The solvent was concentrated to afford 3-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)-5-(trimethylstannyl)pyrazin-2- 
amine (22.63 g, 39.2%) as an orange solid: 1H NMR Spec­
trum; (CDCl3) 0.38 (9H, s), 1.53 (9H, s), 6.49 (2H, brs), 8.13 
(1H, s); Mass Spectrum [M+H]+=384.
[0554] To a stirred suspension o f tert-butyl 4-(5-brom o-l- 
methyl-lH-l,2,4-triazol-3-yl)piperidine-l-carboxylate 
(2700 mg, 7.82 mmol) and 3-(5-tert-butyl-l ,3,4-oxadiazol-2- 
yl)-5-(trimethylstannyl)pyrazin-2-amine (2988 mg, 7.82 
mmol) in 4-methyl-2-pentanol (28 mL) were added lithium 
chloride (995 mg, 23.46 mmol) and bis(triphenylphosphine) 
palladium (II) chloride (220 mg, 0.31 mmol). The mixture 
was degassed with argon and heated at 140° C. for 2 h. The 
reaction was cooled down and the resulting precipitate was 
collected by filtration, washed with isopropanol (25 mL), 
water (25 mL) and dried under suction. The isopropanol 
organic fraction was concentrated and the precipitate formed 
was collected and combined with the main precipitate afford­
ing tert-butyl 4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-
2-yl)pyrazin-2 -yl)-l -methyl-IH -1,2,4-triazol-3-yl)piperi- 
dine-1-carboxylate (3.0 g, 79%): 1H NMR Spectrum: 
(DMSCLd6) 1.41 (9H, s), 1.45 (9H, s), 1.50-1.68 (2H, m), 
1.95 (3H, dd), 2.78-3.05 (1H, m), 3.96 (3H, d), 4.21 (3H, s),
8.86 (1H, s); Mass Spectrum [M+H]+=484.
[0555] A solution o f tert-butyl 4-(5-(5-amino-6-(5-tert-bu- 
tyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-m ethyl-lH-l,2,4- 
triazol-3-yl)piperidine-l-carboxylate (3 g, 6.20 mmol) in 
TFA (15 mL) and CH2Cl2 (15 mL) was stirred at 25° C. for I 
hour. The mixture was azeotroped with toluene, a 7N solution 
o f ammonia in methanol and dichloromethane were added 
and the mixture was adsorbed on silica gel. The crude product 
was purified by flash chromatography on silica gel eluting 
with 0 to 8% methanol in dichloromethane followed by 0 to 
10% methanolic ammonia in dichloromethane The solvent 
was evaporated to dryness to afford 3-(5-tert-butyl-l,3,4-oxa- 
diazol-2-yl)-5-(l-methyl-3-(piperidin-4-yl)-lH-l,2,4-tria- 
zol-5-yl)pyrazin-2-amine (2.040 g, 86%) as a yellow crystal­
line solid: 1H NMR Spectrum: (DMSCLd6) 1.45 (9H, s),
1.55-1.66 (2H, m), 1.86 (2H, dd), 2.52-2.61 (2H, m), 2.69-2. 
78 (1H, m), 2.95-3.02 (2H, m), 4.20 (3H, s), 8.86 (1H, s); 
Mass Spectrum [M+H]+=384.
Isolation o f Single Crystalline Form o f Example I
[0556] The X-ray powder diffraction spectra o f the material 
isolated above showed the material to be crystalline but a 
mixture of polymorphic forms. This material had a melting 
point o f 226.4° C. (onset).
[0557] Form A material was produced by slurrying the 
original material in acetonitrile at 25° C. Approximately 20 
mg of the original material was placed in a vial with a m ag­
netic stirrer bar, and approximately 2 mL o f acetonitrile 
added, the vial was then sealed tightly with a cap and left to 
stir on a magnetic stirrer plate. After approximately 5 days, 
the sample was removed from the plate, the cap taken off and 
the slurry left to dry under ambient conditions before it was 
analysed by XRPD and DSC. This form (FormA) was deter­
mined to be crystalline by XRPD. This material had a melting 
point o f 227.2° C. (onset).
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[0558] The same crystalline form may be made by stirring 
the crude material in acetonitrile overnight at room tempera­
ture, then filtering the resulting solid, washing with cold 
acetonitrile and drying.
[0559] In one aspect o f the invention there is provided a 
process for forming a crystalline form of Example I (FormA) 
by slurrying a sample of the compound in acetonitrile. Ten 
X-Ray powder diffraction peaks are shown in the Table 
below:
Ten X-Ray Powder Diffraction Peaks for Example I Form A
[0560]
Angle 2-
Theta (2Θ) Intensity %
5.1 100.0
18.0 22.5
10.2 22.0
11.7 17.8
19.4 14.5
18.5 14.2
14.8 12.6
26.7 11.0
26.6 10.6
17.8 9.9
[0561] An X-Ray powder diffraction spectrum o f Example 
I Form A is shown in FIG. I.
[0562] DSC analysis o f Example I Form A shows a melting 
endotherm with an onset o f 227.2° C. and a peak at 228.6° C. 
(FIG. 2).
[0563] Thus DSC analysis shows Example I Form A  is a 
highm elting solidwith an onset o f melting at about 227.2° C. 
and a peak at 228.6° C.
[0564] A DSC of Example I Form A is shown in FIG. 2. 
X-Ray Powder Diffraction
Analytical Instrument: Bruker D4.
[0565] The X-ray powder diffractogram was determined by 
mounting a sample o f the crystalline material on a Bruker 
single silicon crystal (SSC) wafer mount and spreading out 
the sample into a thin layer with the aid o f a microscope slide.
The sample was spun at 30 revolutions per minute (to improve 
counting statistics) and irradiated with X-rays generated by a 
copper long-fine focus tube operated at 40 kV and 40 mA with 
a wavelength o f 1.5418 angstroms. The collimated X-ray 
source was passed through an automatic variable divergence 
slit set at V20 and the reflected radiation directed through a
5.89 mm antiscatter slit and a 9.55 mm detector slit. The 
sample was exposed for 0.03 seconds per 0.00570° 2-theta 
increment (continuous scan mode) over the range 2 degrees to 
40 degrees 2-theta in theta-theta mode. The running time was 
3 minutes and 36 seconds. The instrument was equipped with 
a Position sensitive detector (Lynxeye). Control and data 
capture was by means o f a Dell Optiplex 686 NT 4.0 Work­
station operating with Diffrac+ software. Persons skilled in 
the art o f X-ray powder diffraction will realise that the relative 
intensity o f peaks can be affected by, for example, grains 
above 30 microns in size and non-unitary aspect ratios that 
may affect analysis o f samples. The skilled person will also 
realise that the position o f reflections can be affected by the 
precise height at which the sample sits in the diffractometer 
and the zero calibration o f the diffractometer. The surface 
planarity o f the sample may also have a small effect. Flence 
the diffraction pattern data presented are not to be taken as 
absolute values.
Differential Scanning Calorimetry
Analytical Instrument: TA Instruments Q1000 DSC.
[0566] Typically less than 5 mg o f material contained in a 
standard aluminium pan fitted with a lid was heated over the 
temperature range 25° C. to 300° C. at a constant heating rate 
o f 10° C. per minute. A  purge gas using nitrogen was used- 
flow rate 50 ml per minute.
[0567] An alternative synthesis o f the compound of 
Example I is provided below as Example 2.
Example 2
l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl)-l-methyl-lH-l,2,4-triazol-3-yl) 
piperidin-1 -yl)-3-hydroxypropan-1 -one
[0568]
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[0569] Pyridine 4-methylbenzenesulfonate (3.58 g, 14.25 
mmol) was added to a suspension of l-(4-(5-(5-amino-6-(5- 
tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1 -methyl-1H-
l,2,4-triazol-3-yl)piperidin-l-yl)-3-(tetrahydro-2H-pyran-2- 
yloxy)propan-l-one (37 g, 68.57 mmol) in methanol (275 
mL) under nitrogen. The mixture was stirred at 60° C. for 1.5 
hours. The mixture was soluble after 5 minutes. The mixture 
was held at 50° C. overnight during which time a precipitate 
formed. The reaction mixture was dissolved in dichlo­
romethane (400 mL), washed with water (300 mL), and brine 
(100 m L). The aqueous extracts were backwashed with DCM 
(100 mL) and the combined organic layers were dried over 
MgSO4 and concentrated. The crude product was purified by 
flash chromatography on silica gel eluting with 100% ethyl 
acetate to 10:50:40 methanol/ethyl acetate/DCM. The prod­
uct containing fractions were evaporated to dryness to afford 
a beige solid (24.5 g). The solid was slurried overnight in 
acetonitrile (500 mL), filtered and dried under high vacuum to 
afford l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl)-l-methyl-IH -1,2,4-triazol-3-yl)piperidin- 
l-yl)-3-hydroxypropan-l-one (Example 2) (24 g, 78%) as a 
cream solid: 1H NMR Spectrum: (DMSCEd6) 1.51 (9H, s),
1.55-1.68 (1H, m), 1.68-1.84 (1H, m), 1.96-2.13 (2H, m), 
2.78-2.93 (1H, m), 2.98-3.1 (1H, m), 3.19-3.3 (1H, m), 3.71 
(2H, q), 3.93-4.04 (1H, m), 4.27 (3H, s), 4.35-4.48 (1H, m),
4.54 (1H, t), 7.96 (2H, s), 8.92 (1H, s); Mass Spectrum 
[M+H]+=456
[0570] (4-(5-(5-Amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl)-l-methyl-IH -1,2,4-triazol-3-yl)piperidin-
l-yl)-3-(tetrahydro-2H-pyran-2-yloxy)propan-l-one (Ex­
ample 2.1) was prepared as follows:
[0571] Hydrazine hydrate (23.59 mL, 480.75 mmol) was 
added dropwise to a stirred mixture o f methyl 3-amino-6- 
bromopyrazine-2-carboxylate (100 g, 418.04 mmol) in EtOH 
(2 L). The mixture was heated at 50° C. under nitrogen. The 
resulting thick suspension was stirred at 50° C. for 16 hours. 
Further hydrazine (2.5 mL) was added in one portion and the 
suspension was stirred at 50° C. for a further 24 hours. Etha­
nol (500 mL) was charged to the thick reaction mixture and 
the mixture was allowed to cool to room temperature. The 
resulting suspension was filtered and the solid washed with 
ethanol (I L) and dried in vacuo to give 3-amino-6-bromopy- 
razine-2-carbohydrazide (98 g, quantitative) as a cream solid: 
1H NMR Spectrum; (DMSCEd6) 4.52 (2H, s), 7.59 (2H, s), 
8.30 (1H, s), 9.74 (1H, s); Mass Spectrum [M+H]+=232.
[0572] Pivalic anhydride (165 mL, 815.38 mmol) was 
added to a stirred mixture o f 3-amino-6-bromopyrazine-2- 
carbohydrazide (172 g, 741.26 mmol) in acetonitrile (1.8 L) 
and the mixture was heated at 80° C. for I hour. The reaction 
was left to stir for 16 hours. The required yellow solid mate­
rial was isolated by filtration. The filtrate was partitioned 
between EtOAc (2 L) and aqueous sodium bicarbonate (2 L). 
The organic layer was washed with saturated brine and dried 
over MgSO4. The solution was filtered and concentrated to 
give an orange sticky solid which was triturated with MTBE 
(250 mL). The insoluble yellow solid was isolated by filtra­
tion and this material was shown to be identical to the first 
solid. The combined solids were dried in the vacuum oven at 
50° C. for 3 days to afford 3-amino-6-bromo-N'-piv- 
aloylpyrazine-2-carbohydrazide (224 g, 96%) as a yellow 
solid: 1HNM RSpectrum: (DMSO-d6) 1.17 (9H, s),7.62 (2H, 
s), 8.37 (1H, s), 9.42-9.56 (1H, m), 10.09-10.23 (1H, m); 
Mass Spectrum [M+H]+=318. p-Toluenesulfonyl chloride 
(164 g, 861.60 mmol) was added portion wise to a suspension
o f 3-amino-6-bromo-N'-pivaloylpyrazine-2-carbohydrazide 
(227 g, 718.00 mmol) and N,N-diisopropylethylamine (297 
mL, 1795.01 mmol) in acetonitrile (2200 mL). The mixture 
was stirred for 2 hours at 70° C. The reaction was left to cool 
to room temperature overnight. The reaction mixture was 
partitioned between ethyl acetate (2 L) and sodium bicarbon­
ate solution (2 L). The organic layer was washed with satu­
rated brine, dried with magnesium sulfate, filtered, and con­
centrated under reduced pressure. The resulting brown/beige 
solid was triturated with hot MTBE (1000 mL) and isolated 
by filtration and dried to afford 5-bromo-3-(5-tert-butyl-l,3,
4-oxadiazol-2-yl)pyrazin-2-amine as a yellow solid (187 g, 
87%). The mother liquors were evaporated to dryness. The 
crude solid was triturated with MTBE (500 mL) filtered and 
washed with 100 mL o f MTBE. The resulting solid was air 
dried overnight to afford a second crop of 5-bromo-3-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-amine (36 g, 17%): 1H 
NMR Spectrum: (DMSCEd6) 1.43 (9H, s), 7.70 (2H, s), 8.39 
(1H, s); Mass Spectrum [M+H]+=298.
[0573] In an alternative preparation, to 3-amino-6-bromo- 
N'-pivaloylpyrazine-2-carbohydrazide (2301 g, 7.28 mol) in 
MeCN (10.8 L) was added DIPEA (3.044 L, 17.48 mol) and 
p-toluenesulfonyl chloride (1665 g, 8.73 mol) portion-wise 
(-280 gx6) at 50° C. over a period of 30 mins. The reaction 
temperature was maintained between 65-70° C. by control­
ling the rate o f addition. After the addition was complete, the 
reaction mixture was stirredat70° C. for I h. Them ixturewas 
cooled to room temperature and quenched with 5% NaHCO3 
(aqueous, 24.2 L). Theresulting suspension was stirred for 30 
min then filtered. The product was washed with water (14.8 
L), pulled dry and dried at 50° C. for 16 h. The product was 
dissolved in DCM (12 L) and the phases separated. The 
oiganic phase was loaded onto a silica pad (6 kg) and the 
product was eluted with 20% EtOAc/DCM (8x10 L). Con­
centration o f the product containing fractions gave 1987 g 
(92% yield) with a purity o f 99.8% by HPLC.
[0574] A stream o f nitrogen gas was passed through a solu­
tion o f 5-bromo-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl) 
pyrazin-2-amine (89.35 g, 239.75 mmol) in DMA (1.2 L) for 
20 minutes. Dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl) 
phosphine (11.43 g, 23.98 mmol), tris(dibenzylideneacetone) 
dipalladium(O) (5.49 g, 5.99 mmol), zinc (1.568 g, 23.98 
mmol) and dicyanozinc (16.89 g, 143.85 mmol) were added 
sequentially to the stirred mixture. The mixture was heated to 
100° C. and stirred for I hour. The mixture was cooled and 
partitioned between DCM (3 L) and water (I L). The black 
mixture was filtered through celite and the organic layer was 
separated. The solution was washed with water then brine. 
The solution was dried with magnesium sulfate and concen­
trated under reduced pressure. The residue was triturated with 
MTBE and isolated by filtration, washing with MTBE. The 
filter cake was dried in vacuo to afford 5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazine-2-carbonitrile (55.7 g, 
95%) as a pale orange solid: 1H NM R Spectrum: (DMSCEd6)
1.46 (9H, s), 6.02 (1H, s), 8.38 (2H, s); Mass Spectrum 
[M -H ]-=242.
[0575] The product may be slurried in heptanes then fil­
tered and dried as an alternative to trituration with MTBE.
[0576] Hydrazine hydrate (82 mL, 1.69 mol) was added to
5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazine-2- 
carbonitrile (55 g, 225.18 mmol) in IPA (200 mL) and the 
mixture was heated at 50° C. under nitrogen for 16 hours. The 
mixture was cooled in an ice bath. The resulting precipitate 
was collected by filtration, washed with IPA and diethyl ether
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and dried to a constant weight to afford (Z)-5-amino-6-(5- 
tert-butyl-l,3,4-oxadiazol-2-yl)pyrazine-2-carbohydrazona- 
mide (49.2 g, 79%) as a yellow solid: 1H NMR Spectrum: 
(DMSCLd6) 1.45 (9H, s), 5.26 (2H, s), 5.58 (2H, s), 7.56 (2H, 
s), 8.75 (1H, s); Mass Spectrum [M+H]+=277.
[0577] 0 -(7 -Azabenzotriazol-I -yl)-N,N,N',N'-tetramethy- 
luronium hexafluorophosphate (74.3 g, 195.44 mmol) was 
added to a solution o f N-Boc-isonipecotic acid (41.1 g, 179. 
15 mmol) and 4-methylmorpholine (35.9 mL, 325.74 mmol) 
in DMA (800 mL). The mixture was stirred for 10 minutes 
then (Z)-5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyra- 
zine-2-carbohydrazonamide (45 g, 162.87 mmol) was added 
to the solution in one portion (exotherm observed from 22° C. 
to 27° C.). After a few minutes the product crystallised from 
the reaction mixture. The reaction mixture was removed from 
the vessel and filtered through a sinter. Additional DMA was 
added to wash product from the sides o f the vessel (150 mL) 
and this was poured onto the filter cake. Isopropanol (600 mL) 
was added to the vessel and the remainder o f the product in the 
vessel was suspended in this solvent using vigorous agitation. 
The isopropanol suspension was used to wash the filter cake 
once the DMA had been removed by suction. The filter cake 
was sucked dry then washed with MTBE and sucked dry once 
again. The filter cake was dried in vacuo to afford (Z)-tert- 
butyl 4-(2-(amino(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-
2-yl)pyrazin-2-yl)methylene)hydrazinecarbonyl)piperidine-
1-carboxylate (76 g, 95%) as a yellow solid: 1H NMR 
Spectrum: (DMSCLd6) 1.40 (9H, s), 1.46 (9H, s), 1.63-1.9 
(2H, m), 2.33-2.6 (2H, m, obscured by DMSO signal), 2.63-
3.03 (2H, m), 3.18-3.48 (4H, m, obscured by water signal),
3.88-4.11 (2H, m), 6.43 (2H, s), 7.76 (2H, br), 8.84 (0.5H, s),
8.87 (0.5H, s), 9.85 (1H, s); Mass Spectrum [M+H]+=488
[0578] In an alternative preparation, the N-Boc-isonipe- 
cotic acid may be made in situ as follows: Isonipecotic acid 
(858 g, 3.74 mol) was dissolved in DMA (25.3 L) and 4-me- 
thylmorpholine (393 mL, 3.74 mol) added. Stirred for 5 mins 
and isobutyl chloroformate (489 mL, 3.74 mol) added. The 
reaction mixture was stirredat25° C. for 2 hand  cooled to 15° 
C. before (Z)-5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl) 
pyrazine-2-carbohydrazonamide (940 g, 3.4 mol) was added 
portionwise over 10 mins. The reaction mixture was stirred 
for I-2 h a t 15° C. Water (20.5 L) was added portionwise over 
I h  and stirred for a further I h  before being filtered. The 
filtercake was then washed with water (4x4 L) and pulled dry 
on the filter before being dried in a vacuum oven at 50° C. 
until dry to give the desired product.
[0579] Acetic acid (200 mL) was added to dioxane (500 
mL) in a 3 L fixed double jacketed vessel and the solution was 
heated to 70° C. under nitrogen. (Z)-tert-butyl 4-(2-(amino 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl) 
methylene)hydrazinecarbonyl)-piperidine-1 -carboxylate 
(74.5 g, 152.80 mmol) was added portionwise to the warm 
mixture. After 10 minutes the temperature was increased to 
100° C. (slight reflux). The reaction mixture was stirred at 
100° C. for 1.5 hours (suspension) then held at 80° C. over­
night (solution formed after overnight hold). The resulting 
solution was concentrated under reduced pressure, then 
diluted with toluene, evaporated to dryness, taken up with 
toluene and concentrated again. The residual oil was mixed 
with some ethyl acetate and concentrated to dryness. A  solid 
crystallised from solution which was triturated with MTBE 
(200 mL) and isolated by filtration. The filter cake was 
washed with water and MTBE to afford tert-butyl 4-(5-(5-
amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)- 
lEl-l,2,4-triazol-3-yl)piperidine-l-carboxylate (50 g, 70%) 
as a grey solid.
[0580] The filtrate was concentrated under reduced pres­
sure to give a yellow solid. This material was triturated with 
MTBE and filtered. The filter cake was washed with ethyl 
acetate and then MTBE to give a second crop as a pale yellow 
solid (4.93 g, 7%). This material was identical to the first crop: 
1H NMR Spectrum: (DMSCLd6) 1.17 (9H, s), 1.22 (9H, s), 
1.29-1.47 (2H, m), 1.67-1.78 (2H, m), 2.57-2.87 (3H, m), 
3.57-3.92 (2H, m), 7.56 (2H, br), 8.56 (1H, s), 13.47 (2H, br 
s); Mass Spectrum [M+El]+=470.
[0581] l,8-Diazabicyclo[5.4.0]undec-7-ene (19.87 mL, 
132.90 mmol) was added to a suspension of tert-butyl 4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
yl)-lH-l,2,4-triazol-3-yl)piperidine-l-carboxylate (48 g, 
102.23 mmol) in 2-methylTHF (300 mL). A  dark solution 
was obtained after 5 minutes which was treated with charcoal 
and filtered through a celite pad, washing the charcoal and 
charcoal with additional 2-methylTHF (100 mL). The filtrate 
was stirred with an air stirrer a t-5 ° C . i n a 3 L j  acketed fixed 
vessel under an atmosphere of nitrogen. 2-methylTFlF (100 
mL) was added to help stir the yellow suspension. 
Iodomethane (7.96 mL, 127.78 mmol) was added dropwise 
over 15 minutes. The mixture was stirred for 2 hours and the 
reaction mixture was warmed to room temperature. After 16 
hours, additional iodomethane (6 mL) and DBU (20 mL) was 
added and stirring was continued for 16 hours. The mixture 
was poured into water and stirred for 5 minutes. The insoluble 
material was isolated as a beige solid and dried in vacuo to 
afford tert-butyl 4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadia- 
zol-2-yl)pyrazin-2-yl)-l-methyl-IFl-1,2,4-triazol-3-yl)pip- 
eridine-1-carboxylate (24.77 g, 50.1%). The mother liquors 
were concentrated under reduced pressure and the residue 
was purified by flash column chromatography on silica using 
MTBE as the eluant. A  second crop o f the desired product 
(13.04 g, 26%), was thus obtained as a yellow solid: 1FlNMR 
Spectrum: (DMSCLd6) 1.47 (9H, s), 1.51 (9H, s), 1.57-1.76 
(2H, m), 1.94-2.1 (2H, m), 2.87-3.09 (3H, m), 3.9-4.08 (2H, 
m), 4.26 (3H, s), 7.97 (2H, br, s), 8.92 (1H, s); Mass Spectrum 
[M+H]+=484
[0582] tert-Butyl 4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxa- 
diazol-2-yl)pyrazin-2-yl)-l-methyl-lFl-l,2,4-triazol-3-yl) 
piperidine-1 -carboxylate (36.81g,76.12 mmol) was added to 
a solution o f 2,2,2-trifluoroacetic acid (100 mL, 1305.87 
mmol) in DCM (100 mL). The mixture was stirred for 3 hours 
at room temperature. The mixture was concentrated under 
reduced pressure. The residue was dissolved in DCM (1.5 L) 
and added to vigorously stirred concentrated ammonia (150 
mL) in water (400 mL). The aqueous was washed with DCM 
(400 mL) and the combined oiganic solutions were dried with 
magnesium sulfate, filtered and concentrated to dryness to 
afford 3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(l-methyl-3- 
(piperidin-4-yl)-lFl-l,2,4-triazol-5-yl)pyrazin-2-amine 
(30.0 g, 103%) as a yellow solid:
[0583] 1H NM R Spectrum: (DMSCLd6) 1.44 (9H, s), 1.54- 
1.69 (2H, m), 1.8-1.92 (2H, m), 2.53-2.63 (2H, m), 2.68-2.83 
( IFT, m), 2.93-3.05 (2H, m), 4.19 (3H, s), 7.89 (2H, br), 8.85 
(ITT, s); Mass Spectrum [M+Fl]+=384.
[0584] CL(7-Azabenzotriazol-l-yl)-N,N,N',N'-tetramethy- 
luronium hexafluorophosphate (30.4 g, 80.04 mmol), was 
added portionwise to a stirred solution o f 3-(tetrahydro-2Fl- 
pyran-2-yloxy)propanoic acid (12.67 g, 72.76 mmol) and 
N-ethyl-N-isopropylpropan-2-amine (25.3 mL, 145.52
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mmol) dissolved in acetonitrile (200 mL) at 25° C. The result­
ing solution was stirred at 25° C. for 20 minutes then 3-(5- 
tert-butyl-1,3,4-oxadiazol-2-yl)-5-(l -methyl-3-(piperidin-4- 
yl)-lH-l,2,4-triazol-5-yl)pyrazin-2-amine (30 g, 72.76 
mmol) was added portionwise, washing the last portion into 
the mixture as a slurry in acetonitrile (100 mL). After stirring 
for I hour the precipitate was collected by filtration, washed 
with acetonitrile and drying in vacuo to afford I -(4-(5-(5- 
amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l- 
methyl-lH-l,2,4-triazol-3-yl)piperidin-l-yl)-3-(tetrahydro- 
2H-pyran-2-yloxy)propan-l-one (35.0 g, 89%) as a beige 
solid. The filtrate was diluted with DCM (600 mL), washed 
with water, dried over magnesium sulfate and concentrated. 
The residue was purified by flash chromatography on silica 
gel eluting with a gradient o f 2 to 2.5% 7N ammonia in 
methanol with dichloromethane. A  second crop o f product
(3.31 g, 6.13 mmol, 8.43%) was also obtained as a cream 
solid. Both samples were combined to give a beige solid: 1H 
NMR Spectrum: (DMSCLd6) 1.44 (9H, s), 1.52-1.79 (4H, m),
1.88-2.04 (2H, m), 2.53-2.73 (2H, m), 2.73-2.87 (1H, m),
2.91-3.05 (1H, m), 3.13-3.24 (1H, m), 3.37-3.47 (1H, m), 
3.53-3.65 (1H, m), 3.7-3.8 (1H, m), 3.81-3.89 (1H, m), 3.89- 
3.99 (1H, m), 4.20 (3H, s), 4.29-4.4 (1H, m), 4.54-4.61 (1H, 
m), 7.60-8.20 (2H, br), 8.85 (1H, s); Mass Spectrum [M+H]+ 
=540.
Example 3
l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl)-l-ethyl-IH -1,2,4-triazol-3-yl)piperi- 
din-1 -y I) -3 -hy droxypropan-1 -one
[0585]
NH-
OH
Example 3.1
US 2014/0206700 Al
46
Jul. 24, 2014
-continued
HO
NH-
Example 3
HO
OH
[0586] Pyridine 4-methylbenzenesulfonate (11.62 g, 46.24 
mmol) was added to a suspension of l-(4-(5-(5-amino-6-(5- 
tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,
2,4-triazol-3-yl)piperidin-l-yl)-3-(tetrahydro-2H-pyran-2- 
yloxy)propan-l-one (128 g, 231.19 mmol) in methanol (I L) 
under nitrogen. The mixture was stirred at 60° C. for 1.5 
hours. The mixture was soluble after 5 minutes. The mixture 
was held at 50° C. overnight during which time a precipitate 
formed. The solid material was isolated by filtration and 
washed with water and acetonitrile. This material still con­
tained minor impurities from the previous stage and required 
further purification. The material was dissolved in dichlo­
romethane and purified by flash chromatography on silica gel 
(0% methanol/DCM to 10% methanol/DCM). The desired 
product, l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-
2-yl)pyrazin-2-yl)-l-ethyl-IH -1,2,4-triazol-3-yl)piperidin-
1-yl)-3-hydroxypropan-l-one (Example 3) (92 g, 85%), was 
thus isolated as a cream solid (Form A): 1H NMR Spectrum: 
(DMSCEd6) 1.4-1.51 (12H,m), 1.51-1.78 (2H,m ), 1.89-2.05 
(2H, m), 2.72-2.86 (1H, m), 2.91-3.05 (1H, m), 3.12-3.24 
(1H, m), 3.64 (2H, q), 3.83-4.01 (1H, m), 4.29-4.41 (1H, m),
4.47 (1H, t), 4.58 (2H, q), 8.26 (2H, s), 8.85 (1H, s); Mass 
Spectrum [M+H]+=470.
[0587] l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-
2-yl)pyrazin-2-yl)-l-ethyl-IH -1,2,4-triazol-3-yl)piperidin-
l-yl)-3-(tetrahydro-2H-pyran-2-yloxy)propan-l-one (Ex­
ample 3.1) was prepared as follows:
[0588] l,8-Diazabicyclo[5.4.0]undec-7-ene (76 mL, 511. 
14 mmol) was added to a suspension o f tert-butyl 4-(5-(5- 
amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)- 
lH-l,2,4-triazol-3-yl)piperidine-l-carboxylate (150 g, 319. 
46 mmol) in 2-methylTHF (1.2 L). Iodoethane (46 mL, 575. 
03 mmol) was added and the mixture was stirred for 16 hours 
at 35° C. Further iodoethane (46 mL, 575.03 mmol) and 
l,8-diazabicyclo[5.4.0]undec-7-ene (76 mL, 511.14 mmol) 
were added and stirring was continued for 24 hours at 35° C. 
The mixture was poured into water and the insoluble material 
was isolated by filtration, washed with water and MTBE and 
dried in vacuo to afford tert-butyl 4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidine-l-carboxylate (116 g, 73.0%) as a yel­
low solid. The filtrate was extracted with DCM and the 
organic solution was dried with magnesium sulfate, filtered, 
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica using gra­
dient elution (30% MTBE/heptane to 100% MTBE). A  sec­
ond crop o f the desired product (12 g, 24.12 mmol, 7.55%), 
was thus isolated as a yellow solid which was later combined 
with the first crop: 1HNM RSpectrum: (DMSCEd6) 1.41 (9H, 
s), 1.44 (9H, s), 1.48 (3H, t), 1.52-1.69 (2H, m), 1.87-2.04 
(2H, m), 2.79-3.03 (3H, m), 3.86-4.03 (2H, m), 4.59 (2H, q),
7.89 (2H, s), 8.85 (1H, s); Mass Spectrum [M+H]+=498. THF 
may also be a suitable solvent for the above reaction.
[0589] TFA (400 mL) was added portionwise to a solution 
o f tert-butyl 4-(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-
2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4-triazol-3-yl)piperidine-
1-carboxylate (126 g, 253.22 mmol) in DCM (400 mL). The 
mixture was stirred for 16 hours at room temperature. The 
mixture was concentrated under reduced pressure, dissolved 
in DCM (I L) and added slowly to a vigorously stirred solu­
tion o f concentrated aqueous ammonia (500 mL) in water at 
0° C. The oiganic solution was separated from the aqueous 
and concentrated under reduced pressure* to afford 3-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)-5-(l-ethyl-3-(piperidin-4-yl)- 
lH-l,2,4-triazol-5-yl)pyrazin-2-amine (101 g, 100%) as a 
yellow solid: 1HNM RSpectrum: (DMSCEd6) 1.4-1.52 (12H, 
m), 1.57-1.73 (2H, m), 1.83-1.93 (2H, m), 2.57-2.7 (2H, m), 
2.71-2.84 (1H, m), 2.96-3.09 (2H, m), 4.58 (2H, q), 8.06 (2H, 
s), 8.84 (1H, s); Mass Spectrum [M+H]+=398.
[0590] *In another experiment on a similar scale (approxi­
mately 170 g o f starting material) the following isolation 
procedure was utilised: The layers were separated and the top 
layer (emulsion with a solid) was filtered. The solid was 
washed with DCM (0.5 L) and the filtrate was transferred to a 
separating funnel. The layers were separated and the aqueous 
layer was extracted with DCM (0.5 L). The organic layers 
were dried over MgSO4, filtered and concentrated. The prod­
uct was dried at 50° C. overnight (81.75 g). The solid from the 
extraction was slurried in water (200 mL) for 30 min at room 
temperature and filtered off.
[0591] The product was dried at 50° C. in vacuo (61.8 g).
[0592] A further variation is as follows;
[0593] A suspension of tert-butyl 4-(5-(5-amino-6-(5-tert- 
butyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidine-l-carboxylate (3009.5 g, 6.05 mol) in 
DCM (9 L) was cooled to 5-10° C. under N2 TFA (9 L) was 
added portionwise to the suspension whilst maintaining the 
temperature <30° C. The reaction mixture was stirred at room
US 2014/0206700 Al
47
Jul. 24, 2014
temperature for I h. The mixture was concentrated, the result­
ing residue was dissolved in water (30 L) and added slowly to 
a 35% aqueous ammonia solution (12 L) at 0-5° C. The 
suspension was stirred for 30 min then the product was fil­
tered off and washed with water (2x6 L). The product was 
dried at 50° C. in vacuo for 2 days (2496 g).
[0594] 0 -(7 -Azabenzotriazol-I -yl)-N,N,N',N'-tetramethy- 
luronium hexafluorophosphate (HATU, 106 g, 279.51 
mmol), was added portionwise to a stirred solution o f 3-(tet- 
rahydro-2H-pyran-2-yloxy)propanoic acid (44.3 g, 254.10 
mmol) and N-ethyl-N-isopropylpropan-2-amine (89 mL, 
508.21 mmol) dissolved in acetonitrile (600 mL) at 25° C. 
The resulting solution was stirred at 25° C. for 20 rnn then 
3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(l-ethyl-3-(piperi- 
din-4-yl)-lH-l,2,4-triazol-5-yl)pyrazin-2-amine (101 g, 254. 
10 mmol) was added portionwise washing the last portion 
into the mixture as a slurry in acetonitrile (300 mL). After 
stirring for I hour the precipitate was collected by filtration, 
washing with acetonitrile and drying in vacuo to afford 1-(4- 
(5-(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
yl)-l-ethyl-lH-l,2,4-triazol-3-yl)piperidin-l-yl)-3-(tetrahy- 
dro-2H-pyran-2-yloxy)propan-l-one (128 g, 91%) as a beige 
solid. The filtrate was diluted with DCM (600 ml), washed 
with water, dried over magnesium sulfate and concentrated. 
The residue was purified by flash chromatography on silica 
gel eluting with a gradient o f 2 to 2.5% 7N ammonia in 
methanol with dichloromethane. A  second crop of the desired 
product (40 g, 72.2 mmol, 28.4%) was obtained as a cream 
solid which was combined with the first crop: 1H N M R  Spec­
trum: (DMSCLd6) 1.29-1.48 (16H, m), 1.48-1.75 (4H, m),
1.83-1.99 (2H, m), 2.48-2.68 (2H, m), 2.68-2.79 (1H, m), 
2.87-2.99 (1H, m), 3.07-3.19 (1H, m), 3.32-3.42 (1H, m), 
3.47-3.6 (1H, m), 3.64-3.75 (1H, m), 3.75-3.84 (1H, m),
3.84-3.95 (1H, m), 4.24-4.39 (1H, m), 4.47-4.6 (3H, m), 7.84 
(2H, s), 8.79 (1H, s): Mass Spectrum [M+Na]+=577.
Alternative Preparation:
[0595] To a solution o f 3-(tetrahydro-2H-pyran-2-yloxy) 
propanoic acid (48.80 g 0.2774 mol) and N-ethyl-N-isopro- 
pylpropan-2-amine (86.96 mL, 0.4993 mol) in THF (552 mL) 
was added 0-(7-Azabenzotriazol-l-yl)-N,N,N',N'-tetram- 
ethyluronium hexafluorophosphate (115.73 g, 0.3051 mol) 
portionwise at RT under nitrogen. The resulting mixture was 
stirred for 20 min then 3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-
5-(1-ethyl-3-(piperidin-4-yl)-l H -1,2,4-triazol-5-yl)pyrazin-
2-amine (122.5 g (110.25 g active), 0.2774 mol) was added 
portionwise over I h. After 3.5 h, the mixture was concen­
trated and the residue was slurried in MeCN (275 mL) for 15 
min at room temperature. The product was filtered off, 
washed with MeCN (3x110 mL) and dried overnight at 50° C. 
in vacuo. This gave l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4- 
oxadiazol -2 -yl)pyrazin-2 -yI) -1 -ethyl-1H -1,2,4 -triazol -3 -yI) 
piperidin-l-yl)-3-(tetrahydro-2H-pyran-2-yloxy)propan-l- 
one (131.9 g, 96%). In a further alternative preparation, 
HBTU (0-(benzotriazol-1 -yl)-N,N,N',N'-tetramethyluro- 
nium hexafluorophosphate) in THF may be used as coupling 
agent instead o f HATU.
Alternative Preparation o f Example 3
[0596] To a suspension o f l-(4-(5-(5-amino-6-(5-tert-bu- 
tyl-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l-yl)-3-(tetrahydro-2H-pyran-2- 
yloxy)propan-l-one (131.9 g, 0.2382 mol) inmethanol (1045
mL) was addedpyridinium p-toluenesulfonate (11.97 g, 47.7 
mmol) under N2. The reaction mixture was stirred at 60° C. 
for 5.5 h  then at 50° C. overnight. The reaction mixture was 
cooled to 0° C. and the solid was filtered off. The product was 
slurried in water (250 mL) for 20 min at room temperature, 
filtered off, washed with water (3x40 mL) and dried at 50° C. 
in vacuo. This gave l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4- 
oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4-triazol-3-yl) 
piperidin-l-yl)-3-hydroxypropan-l-one (21.4 g) as Form A  
(see below).
[0597] The methanol liquors were concentrated and the 
resulting solid was slurried in water (0.6 L) for 20 min at room 
temperature. The solid was isolated by filtration and washed 
with water (3x100 mL). The filter cake was slurried for a 
second time in water (0.5 L) for a further 20 minutes. The 
product was isolated by filtration, washed with water (100 
mL) and dried at 50° C. in vacuo. This gave 81.9 g 1-(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-l -ethyl-lH-1,2,4-triazol-3-yl)piperidin-l -yl)-3-hydrox- 
ypropan-l-one (81.9 g) as Form A.
[0598] Both crops were combined (103.3 g), seeded with 
Form B (16.68 g) and slurried in MeCN (826 mL) at room 
temperature overnight. This gave 117.4 g o f I -(4-(5-(5- 
amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l- 
ethyl-lH-l,2,4-triazol-3-yl)piperidin-l-yl)-3-hydroxypro- 
pan-l-one as a pale yellow solid (117.4 g), Form B (see 
below). This material was further purified by slurrying in 
heptane (7.5 rel vols) for I hour. The mixture was filtered, 
pulled dry on the filter, and dried at 50° C. in a vacuum oven 
overnight to afford l-(4-(5-(5-amino-6-(5-tert-butyl-l,3,4- 
oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4-triazol-3-yl) 
piperidin-l-yl)-3-hydroxypropan-l-one (102.5 g) as Form B.
[0599] Form B may also be made by slurrying Form A in 
MeCN without seeding.
[0600] Form A or B may also be converted to Form C as 
follows:
[0601] A suspension o f l-(4-(5-(5-amino-6-(5-tert-butyl-
l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4-tria- 
zol-3-yl)piperidin-l-yl)-3-hydroxypropan-l-one (eg Form B 
made by the processes outlined above) in IPA (12 vol) was 
heated at reflux until the solid dissolved. The solution was hot 
filtered then cooled to room temperature. This gave 1-(4-(5- 
(5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl)pyrazin-2- 
y l)-l -ethyl-lH-1,2,4-triazol-3-yl)piperidin-l -yl)-3-hydrox- 
ypropan-l-one as a pale yellow solid (99.3 g, 97%) as Form 
C.
[0602] Form C may also be converted to Form B as follows:
[0603] In a  10 L flange flask, Form C  (377.8 g portion I) in 
MIBK (7900 mL) was heated to 110-115 ° C. to give a solu­
tion. The solution was allowed to cool to 97-103° C. and 
immediately polish filtered into a 50 L vessel containing a 
seed o f Form B (0.8 g) in acetonitrile (8220 mL) stirring at 
-15° C. During the addition the temperature in the 50 L vessel 
was maintained between -15  and 25° C. by means o f jacket 
cooling. Three further portions o f the compound dissolved in 
MIBK were added by a similar method. To the resulting slurry 
was added a seed o f form B (0.8 g) and the mixture was then 
stirred at 10-20° C. overnight. In-process analysis confirmed 
the desired form (Form B) with no Form C or amorphous 
visible. The mixture was filtered and washed with acetonitrile 
(3340 mL). The solid was oven dried for 2 days (solid was 
broken up during the drying to a powder and a mixture of 
small lumps - I  mm to -3 -4  mm size) until constant weight 
was obtained. Yield=1532.8 g (93.5%)
US 2014/0206700 Al
48
Jul. 24, 2014
[0604] 3-(Tetrahydro-2H-pyran-2-yloxy)propanoic acid 
was prepared as follows:
[0605] To a stirred solution o f methanol (2.4 L) and con­
centrated sulfuric acid (44.4 mL, 832.61 mmol) at 0° C. under 
nitrogen was added, dropwise, beta-propiolactone (175 mL, 
2.78 mol). This solution was allowed to stir at room tempera­
ture for 2 days. The reaction mixture was cooled to 10° C. 
before adding, portionwise, sodium bicarbonate (145 g, 1.72 
mol), the resulting suspension was left to stir at room tem­
perature for 75 minutes. This solution was filtered, the filter- 
cake was washed with methanol (800 mL). The filtrate was 
evaporated to an oil which was redissolved in dichlo­
romethane (1.2 L) and stirred for 60 minutes before refilter­
ing. This solution was filtered before evaporating to give 
methyl 3-hydroxypropanoate (219 g, 76%) as an oil. 1H NMR 
Spectrum: (CDCl3) 2.50 (2H, t), 3.63 (3H, s), 3.78 (2H, t).
[0606] Pyridinium p-toluenesulfonate (7.65 g, 30.45 
mmol) was added to a clear solution o f methyl 3-hydroxypro- 
panoate (63.4 g, 609.00 mmol) and 3,4-dihydro-2H-pyran 
(78 mL, 852.60 mmol) in dichloromethane (650 mL) at room 
temperature under nitrogen to give a cloudy solution. This 
was allowed to stir at room temperature overnight. The reac­
tion mixture was washed with water (250 mL) and brine (250 
mL) before drying (MgSO4) and evaporating to an oil. This 
crude product was purified by flash silica chromatography, 
elution gradient 15 to 30% EtOAc in heptane. Pure fractions 
were evaporated to dryness to afford methyl 3-(tetrahydro- 
2H-pyran-2-yloxy)propanoate (67.7 g, 59.0%) as a colour­
less oil: 1H NM R Spectrum: (CDCl3) 1.47 (4H, dddd), 1.55-
1.84 (2H, m), 2.55 (2H, t), 3.33-3.53 (1H, m), 3.53-3.7 (4H, 
m), 3.78 (1H, ddd), 3.93 (1H, dt), 4.42-4.72 (1H, m); Mass 
Spectrum [MH]+=I 89.
[0607] Sodium hydroxide (2M, 349mL, 697.58 mmol) was 
added to a solution o f methyl 3-(tetrahydro-2H-pyran-2- 
yloxy)propanoate (67.68 g, 359.58 mmol) in THF (680 mL) 
at room temperature. The reaction mixture was stirred at 
room temperature for 3 hours. The THF was removed in 
vacuo, the aqueous layer was then washed with ethyl acetate 
(260 mL), before cooling to 0° C. and careful acidification to 
pH 5 by the addition o f hydrochloric acid (2M). The product 
was extracted with ethyl acetate (3x250 mL) before drying 
(MgSO4) and evaporation to give 3-(tetrahydro-2H-pyran-2- 
yloxy)propanoic acid (57.0 g, 91%) as a clear oil. This mate­
rial was dissolved in ethyl acetate (750 mL) then washed with 
water (3x250 mL) and brine (250 mL) to remove remaining 
acetic acid. The organic solution was dried (MgSO4) and 
evaporated to give 3-(tetrahydro-2H-pyran-2-yloxy)pro- 
panoic acid (45.67 g, 72.9%) as a colourless oil: 1H NMR 
Spectrum: 1H NMR (CDCl3) 1.43-1.67 (4H, m), 1.65-1.95 
(2H, m), 2.68 (2H, t), 3.48-3.58 (1H, m), 3.73 (1H, dt), 3.88 
(1H, ddd), 4.02 (1H, dt), 4.59-4.7 (1H, m); Mass Spectrum 
[M -H ]“=173. Example 3 as isolated above was a crystalline 
solid in three different crystalline forms, described herein as 
Forms A, B and C.
[0608] The crystal structure o f Form A o f Example 3 may 
be characterised by XRPD and DSC.
[0609] The methods for carrying out these techniques are as 
described for Example I .
Ten X-Ray Powder Diffraction Peaks for Example 3 Form A
[0610]
Angle 2-
Theta (2Θ) Intensity %
4.8 100
10.0 89.2
14.6 81.9
5.2 59.4
19.9 53.6
10.4 49.3
25.4 48.7
23.6 48.6
24.4 43.9
16.2 36.3
[0611] The XRPD for Example 3 Form A is shown in FIG.
3.
[0612] DSC analysis o f Example 3 Form A shows an initial 
endotherm with an onset o f 27.0° C. and a peak at 63.0° C., 
further endothermic shifts are seen with onsets and peaks at 
the following temperatures; 166.5° C. and 168.7° C., 172.2° 
C. and 173.2° C. and a final melt at 174.8° C. and a peak at 
175.7° C. (FIG. 4).
[0613] Thus DSC analysis shows Example 3 Form A i s a  
solvated material with an onset o f desolvation at about 27.0° 
C. and a peak at about 63.0° C.
[0614] The X-ray powder diffraction spectra for Example 3 
(FormA) showed the material to be crystalline. This material 
had a desolvation point o f 28.0° C. (onset).
[0615] Example 3 can also exist in an alternative polymor­
phic form, referred to herein as Form B. Preparation o f Form 
B was described above.
[0616] This material had a melting point o f 172.5° C. (on­
set).
[0617] In a further aspect o f the invention, there is provided 
a process for making Form B o f Example 3 by slurrying a 
sample o f Example 3 in acetonitrile. In a further aspect of the 
invention there is provided a process for making Form B of 
Example 3 from a solution o f Form C o f Example 3 in MIBK.
Ten X-Ray Powder Diffraction Peaks for Example 3 Form B
[0618]
Angle 2-
Theta (2Θ) Intensity %
5.8 100.0
10.9 59.8
11.5 33.8
25.9 18.2
17.3 15.8
24.0 14.1
19.1 13.4
12.9 11.7
24.7 11.1
27.2 9.7
[0619] The XRPD for Example 3 Form B is shown in FIG.
5.
[0620] DSC analysis o f Example 3 Form B shows a melting 
endotherm with an onset o f 172.5° C. and a peak at 174.2° C. 
(FIG. 6).
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[0621] Thus DSC analysis shows Example 3 B is a high 
melting solid with an onset o f melting at about 172.5° C. and 
a peak at about 174.2° C.
[0622] Example 3 may also exist in a third crystalline form, 
referred to herein as Form C. A  process for making Form C 
material from eg Form B material was described above, by 
crystallisation from isopropyl alcohol (IPA).
[0623] Therefore in a further aspect o f the invention there is 
provided a process for making Form C o f Example 3 by 
crystallising Example 3 from IPA.
[0624] Example 3 Form C is characterised in providing at 
least one o f the following 28 values measured using CuKa 
radiation: 6.9 and 12.3. Example 3 Form C is characterised in 
providing an X-ray powder diffraction pattern, substantially 
as shown in Figure A. Ten X-Ray powder diffraction peaks 
are shown below:
Ten X-Ray Powder Diffraction Peaks for Example 3 Form C
[0625]
microns in size and non-unitary aspect ratios that may affect 
analysis o f samples. The skilled person will also realise that 
the position o f reflections can be affected by the precise 
height at which the sample sits in the diffractometer and the 
zero calibration o f the diffractometer. The surface planarity o f 
the sample may also have a small effect. Flence the diffraction 
pattern data presented are not to be taken as absolute values.
Differential Scanning Calorimetry
Analytical Instrument: TA Instruments QlOOO DSC.
[0629] Typically less than 5 mg o f material contained in a 
standard aluminium pan fitted with a lid was heated over the 
temperature range 25° C. to 300° C. at a constant heating rate 
o f 10° C. per minute. A  purge gas using nitrogen was used- 
flow rate 50 ml per minute.
Example 4
(3R)-l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadia- 
zol -2 -yl)pyrazin-2 -yI] -1 -methyl-1,2,4 -triazol -3 -yI] - 
I -piperidyl] -3-hydroxy-butan-1 -one
[0630]
Angle 2-
Theta (2Θ) Intensity %
6.9 40.1
12.3 100.0
10.5 23.8
21.0 67.9
24.6 36.1
13.6 21.4
16.4 19.9
19.6 18.1
20.2 17.5
22.5 18.4
[0626] DSC analysis o f Example 3 Form C shows a melting 
endotherm with an onset o f 183.0° C. an d ap eak a t 185.6° C. 
(Figure B).
[0627] Thus DSC analysis shows Example 3 Form C is a 
high melting solid with an onset o f melting at about 183.0° C. 
and a peak at about 185.6° C.
Details o f Techniques Used for Form C Analysis
X-Ray Powder Diffraction
Analytical Instrument: Panalytical Cubix.
[0628] The X-ray powder diffractogram was determined by 
mounting a sample o f the crystalline material on a Panalytical 
single silicon crystal (SSC) wafer mount and spreading out 
the sample into a thin layer with the aid o f a microscope slide. 
The sample was spun at 30 revolutions per minute (to improve 
counting statistics) and irradiated with X-rays generated by a 
copper long-fine focus tube operated at 45 kV and 40 mA with 
a wavelength o f 1.5418 angstroms. The X-ray beam was 
passed through a 0.04 rad soller slit, then an automatic vari­
able divergence slit set at 20 mm and finally a 20 mm beam 
mask. The reflected radiation was directed through a 20 mm 
antiscatter slit and a 0.04 rad soller slit. The sample was 
exposed for 1.905 seconds per 0.0025067° 2-theta increment 
(continuous scan mode) over the range 2 degrees to 40 
degrees 2-theta in theta-theta mode. The instrument was 
equipped with an X-Celerator detector. Control and data cap­
ture was by means o f a Dell Pentium 4F1T Workstation oper­
ating with X'Pert Industry software. Persons skilled in the art 
o f X-ray powder diffraction will realise that the relative inten­
sity o f peaks can be affected by, for example, grains above 30
> = N
NH-
[0631] 2-(lH -B enzo[d][l,2,3]triazol-l-yl)-l,l,3,3-tetram - 
ethylisouronium tetrafluoroborate (201 mg, 0.63 mmol) was 
added to a stirred suspension o f 3-(5-tert-butyl-l,3,4-oxadia- 
zol-2-yl)-5-(l-methyl-3-(piperidin-4-yl)-lFl-l,2,4-triazol-5- 
yl)pyrazin-2-amine (200 mg, 0.52 mmol, described in 
Example I), N-ethyl-N-isopropylpropan-2-amine (0.273 
mL, 1.56 mmol) and (R)-3-hydroxybutanoic acid (65.2 mg, 
0.63 mmol) in Ν,Ν-dimethylformamide (3 mL). The result­
ing suspension was stirred at room temperature for 2 hours. 
The resulting mixture was purified by preparative FlPLC 
using a Waters X-Bridge reverse-phase column (C-18, 5 
microns silica, 30 mm diameter, 150 mm length, flow rate o f 
60 ml/minute) using an isocratic mixture o f 31% acetonitrile 
in water (containing ammonium carbonate (2 g/L). The frac­
tions containing the desired compound were evaporated to 
dryness to afford a pale yellow solid. This solid was stirred in 
acetonitrile (3 mL) at room temperature. The resulting solid 
was filtered, washed with cold acetonitrile and dried to afford 
the title compound (125 mg, 51.0%) as a pale yellow solid.
[0632] 1H NMR Spectrum: (CDCl3) 1.24 (3H, d), 1.52 (9H, 
s), 1.85 (2H, m), 2.10 (2H, m), 2.35 (1H, dd), 2.55 (1H, d),
2.90 (1H, m), 3.05 (1H, m), 3.20 (1H, m), 3.90 (1H, m), 4.25 
( IFT, m), 4.31 (3H, s), 4.6 (1H, m), 9.03 (1H, s); Mass Spec­
trum [M+H]+=470.
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Example 5
(3S)-1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadia- 
zol-2-yl)pyrazin-2-yl]-l-methyl-1,2,4-triazol-3-yl]- 
1 -piperidyl] -3-hydroxy-butan-1 -one
[0633]
HO,
> = N
NH-
[0634] Using a similar procedure as Example 4, 3-(5-tert- 
butyl-1,3,4-oxadiazol-2-yl)-5-(l-methyl-3-(piperidin-4-yl)- 
lEl-l,2,4-triazol-5-yl)pyrazin-2-amine was reacted with (S)- 
3-hydroxybutanoic acid to afford the title compound (167 
mg, 68.2%) as a pale yellow solid. 1El NMR Spectrum: 
(CDCl3) 1.24 (3H, d), 1.52 (9H, s), 1.85 (2H, m), 2.10 (2H, 
m), 2.35 (1H, dd), 2.55 (1H, d), 2.90 (1H, m), 3.05 (1H, m), 
3.20 (1H, m), 3.90 (1H, m), 4.25 (1H, m), 4.31 (3H, s), 4.6 
(1H, m), 9.03 (1H, s); Mass Spectrum [M+H]+=470.
Example 6
(2R)-1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadia- 
zol-2-yl)pyrazin-2-yl]-l-methyl-1,2,4-triazol-3-yl]- 
1 -piperidyl] -3 -hydroxy-2-methyl-propan-1 -one
[0635]
HO.
/ > = N
NH-
[0636] Using a similar procedure as Example 4, 3-(5-tert- 
butyl-1,3,4-oxadiazol-2-yl)-5-(l-methyl-3-(piperidin-4-yl)- 
1H-1,2,4-triazol-5-yl)pyrazin-2-amine was reacted with (R)- 
3-hydroxy-2-methylpropanoic acid to afford the title 
compound (87 mg, 47.4%) as a pale yellow solid.
[0637] 1HNM RSpectrum: (CDCl3) 1.55 (9H, s), 1.61 (3H, 
s br), 1.8-2.0 (2H, m), 2.10-2.25 (2H, m), 2.90 (2H, m), 3.10 
(1H, m), 3.3 (2H, m), 3.77 (2H, m), 4.33 (3H, s), 4.6 (1H, m), 
9.05 (1H, s); Mass Spectrum [M+H]+=470.
Example 7
l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl]-1-methyl-1,2,4-triazol-3-yl]-1-pip­
eridyl] -2-hydroxy-2-methyl-propan-1 -one
[0638]
HO
NH-
[0639] I -(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (100 mg, 0.52 mmol) was added in one portion 
to 2-hydroxy-2-methylpropanoic acid (38.0 mg, 0.37 mmol), 
3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(l-methyl-3-(piperi- 
din-4-yl)-lH-l,2,4-triazol-5-yl)pyrazin-2-amine (100 mg, 
0.26 mmol) and 2-hydroxy-pyridine N-oxide (57.9 mg, 0.52 
mmol) dissolved in NMP (1.2 mL) under argon. The resulting 
solution was stirred at 25° C. for 3 hours. Pyridine (100 pL, 
1.24 mmol) was added and the mixture was stirred for 18 
hours. Additional 2-hydroxypyridine I -oxide (57.9 mg, 0.52 
mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (100 mg, 0.52 mmol) was added. The mixture 
was then heated up to 70° C. for 48 hours, more 2-hydroxy-
2-methylpropanoic acid (15 mg, 0.14 mmol), l-(3-dimethy- 
laminopropyl)-3-ethylcarbodiimide hydrochloride (50.0 mg,
0.26 mmol) and 2-hydroxypyridine I -oxide (25.0 mg, 0.23 
mmol) were added and the mixture was then kept to 70° C. for 
8 hours. The solution was purified by preparative HPLC using 
a Waters X-Bridge reverse-phase column (C-18, 5 microns 
silica, 19 mm diameter, 100 mm length, flow rate o f 40 
ml/minute) and decreasingly polar mixtures o f water (con­
taining 0.2% ammonium carbonate) and acetonitrile as eluent 
to afford the title compound (71 mg, 58%) as a pale yellow 
solid. 1HNM RSpectrum: (CDCl3) 1.55 (15H, sbr), 1.90 (2H, 
m), 2.15 (2H, m), 3.05-3.3 (4H, m), 4.32 (3H, s), 4.6 (1H, m),
9.03 (1H, s); Mass Spectrum [M+H]+=470.
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Example 8
3-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl]-l-methyl-l,2,4-triazol-3-yl]-l-pip- 
eridyl]-3-oxo-propanoic acid
[0640]
HO·
[0641] Ethyl 3-chloro-3-oxopropanoate (0.037 mL, 0.29 
mmol) was added dropwise to a stirred solution of 3-(5-tert- 
butyl-1,3,4-oxadiazol-2-yl)-5-(l-methyl-3-(piperidin-4-yl)- 
lEl-l,2,4-triazol-5-yl)pyrazin-2-amine (100 mg, 0.26 mmol) 
and triethylamine (0.047 mL, 0.34 mmol) dissolved in 
CEl2Cl2 (1.5 mL) over a period of 2 minutes at 0° C. under 
nitrogen. The mixture was stirred at 0° C. for 10 minutes then 
allowed to warm to room temperature and stirred for I hour. 
The mixture was evaporated, dissolved in DM F; a white solid 
was filtered off and the filtrate was purified by preparative 
ElPLC using a Waters X-Terra reverse-phase column eluting 
with a mixture o f water (containing 0.2% ammonium carbon­
ate) and acetonitrile to afford ethyl 3-(4-(5-(5-amino-6-(5- 
tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1 -methyl-1H-
l,2,4-triazol-3-yl)piperidin-l-yl)-3-oxopropanoate (80 mg, 
61.7%) as a yellow solid. This material was suspended in THF 
(2 mL). 2N Sodium hydroxide (0.235 mL, 0.47 mmol) and 
water (0.5 ml) were added. The mixture was stirred at room 
temperature overnight. 2N Hydrochloric acid (230 pL) was 
added to the mixture. The solvents were evaporated. The 
residue was diluted with CH2Cl2 (30 mL) and water (5 mL). 
The organic phase was washed with brine and dried over 
MgSO4. The solvents were evaporated. The resulting foam 
was triturated in ether. The resulting yellow solid was filtered, 
dried, triturated in acetonitrile (3 mL). The yellow solid was 
collected by filtration, dried at 40° C. to afford the title com­
pound (50 mg, 68%) as a yellow solid.
[0642] 1H NM R Spectrum: (DMSO-d6) 1.46 (9H, s), 1.58 
(1H, m), 1.74 (1H, m), 1.98 (2H, m), 2.84 (1H, m), 3.0 (1H, 
m), 3.21 (1H, m), 3.46 (2H, m), 3.83 (1H, m), 4.22 (3H, s), 
4.34 (1H, m), 7.8-8.2 (1H, m), 8.87 (1H, s); Mass Spectrum 
[M+H]+=470.
Example 9
3-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2- 
yl)pyrazin-2-yl]-l-ethyl-1,2,4-triazol-3-yl]- I -pip- 
eridyl]-3-oxo-propanoic acid
[0643]
HO·
NH-
[0644] 0-(7-Azabenzotriazol-l-yl)-N,N,N',N'-tetramethy- 
luronium hexafluorophosphate (474 mg, 1.25 mmol) was 
added over 30 seconds in portions to a stirred solution of
3-ethoxy-3-oxopropanoic acid (150 mg, 1.13 mmol), 
N-ethyl-N-isopropylpropan-2-amine (0.394 mL, 2.26 mmol) 
and 3-(5-(tert-butyl)-l,3,4-oxadiazol-2-yl)-5-(l-ethyl-3-(pi- 
peridin-4-yl)-lH-l,2,4-triazol-5-yl)pyrazin-2-amine (450 
mg, 1.13 mmol) dissolved in DMF (20 mL) at 50° C. The 
resulting solution was sampled after I min (complete reac­
tion) and immediately allowed to cool to ambient tempera­
ture. The reaction mixture was concentrated and diluted with 
EtOAc (100 mL), and washed sequentially with water (20 
mL) and saturated brine (20 mL). The organic layer was dried 
over MgSO4, filtered and evaporated to afford crude ethyl
3-(4-(5-(5-amino-6-(5-(tert-butyl)-l,3,4-oxadiazol-2-yl) 
pyrazin-2-yl)-l-ethyl-IH -1,2,4-triazol-3-yl)piperidin-1-yl)-
3-oxopropanoate (850 mg).
[0645] Some o f that material (780 mg) was dissolved in 
THF (20 ml). To this solution was added 2N aqueous sodium 
hydroxide (2.3 ml, 4.57 mmol) and water (5 ml) followed by 
methanol (5 ml) to give a clear solution. The mixture was 
stirred at room temperature for 3 hours. The THF was evapo­
rated. The aqueous layer was acidified to pH3 with 2N aque­
ous hydrochloric acid (2.5 ml). Dichloromethane (50 ml) was 
added and the organic phase extracted. The organic phase was 
washed with brine (10 ml) and dried over MgSO4. The sol­
vents were evaporated. The resulting gum was purified by 
preparative HPLC (Waters X-Bridge Prep C l8  OBD column, 
5μ silica, 50 mm diameter, 100 mm length), using decreas- 
ingly polar mixtures o f water (containing 1% ammonia) and 
acetonitrile as eluents. Fractions containing the desired com­
pound were evaporated to dryness to afford pure ammonium 
salt. This was solubilised in water and acidified to pH3 with 
2N hydrochloric acid (-0.3 ml). Dichloromethane (50 mL) 
was added and the organic phase separated, washed with 
brine (5 ml) and dried over MgSO4. After filtration the result­
ing solution was evaporated to dryness and the residue was 
triturated with diethyl ether (5 mL) and filtered to afford
3-(4-(5-(5-amino-6-(5-(tert-butyl)-l,3,4-oxadiazol-2-yl)
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pyrazin-2-yl)-1 -ethyl-1H-1,2,4-triazol-3-yl)piperidin-1 -yl)-
3-oxopropanoic acid (195 mg, 26.5%) as a cream solid. 1H 
NMR Spectrum: (DMSCEd6) 1.45 (9H, s), 1.48 (3H, m),
1.55-1.62 (1H, m), 1.70-1.80 (1H, m), 1.95-2.05 (2H, m), 
2.80-2.90 (1H, m), 2.95-3.05 (1H, m), 3.15-3.25 (1H, m),
3.45 (2H, s), 3.78-3.85 (1H, m), 4.30-4.40 (1H, m), 4.55-4.65 
(2H, m), 7.80-8.00 (2H, br s), 8.88 (1H, s), 12.60 (1H, s); 
Mass Spectrum [M+H]+=484
Example 10
(2S)-1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadia-
zol-2-yl)pyrazin-2-yl]-l-ethyl-l,2,4-triazol-3-yl]-l- 
piperidyl] -2,3 -dihydroxy-propan-1 -one
[0646] To a mixture o f 3-(5-(tert-butyl)-l ,3,4-oxadiazol-2- 
yl)-5-(l-ethyl-3-(piperidin-4-yl)-lH-l,2,4-triazol-5-yl) 
pyrazin-2-amine (257 mg, 0.50 mmol, TFA salt), potassium 
(S)-2,2-dimethyl-l,3-dioxolane-4-carboxylate (101 mg, 0.55 
mmol) and EDCI (105 mg, 0.55 mmol) in DCM (5 mL) were 
added 1-hydroxy-lH-benzotriazol hydrate (85 mg, 0.56 
mmol) and DIPEA (194 mg, 1.50 mmol). The mixture was 
stirred for 16 hours at room temperature. Water was added to 
the mixture and the mixture was extracted with DCM. The 
organic layers were washed with brine and dried over 
Na2SO4, filtered and concentrated to give (S)-(4-(5-(5- 
amino-6-(5-(tert-butyl)-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)- 
l-ethyl-lH-l,2,4-triazol-3-yl)piperidin-l-yl)(2,2-dim ethyl- 
l,3-dioxolan-4-yl)methanone (320 mg). Mass Spectrum 
[M+H]+=526. To a mixture o f (S)-(4-(5-(5-amino-6-(5-(tert- 
butyl)-l,3,4-oxadiazol-2-yl)pyrazin-2-yl)-l-ethyl-lH-l,2,4- 
triazol-3-yl)piperidin-l -yl)(2,2-dimethyl-l ,3-dioxolan-4-yl) 
methanone (320 mg) in DCM (10 mL) at r.t was added 
dropwise TFA (1.6 ml, 20.77 mmol). The mixture was stirred 
for 16 h at r.t, concentrated and purified by preparative HPLC 
(Waters XBridge Prep C18 OBD column, 5μ silica, 19 mm 
diameter, 100 mm length) using decreasingly polar mixtures 
o f water (containing 0.1% NH3) and MeCN as the eluant. The 
fractions containing the desired compound were evaporated 
to dryness to afford the title compound (142 mg, 48%) as a 
white solid. 1H NMR Spectrum (400 Hz, DMSCEd6, 30° C.):
1.45 (12H ,m), 1 .56(lH ,m ), 1 .70(lH ,m ), 1 .98(2H ,m ),2.85 
(1H, m), 3.00 (1H, m), 3.20 (1H, m), 3.45 (1H, s), 3.55 (1H, 
s), 4.05 (1H, m), 4.35 (2H, m), 4.60 (2H, m), 4.70 (1H, m),
4.85 (1H, m), 7.90 (2H, m), 8.85 (1H, s); Mass Spectrum 
[M+H]+=486.
Example 11
(2R)-1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadia-
zol-2-yl)pyrazin-2-yl]-l-ethyl-l,2,4-triazol-3-yl]-l- 
piperidyl] -2,3 -dihydroxy-propan-1 -one
[0647] 3-(5-(Tert-butyl)-l,3,4-oxadiazol-2-yl)-5-(l-ethyl-
3-(piperidin-4-yl)-lH-l,2,4-triazol-5-yl)pyrazin-2-amine 
was reacted with potassium (R)-2,2-dimethyl-l,3-dioxolane-
4-carboxylate, using a similar procedure than described in 
Example 10 to provide the title compound (0.145 g, 40%) as 
a solid. 1H NMR Spectrum (400 Hz, DMSCEd6, 30° C.): 1.45 
(12H, m), 1.60 (2H, m), 1.98 (2H, m), 2.85 (1H, m), 3.00 (1H, 
m), 3.17 (1H ,m), 3.45 (1H, s), 3.55 (1H, s), 4.05 (1H ,m), 4.35 
(2H, m), 4.60 (2H, m), 4.70 (1H, m), 4.85 (1H, m), 7.90 (2H, 
m), 8.85 (1H, s); Mass Spectrum [M+H]+=486.
BRIEF DESCRIPTION OF THE FIGURES
[0648] FIG. I  shows an X-Ray powder Diffraction Pattern 
for Example I Form A.
[0649] FIG. 2 shows a DSC Thermogram for Example I 
Form A.
[0650] FIG. 3 shows an X-Ray powder Diffraction Pattern 
for Example 3 Form A.
[0651] FIG. 4 shows a DSC Thermogram for Example 3 
Form A.
[0652] FIG. 5 shows an X-Ray powder Diffraction Pattern 
for Example 3 Form B.
[0653] FIG. 6 shows a DSC Thermogram for Example 3 
Form B.
[0654] FIG. 7 shows an X-Ray powder Diffraction Pattern 
for Example 3 Form C.
[0655] FIG. 8 shows a DSC Thermogram for Example 3 
Form C.
[0656] FIG. 9 shows Tumour Growth Inhibition by 
Example 3 in Combination with AKT inhibitor 
(AZD5363)— sequential administration
[0657] FIG. 10 shows Tumour Growth Inhibition by 
Example 3 in Combination with AKT inhibitor (AZD5363), 
co-administration
[0658] FIG. 11 shows Tumour Growth Inhibition by 
Example 3 in Combination with PARP inhibitor (Olaparib) in 
BT474 xenograft model
[0659] FIG. 12 shows Tumour Growth Inhibition by 
Example 3 in Combination with PARP inhibitor (Olaparib) 
MCF7 xenograft model
[0660] FIG. 13 shows Tumour Growth Inhibition by 
Example 3 in Combination with (AZD8186)
I. A  compound o f the Formula (I)
(I)
N —  N
NH-
wherein
R 1 is methyl or ethyl; and 
R2 is (C2-3)alkyl substituted by hydroxy; 
or a pharmaceutically-acceptable salt thereof.
2. A  compound as claimed in claim I, or a pharmaceuti­
cally-acceptable salt thereof, wherein R2 is selected from 
groups (i) to (xi):
(i)
HO
(ii)
IKE
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-continued
(iii)
HO \
(iv)
OH
(viii)
OH
(ix)
OH
(xi)
OH
3. A compound as claimed in claim I, or a pharmaceuti- 
cally-acceptable salt thereof wherein R2 is selected from 
groups (i) to (vi) as defined in claim 2.
4. A  compound as claimed in claim I, or a pharmaceuti- 
cally-acceptable salt thereof wherein R2 is group (i) as 
defined in claim 2.
5. A  compound as claimed in claim I, or a pharmaceuti- 
cally-acceptable salt thereof wherein R l is methyl.
6. A  compound as claimed in claim I, or a pharmaceuti- 
cally-acceptable salt thereof wherein R l is ethyl.
7. A  compound as claimed in claim I  or a pharmaceuti- 
cally-acceptable salt thereof, which compound is selected 
from:
l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl) 
pyrazin-2-yl] -I -methyl-1,2,4-triazol-3-yl] -I -pip­
eridyl] -3 -hydroxy-propan-1 -one;
l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl) 
pyrazin-2-yl] -1 -ethyl-1,2,4-triazol-3 -yl] -1 -piperidyl] -
3-hydroxy-propan-l -one;
(3R)-l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl]-1-methyl-1,2,4-triazol-3-yl]-1-pip­
eridyl] -3 -hydroxy-butan-1 -one;
(3S)-l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl]-1-methyl-1,2,4-triazol-3-yl]-1-pip­
eridyl] -3 -hydroxy-butan-1 -one;
(2R)-l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2- 
yl)pyrazin-2-yl]-1-methyl-1,2,4-triazol-3-yl]-1-pip­
eridyl] -3-hydroxy-2-methyl-propan-l-one;
l-[4-[5-[5-amino-6-(5-tert-butyl-l,3,4-oxadiazol-2-yl) 
pyrazin-2-yl] -I -methyl-1,2,4-triazol-3-yl] -I -pip­
eridyl] -2-hydroxy-2-methyl-propan-1 -one.
8 . A  compound as claimed in claim I, or a pharmaceuti- 
cally-acceptable salt thereof in a crystalline form.
9. (canceled)
10. (canceled)
11. A  combination, wherein said combination comprises a 
compound o f Formula (I) as claimed in claim I  or a pharma­
ceutically acceptable salt thereof and another anti-tumour 
agent.
12. A  pharmaceutical composition comprising a com­
pound o f Formula (I) or a pharmaceutically-acceptable salt 
thereof, as claimed in claim I, and a pharmaceutically-ac­
ceptable diluent or carrier.
13. A  method for selecting a patient for treatment with a 
compound of Formula (I) as claimed in claim I, the method 
comprising providing a sample from a patient containing 
tumour-derived DNA or tumour cells; determining whether 
the PIK3CA gene in the patient’s tumour cells or tumour- 
derived DNA are wild type or mutant; and selecting a patient 
for treatment with a compound o f Formula (I) based thereon.
14. A  method o f treating a patient suffering from cancer 
comprising: providing a tumour cell containing sample from 
a patient; determining whether the PIK3CA gene in the 
patient’s tumour cells are wild type or mutant; and adminis­
tering to the patient an effective amount o f a compound of 
Formula (I) as claimed in claim I  if  the tumour cells possess 
a mutant PIK3CA gene.
15. (canceled)
16. A  method for the prevention or treatment o f cancer in a 
warm blooded animal, in need of such treatment which com­
prises administering to said animal an effective amount o f a 
compound of the Formula (I) as claimed in claim I, or a 
pharmaceutically acceptable salt thereof.
17. The method of claim 16, wherein said cancer is a cancer 
with tumour cells identified as harbouring a mutant PIK3CA 
gene.
